



US 20250262322A1

(19) **United States**

(12) **Patent Application Publication**  
**KREMER et al.**

(10) **Pub. No.: US 2025/0262322 A1**

(43) **Pub. Date: Aug. 21, 2025**

(54) **A VECTOR, COMPOSITION, AND METHOD TO PROVIDE EXOGENOUS NAV1.1 ACTIVITY VIA CAV-2-MEDIATED DELIVERY OF AN SCN1A EXPRESSION CASSETTE**

(71) Applicants: **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, PARIS (FR); FUNDACION PARA INVESTIGACION MEDICA APLICADA, Pamplona (ES); Université de Montpellier, MONTPELLIER (FR)**

(72) Inventors: **Eric KREMER, Montpellier (FR); Bertrand BEUCHER, Montpellier (FR); Iria GONZALEZ DOPESO-REYES, Montpellier (FR); Ruben HERNANDEZ ALCOCEBA, Pamplona (ES); Ana Lourdes RICOBAZARA ABARQUERO, Pamplona (ES); Saja FADILA, Tel Aviv (IL); Moran RUBINSTEIN, Tel Aviv (IL)**

(21) Appl. No.: **18/856,604**

(22) PCT Filed: **Apr. 11, 2023**

(86) PCT No.: **PCT/IB2023/053703**

§ 371 (c)(1),

(2) Date: **Oct. 11, 2024**

(30) **Foreign Application Priority Data**

Apr. 11, 2022 (GB) ..... 2205299.7

**Publication Classification**

(51) **Int. Cl.**

**A61K 48/00** (2006.01)

**A61K 38/17** (2006.01)

**C07K 14/705** (2006.01)

**C12N 15/85** (2006.01)


(52) **U.S. Cl.**

CPC ..... **A61K 48/005** (2013.01); **A61K 38/177** (2013.01); **C07K 14/705** (2013.01); **C12N 15/85** (2013.01)

(57) **ABSTRACT**

A method for use in the treatment of diseases affecting the brain by providing exogenous Nav1.1 via CAV-2 vector-mediated delivery of a copy of SCN1A ORF into central nervous system (CNS) neurons. The method includes injection of the viral vector into the hippocampus and/or thalamus. Transcriptional control of the SCN1A expression cassette can be provided by specific promoters, such as NSE, to achieve targeted neuronal expression. This strategy is suitable as a therapeutic approach regardless of the underlying SCN1A mutation. Moreover, because this approach compensates for the loss of function of Nav1.1, it can potentially ameliorate Dravet Syndrome, epileptic and non-epileptic comorbidities thereof, epilepsy, Alzheimer's, and other Nav1.1-associated pathological conditions.

**Specification includes a Sequence Listing.**








Fig. 1.I






Fig. 3

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




Fig. 4




Fig. 5




Fig 6




Fig 7

FIG. 8A





FIG. 8B




Fig. 8

FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 9G




Fig. 9




Fig. 10



FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




Fig. 11




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




Fig. 12




Fig. 13





Fig. 14

FIG. 15A




FIG. 15B




Fig. 15








Fig. 16

**A VECTOR, COMPOSITION, AND METHOD  
TO PROVIDE EXOGENOUS NAV1.1  
ACTIVITY VIA CAV-2-MEDIATED  
DELIVERY OF AN SCN1A EXPRESSION  
CASSETTE**

**CROSS-REFERENCE TO RELATED  
APPLICATIONS**

**[0001]** The present application is a filing under 35 U.S.C. 371 as the National Stage of International Application No. PCT/IB2023/053703, filed Apr. 11, 2023, entitled “A VECTOR, COMPOSITION, AND METHOD TO PROVIDE EXOGENOUS NAV1.1 ACTIVITY VIA CAV-2-MEDIATED DELIVERY OF AN SCN1A EXPRESSION CASSETTE,” which claims priority to United Kingdom Application No. 2205299.7 filed with the Intellectual Property Office of the United Kingdom on Apr. 11, 2022, both of which are incorporated herein by reference in their entirety for all purposes.

**INCORPORATION BY REFERENCE OF  
MATERIAL IN XML FILE**

**[0002]** This application incorporates by reference the Sequence Listing contained in the following XML file being submitted concurrently herewith:

**[0003]** File name: 4692-19100 BNT241911USPC Sequence listing.xml; created on Oct. 4, 2024; and having a file size of 67.5 KB.

**[0004]** The information in the Sequence Listing is incorporated herein in its entirety for all purposes.

**BACKGROUND**

**[0005]** Dravet syndrome (DS) is a rare and severe genetic neurological form of developmental epileptic encephalopathy (DEE). Children with DS appear to develop normally during the first six months of life, but subsequently start to exhibit febrile seizures. During the following months, recurrent refractory spontaneous seizures become increasingly more frequent and global developmental delays begin. Disease progression includes intellectual disability, behavioral and movement disorders, and a high mortality rate. It is one of the better-known rare diseases where epilepsy is one of the main symptoms. At early school years, during the chronic phase of the disease, the frequency of seizures declines, but the non-epileptic comorbidities persist.

**[0006]** Previously known as severe myoclonic epilepsy of infancy, DS is caused, in the majority of cases, by loss-of-function (LoF) mutations in one of two copies of SCN1A. The vast majority of cases are caused by de novo mutations in one copy of SCN1A, causing LoF and therefore a haploinsufficiency in the activity of the voltage-gated sodium channel, Nav1.1. As a result of these mutations, patients with DS fail to produce sufficient levels of functional Nav1.1 sodium channel, preventing inhibitory neurons from firing properly. The consequence is an imbalance between brain excitation and inhibition that results in refractory epilepsy, intellectual disability, and behavioral and movement disorders.

**[0007]** The first generation of therapies for the treatment of DS focused primarily on addressing symptoms, for example, by improving seizure control through use of anti-epileptic medications. This includes compounds against traditional epilepsy targets, such as GABA receptors, as well

as novel first-in-class therapeutics that target new pathways not previously used in epilepsy. In recent years DS has received significant attention from the pharmaceutical industry. Following the approvals of Diacomit (stiripentol) from Biocodex and Epidiolex/Epidyolex (cannabidiol oral formulation) from GW Pharmaceuticals, Fintepla (fenfluramine) by Zogenix has recently become the third drug approved by both the FDA and the EMA for the treatment of seizures in DS.

**[0008]** Importantly, sodium channel blockers, which are often a first-line medication for the treatment of epilepsy, are contraindicated in DS and can aggravate the disease severity. Most patients must take combinations of three or more anti-epileptic drugs, most commonly valproate, clobazam, stiripentol, and topiramate and levetiracetam. None of these drugs alone achieve complete seizure suppression and only a minority (about 10%) of the patients become seizure-free.

**[0009]** There is also an emergent class of second-generation therapeutics that follow the step of the most advanced cannabidiol formulation, Epidiolex, and the most advanced serotonergic drug, Fintepla. Most of these compounds have the potential to treat other forms of epilepsy as well.

**[0010]** As the DS pipeline becomes more mature and competition increases, focus is shifting towards less symptomatic treatments and more disease-targeting therapeutics. A third generation of treatments aims to restore the abnormal Nav1.1 channel function or expression levels. There are currently several types of disease-targeting gene therapy approaches in development.

**[0011]** So called, “read-through therapies” such as the types produced by PTC Therapeutics and Tevard Biosciences enable the ribosome to move past a nonsense mutation to complete a functional protein. Nonsense mutations are those that introduce a premature stop codon into a gene sequence, preventing the cell from producing a complete protein. Despite its promise, an investigator-initiated study evaluated the safety and efficacy of ataluren for treating DS caused by nonsense mutations, and it indicated that ataluren failed to show efficacy.

**[0012]** Tevard Biosciences announced it was developing two novel tRNA-based gene therapy platforms for the treatment of DS and other rare diseases caused by haploinsufficiency and/or nonsense mutations that were not amenable to traditional approaches of gene therapy. Tevard’s approach focused on mRNA stabilization and nonsense codon suppression (or read-through).

**[0013]** Stoke Therapeutics is developing the first disease-modifying treatment for DS, an antisense oligonucleotide (ASO) therapy targeting SCN1A pre-mRNA maturation that upregulates Nav1.1 protein expression in rodents, human cell lines, and non-human primates. The lead candidate uses Stoke’s TANGO (Targeted Augmentation of Nuclear Gene Output) technology to target RNA splicing and increase protein expression in diseases caused by haploinsufficiency. The program, named STK-001, follows a similar approach to Spinraza and will be administered via intrathecal injection into the spinal fluid.

**[0014]** In mice with Scn1a haploinsufficiency, a single intracerebroventricular dose of a lead ASO increased production of Nav1.1 and met the two main preclinical endpoints in DS mouse models, which are seizure reduction and animal survival. Stoke has also shown biodistribution and

target engagement of STK-001 in non-human primates (AES 2019 meeting) and dosed the first patient in a Phase 1a/2b study in August 2020.

**[0015]** Encoded Therapeutics is developing an adeno-associated virus (AAV)-based gene therapy approach to increasing SCN1A transcription and rescuing haploinsufficiency in patients with DS. The therapy, named ETX101, has the potential to become the second disease-modifying therapy to reach clinical trials for the treatment of DS after Stoke Therapeutics' ASO lead program. ETX101 was granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of SCN1A+ DS.

**[0016]** The SCN1A ORF is poorly amenable for AAV-based gene therapy due to the limited cloning capacity of <5,000 nt. Encoded Therapeutics attempted to overcome the limitations of AAV viral gene therapy by expressing an engineered transcription factor to upregulate *Scn1a* expression in these cells, and presented preclinical data from their program in 2019 showing GABAergic cell-specific expression of SCN1A mRNA and Nav1.1 channel in a mouse model of DS, leading to a reduction in seizures and mortality. In December 2020, the company also presented data on biodistribution of ETX101 in non-human primates.

**[0017]** The present disclosure relates to a method of providing exogenous Nav1.1 via vector delivery of an SCN1A expression cassette into the central nervous system (CNS). This strategy is suitable as a therapeutic approach regardless of the underlying SCN1A mutation. Moreover, because this treatment compensates for the LoF of Nav1.1, it can potentially ameliorate DS epileptic and non-epileptic comorbidities as well as Alzheimer's and other Nav1.1 related pathological conditions. The minimum size of the expression cassette is ~7 kbp. To overcome the "size" obstacle, previous gene therapy strategies for DS included (i) expression enhancement of the endogenous *Scn1a* via transcriptional activation (Colasante et al., 2019; Han et al., 2020; Yamagata et al., 2020); (ii) overexpression of the *Scn1b* auxiliary subunit for an increase of channel complex efficacy; and, (iii) antisense oligonucleotide-mediated down-regulation of *SCN8A*.

**[0018]** While previous approaches to treating DS have shown potential improvements in "DS mice", therapeutic potential in these approaches was only shown in cases of mild DS when administered soon after birth, during the asymptomatic, pre-epileptic stage. In essence, these approaches did not distinguish between models having a severe versus mild symptoms. Clinical efficacy in cases of severe condition of DS was not established. Moreover, as clinical diagnoses are rarely confirmed prior to progression to recurrent spontaneous seizures, therapies that prevent the onset of severe intractable seizures and sudden unexpected death in epilepsy (SUDEP) are critically needed.

**[0019]** In 2020, there was a transition in clinical trials for DS with the initiation of the first clinical trial of a therapy specifically designed to increase Nav1.1 activity via STK-001 by Stoke Therapeutics. There are additional genetic and potentially disease-modifying treatments in early and late preclinical development, including an AAV-based gene therapy.

**[0020]** In contrast to AAV, adenovirus (AdV) vectors can harbor up to 36 kbp of exogenous sequence. Similar to AAV vectors, some AdV types (e.g., E1-deleted and helper-dependent CAV-2 vectors) can generate long-term transgene

expression in rodents and primate brain. Moreover, a human AdV (HAdVs) harboring an SCN1A expression cassette injected into the CNS of adolescent DS mice was well tolerated and reduced the epilepsy at the chronic stage. While AAV vectors have shown some promise in clinical trials, there remain safety concerns, including the extremely high doses needed and the tendency of AAV vectors to integrate into the genome of transduced cells. Like HAdV-based vector, most AAV vectors are also readily taken up by non-neuronal cells, including those that present antigens to immune cells. Moreover, most potential patients will have cross-reactive, memory T cells that recognize conserved AAV epitopes. Thus, the use of AAV and HAdV as a neuronal gene therapy vector could pose a risk. In addition, recent evidence demonstrated that AAV vectors are not as safe as originally thought, with reports of hepatotoxic, haematological toxicity, neurological safety issues and cancer concerns following AAV-mediated gene therapy, leading to premature termination of two studies (Mullard, 2021).

**[0021]** Therefore, a gene transfer vector is needed for preferential neuronal-uptake by a vector capable of harboring large expression cassettes for the delivery of SCN1A to the brain.

## SUMMARY

**[0022]** The vast majority of DS cases are caused by de novo mutations in one copy of SCN1A, causing LoF and, therefore, a haploinsufficiency in the activity of voltage-gated sodium channel, Nav1.1. Thus, a strategy in which exogenous Nav1.1 channels are provided into CNS neurons, can be used as therapeutic approach that will be suitable-regardless of the underlying SCN1A mutation. Moreover, as this treatment compensates for the LoF of Nav1.1, it can potentially ameliorate epileptic and non-epileptic comorbidities as well as Alzheimer's and other Nav1.1 association pathological conditions.

**[0023]** One therapeutic approach is gene therapy, where one provides exogenous Nav1.1 via delivery of an SCN1A expression cassette. The gene therapy pipeline is intransigently linked to vector efficacy. Due to a paucity of vectors capable of harboring large expression cassettes, several rare diseases have little hope of being targets of gene replacement. Due to the complex physiopathology of Nav1.1 associated pathological conditions such as DS and Alzheimers, etiological approaches such as gene therapy have unique chances to obtain a global improvement in the life of these patients. However, several challenges for treatment include the large (6 kb) SCN1A ORF, which precludes efficient expression by some viral vectors, the possibility that supraphysiological Nav1.1 levels in non-neuronal cells could be harmful, infecting enough neurons in the pertinent regions, and providing long-term expression. The present disclosure relates to a gene transfer vector and method of treatment that will pave the way for clinical trials for DS, epilepsy, Alzheimer's, and other genetic diseases and pathological conditions associated with mis-coded Nav1.1.

**[0024]** Due to the ~6 kbp ORF of SCN1A, commonly used vectors, such as adeno-associated virus (AAV), are poorly suitable. In contrast to AAV, AdV vectors can harbor up to 36 kbp of exogenous sequence (Cots et al., 2013; del Rio et al., 2019; Parks et al., 1996). AdV-mediated transgene expression is also stable for at least 1 year in the brain of rodents (Soudais et al., 2004). Moreover, a human AdV harboring the SCN1A injected into the CNS of adolescent

mice with DS was well tolerated and reduced the epilepsy at the chronic stage (Mora-Jimenez et al., 2021). However, HAdVs lack neuronal specificity, relied on a different non-neuronal specific promoter, CAG, and have only shown efficacy at ameliorating epilepsy and behavioral problems in older mice who have a less severe expression of DS.

**[0025]** Fatality in DS mice is ~50-60%, with most deaths clustered in the 4th week of life. DS mice that survive beyond P28 are less likely to die and their seizure frequency is reduced. Previously, studies have been conducted on older mice at around 5 weeks, wherein their brains were injected with a HAdV harboring the SCN1A expression cassette. However, as the severe stage of DS corresponds to the 4th week of life, by treating adolescent mice at five weeks of age, these studies were preselecting for mice with milder conditions of DS. These studies do not relate to the reversion of DS at the severe stage of the disease when epilepsy is most severe and the occurrence of premature mortality is higher.

**[0026]** This disclosure relates to a canine adenovirus type 2 (CAV-2)-mediated SCN1A ORF delivery for use in the treatment of SCN1A mutation and Nav1.1 sodium channel miscoding as well as rescue from the severe stage of DS and prevention of premature death. For example, in certain embodiments, the present disclosure relates to CAV-2-mediated delivery of an SCN1A ORF expression cassette for use in the treatment of SCN1A mutation and Nav1.1 sodium channel miscoding. This could enable rescue from severe DS and prevention of premature death. It would also provide significant therapeutic value in the treatment of Alzheimer's and other Nav1.1 associated pathological conditions.

**[0027]** CAV-2 vectors offer notable advantages for gene transfer to the CNS. First, by preferentially using the coxsackievirus and adenovirus receptor (CAR) as an attachment molecule—whose expression is found primarily by neurons in the brain parenchyma, CAV-2-mediated gene transfer is delimited to neurons. Second, the 35 kbp cloning capacity offers the ability to include different promoter sequences, enabling control over expression in various sub-neuronal populations. Finally, with its robust retrograde axonal transport capability, CAV-2 vector injections can lead to expression across connected brain regions.

**[0028]** In some aspects, the present disclosure relates to a CAV-2 vector comprising a region of SCN1A ORF. The disclosure also relates to an engineered CAV-2 vector comprising a region of SCN1A ORF and further comprising an inducible promoter region for the controlled expression of the SCN1A ORF. The disclosure also relates to a CAV-2 vector. In certain embodiments, the CAV-2 vector can be enhanced for selective neuronal transgene expression. The disclosure also relates to a CAV-2 vector comprising a region of SCN1A ORF and can further comprise regions encoding for controlled (e.g., transcriptionally or translationally, or post-translational) SCN1A transcription, mRNA processing, protein stability or protein targeting.

**[0029]** In some aspects, the present disclosure relates to CAV-2-mediated CNS delivery of SCN1A ORF (CAV-2 SCN1A treatment) for rescue from DS and prevention of premature death. For example, the disclosure relates to CAV-2 SCN1A treatment for rescue from DS during the severe stage of the disease and prevention of premature death in mice with DS, and for correction of DS comorbidities. Importantly, exogenous Nav1.1 activity in CAV-2 SCN1A treated adolescent mice that survived to the chronic

stage of DS, as well as in juvenile mice at the onset of severe epilepsy, improved survival of the mice, reduced the occurrence of spontaneous seizures and epileptic spike frequency, and increased the temperature threshold for febrile seizures. The present disclosure relates to the efficient delivery of an SCN1A expression cassette in excitatory and inhibitory neurons as a viable therapeutic approach for rescuing and treating DS. This disclosure also relates to treatment of DS and, specifically, treatment with CAV-2-mediated CNS delivery of SCN1A ORF in animal models with DS to correct DS comorbidities.

**[0030]** In some aspects, this disclosure relates to the design and use of a CAV-2 vector for the transfer of the SCN1A ORF to the CNS for the treatment of DS. By preferentially using the coxsackievirus and adenovirus receptor (CAR) as an attachment molecule—whose expression is found primarily by neurons in the brain parenchyma, CAV-2-mediated gene transfer is delimited to neurons. The cloning capacity of CAV-2 offers the ability to include different promoter sequences, enabling control over expression in various sub-neuronal populations. Additional features include its retrograde axonal transport capability, allowing CAV-2-mediated transduction to lead to expression across a plurality of connected brain regions.

**[0031]** In another aspect, the present disclosure relates to the inclusion of a suitable promoter to be used in an expression cassette for the SCN1A ORF, the expression cassette to be incorporated into the sequence of a CAV-2 vector. The promoter can be used for purposes of controlling expression levels of the SCN1A ORF. The promoter can also be selected based on the need to make modifications in the neuronal tropism of the vector. The CAV-2 sequence can also be engineered for purposes of selective neuronal and stable long-term expression.

**[0032]** In another aspect, the present disclosure relates to a method for producing an engineered CAV-2 SCN1A treatment vector. The production is carried out following methods developed at the collaborating center (CNRS, Montpellier), which rely on the use of a helper CAV-2 vectors. This helper vector replicates together with CAV-2 SCN1A treatment vector, however infectious helper vectors particles are not encapsidated because its packaging sequence, flanked by lox sequences, is eliminated by Cre recombinase.

**[0033]** In other embodiments, this disclosure relates to the efficient delivery of an SCN1A expression cassette in excitatory and/or inhibitory neurons as a viable therapeutic approach for DS. Thus, this disclosure relates to a strategy in which exogenous functional Nav1.1 channels are provided into CNS neurons via CAV-2 mediated delivery of SCN1A ORF, as a therapeutic approach that is suitable for children and adolescents-regardless of the underlying SCN1A mutation. Moreover, this disclosure relates to a treatment that compensates for the LoF of Nav1.1, and can ameliorate DS epileptic and non-epileptic comorbidities and achieve rescue and reversion of DS as well as provide treatment and therapeutic methods for Nav1.1 associated pathological conditions.

**[0034]** Therefore, based on the foregoing and continuing description, the subject invention in its various embodiments may comprise one or more of the following features in any non-mutually-exclusive combination:

- [0035] A vector for providing exogenous Nav1.1 sodium channels having a first nucleic acid sequence encoding at least one portion of a CAV-2 genome;
- [0036] A vector for providing exogenous Nav1.1 sodium channels having a second nucleic acid sequence encoding a functional Nav1.1 sodium channel;
- [0037] A vector for providing exogenous Nav1.1 sodium channels having a first regulatory sequence encoding a transcriptional control region.
- [0038] A vector for providing exogenous Nav1.1 sodium channels wherein the transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding at least one promoter/enhancer/elongation factor.
- [0039] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding E2, E6, EF1, CAG, hSyn, Dlx5/6, and NSE, and preferably, NSE;
- [0040] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding an endogenous SCN1A promoter;
- [0041] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding an endogenous SCN1A enhancer;
- [0042] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding an endogenous SCN1A transcription factor;
- [0043] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding an endogenous SCN1A promoter;
- [0044] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding an endogenous SCN1A enhancer;
- [0045] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding E6;
- [0046] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding EF1;
- [0047] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding CAG;
- [0048] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding hSyn;
- [0049] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding Dlx5/6;
- [0050] A vector for providing exogenous Nav1.1 sodium channels wherein a transcriptional control region contains a promoter/enhancer/elongation factor sequence encoding NSE;
- [0051] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence is operably linked to the first regulatory sequence for controlled transcriptional expression of an SCN1A open reading frame (ORF) in mammalian cells;
- [0052] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence is Sequence ID Number 12;
- [0053] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence is Sequence ID Number 14;
- [0054] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence encodes for Sequence ID Number 15;
- [0055] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence encodes for Sequence ID Number 16;
- [0056] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence is an engineered SCN1A ORF;
- [0057] A vector for providing exogenous Nav1.1 sodium channels wherein a engineered SCN1A ORF is created by eliminating at least one short repeat sequence from a codon-modified SCN1A ORF;
- [0058] A vector for providing exogenous Nav1.1 sodium channels wherein a second nucleic acid sequence is created by eliminating at least one short repeat sequence in an ORF encoding a transmembrane section of the functional Nav1.1 sodium channel;
- [0059] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is designed for use in the treatment of pathological conditions associated with SCN1A mutation;
- [0060] A vector for providing exogenous Nav1.1 sodium channels having an NSE promoter;
- [0061] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with SCN1A missense mutations or SCN1A truncation mutations;
- [0062] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is optimized for preferential expression of SCN1A ORF in neurons;
- [0063] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with Dravet Syndrome;
- [0064] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with Epilepsy;
- [0065] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with Alzheimer's disease;
- [0066] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with Autism Spectrum Disorder;
- [0067] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with neuronal disfunction;
- [0068] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with network disfunction;
- [0069] A vector for providing exogenous Nav1.1 sodium channels wherein the vector is therapeutically active in individuals with a loss of function of endogenous Nav1.1;



- [0070] A method for providing exogenous Nav1.1 channels via a vector including administering a therapeutically effective amount of any of the aforementioned vectors, including a vector for providing exogenous Nav1.1 sodium channels;
- [0071] A method for providing exogenous Nav1.1 channels via a vector including wherein the vector is administered into a central nervous system of the mammal;
- [0072] A method for providing exogenous Nav1.1 channels via a vector including wherein the vector is administered into at least one brain region;
- [0073] A method for providing exogenous Nav1.1 channels via a vector including wherein the vector is administered into the hippocampus;
- [0074] A method for providing exogenous Nav1.1 channels via a vector including wherein the vector is administered into the thalamus;
- [0075] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered prior to development of a chronic form of Dravet Syndrome or comorbidities thereof;
- [0076] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to treat a chronic form of Dravet Syndrome or comorbidities thereof; · A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to treat Dravet Syndrome or comorbidities thereof;
- [0077] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to prevent the development of Dravet Syndrome or comorbidities thereof;
- [0078] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a missense mutation in SCN1A;
- [0079] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a nonsense mutation in SCN1A;
- [0080] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a truncation mutation in SCN1A;
- [0081] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a deletion mutation in SCN1A;
- [0082] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a frameshift mutation in SCN1A;
- [0083] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a splice site mutation in SCN1A;
- [0084] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a mutation in SCN1A;
- [0085] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a mutation in a promoter/enhancer/regulatory region of SCN1A;
- [0086] A method for providing exogenous Nav1.1 channels via a vector wherein after administration of the vector, the method further includes inducing expression of the functional Nav1.1 sodium channel;
- [0087] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered to individuals with a missense mutation in SCN1A or truncation mutation in SCN1A;
- [0088] A method for providing exogenous Nav1.1 channels via a vector wherein after administration of the vector, the method further comprises monitoring the mammal for desired clinical results, and if the desired clinical results are not obtained, administering a second therapeutically effective amount of the vector;
- [0089] A method for providing exogenous Nav1.1 channels via a vector wherein the vector is administered via injection into a patient's brain;
- [0090] A method for providing exogenous Nav1.1 channels via a vector including administering a therapeutically effective amount of seizure medication;
- [0091] A method for providing exogenous Nav1.1 channels via a vector including administering a therapeutically effective amount of Alzheimer's medication;
- [0092] A method for providing exogenous Nav1.1 channels via a vector including administering a therapeutically effective amount of epilepsy medication;
- [0093] A method for providing exogenous Nav1.1 channels via a vector wherein therapeutically effective amount of the vector is administered for the treatment of Dravet Syndrome;
- [0094] A method for providing exogenous Nav1.1 channels via a vector wherein therapeutically effective amount of the vector is administered for the treatment of Epilepsy;
- [0095] A method for providing exogenous Nav1.1 channels via a vector wherein therapeutically effective amount of the vector is administered for the treatment of Alzheimer's;
- [0096] A method for providing exogenous Nav1.1 channels via a vector to modify a brain neural network to reduce symptoms of a pathological condition.
- [0097] A method for providing exogenous Nav1.1 channels via a vector to modify a brain neural network to reduce symptoms of Autism Spectrum Disorder (ASD).
- [0098] A composition for providing exogenous Nav1.1 channels, the composition including any of the aforementioned vectors, or a vector for providing exogenous Nav1.1 sodium channels.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- [0099] FIG. 1. Promoter-driven variations in CAV-2 vector transgene expression.
- [0100] FIG. 1.1 Enhancer/promoter-driven variations in CAV-2 vector transgene expression.
- [0101] FIG. 2. Functional expression of the SCN1A ORF.
- [0102] FIG. 3. Survival of adolescent mice following injection of CAV-GFP or CAV-SCN1A.
- [0103] FIG. 4. Hippocampal injection of CAV-SCN1A at the chronic stage of DS improves epilepsy and cognitive abilities.
- [0104] FIG. 5. Sexual divergent effects following CAV-SCN1A injections into the hippocamps.
- [0105] FIG. 6. Behavioral characterization of male and female mice.
- [0106] FIG. 7. Hippocampal injection of CAV-SCN1A at the severe stage of DS ameliorates the epileptic phenotypes.
- [0107] FIG. 8. Video monitoring of convulsive spontaneous seizures.

[0108] FIG. 9. Correction of background ECoG activity, and partial correction of cognitive functions following treatment with CAV-SCN1A.

[0109] FIG. 10. Relative expression of voltage-gated sodium channels expression.

[0110] FIG. 11. Thalamic injection of CAV-SCN1A ameliorates DS phenotypes in juvenile mice.

[0111] FIG. 12. Similar effects CAV-SCN1A injections into the thalamus of males and females DS mice.

[0112] FIG. 13. Combined thalamic and hippocampal injection of CAV-SCN1A in juvenile mice protects from thermally-induced seizures.

[0113] FIG. 14. Similar effects CAV-SCN1A injections into the thalamus and the hippocampus of males and females DS mice.

[0114] FIG. 15. The effect of CAV-SCN1A injections into the hippocampus and/or thalamus of juvenile mice.

[0115] FIG. 16. (A) Map of two CAV-2 vectors harboring either an mCitrine cassette or a codon-modified SCN1A cDNA with fused HA tag, and the experimental design of the study in which they are bilaterally injected in the hippocampus of Alzheimer's mouse models. ITR: inverted terminal repeat.  $\psi$ : packaging signal. NSE (promoter): neuron-specific enolase. pA: polyadenylation signal. (B) Expression pattern of the vectors injected in the hippocampus. Second and third column are a higher magnification of, respectively, black and white frames of the first column. (C) Therapeutic effect of CAV-NSE-SCN1A-HA on working memory in the Y-maze test in 4 and 5-months-old J20 and 5XFAD mice. (D-E) Amyloid loads (white frames) analysis and quantification in the hippocampus and cortex of 9-months-old J20 mice.

#### DETAILED SUMMARY

[0116] A detailed description of one or more embodiments of the claimed subject matter is provided below and herein along with accompanying figures that illustrate the principles of the claimed subject matter. The claimed subject matter is described in connection with such embodiments, but is not limited to any particular embodiment. It is to be understood that the claimed subject matter may be embodied in various forms, and encompasses numerous alternatives, modifications and equivalents. Therefore, specific details disclosed herein are not to be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching one skilled in the art to employ the claimed subject matter in virtually any appropriately detailed system, structure, or manner. Numerous specific details are set forth in the following description in order to provide a thorough understanding of the present disclosure. These details are provided for the purpose of example and the claimed subject matter may be practiced according to the claims without some or all of these specific details. It is to be understood that other embodiments can be used and structural changes can be made without departing from the scope of the claimed subject matter. It should be understood that the various features and functionality described in one or more of the individual embodiments are not limited in their applicability to the particular embodiment with which they are described. They instead can be applied alone or in some combination to one or more of the other embodiments of the disclosure, whether or not such embodiments are described, and whether or not such features are presented as being a part of a described embodiment. For the purpose of clarity, techni-

cal material that is known in the technical fields related to the claimed subject matter has not been described in detail so that the claimed subject matter is not unnecessarily obscured.

[0117] All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.

[0118] Throughout this disclosure, various aspects of the claimed subject matter are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the claimed subject matter. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, where a range of values is provided, it is understood that each intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the claimed subject matter. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the claimed subject matter, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the claimed subject matter. This applies regardless of the breadth of the range. For example, description of a percentage range such as at least 75 should be considered to have specifically disclosed sub-ranges such as from 75 to 100, from 80 to 100, from 85 to 100, from 95 to 100, from 99 to 100, etc., as well as individual numbers within that range, for example, 75, 76, 77, 78, 79, etc.

#### Transcriptionally-Targeted Transgene Expression

[0119] Currently, DS is thought to be caused by inhibitory neuron dysfunction. It has also been postulated that reduced Nav1.1 activity in excitatory neurons may also be associated with DS comorbidities. Moreover, hippocampal dysfunction likely plays a key role in DS pathophysiology.

#### Enhancer/Promoter-Driven Variations in CAV-2 Vector Expression

[0120] Assays were initiated to determine whether expression could be selectively targeted in different neuronal populations in the hippocampus and afferent regions. Because selective targeting of infection of various neuronal subtypes is not yet technically feasible, transcriptional control of the expression cassette was chosen to achieve targeted neuronal expression. For this purpose, CAV-2 vectors containing a fluorescent reporter driven by i) a strong non-specific CAG promoter (cytomegalovirus enhancer, chicken b-actin promoter and rabbit b-globin splice acceptor site) that drives expression in all vector-transduced cells; ii) a human synapsin promoter (hSyn), which drives transgene expression in most neuron populations; iii) a neuron-specific enolase (NSE) promoter, which drives moderate levels of transgene expression in excitatory and inhibitory neurons; iv) a Dlx5/6 promoter (Dlx5 and Dlx6 encode two homeobox transcription factors expressed by developing and mature GABAergic interneurons), which, when incorporated into a viral vector, can lead to preferential expression in inhibitory neurons; the *Scn1a* enhancers E2 and E6.

**[0121]** Following bilateral vector injection into the hippocampus of adolescent mice (5-6-week-old), the expression pattern varied depending on the promoter. As expected, the CAG promoter generated robust and widespread transgene expression at the site of injection and, due to the retrograde transport of CAV-2, also in excitatory neurons from the subiculum and multiple neocortical layers that project into the hippocampus (FIGS. 1A-D). Although at lower levels, the hSyn promoter also led to widespread transgene expression at the site of injection and afferent regions (FIG. 1E-H). The NSE promoter resulted in an intermediate expression level in excitatory and inhibitory neurons around the injection sites (with a ratio of 80-90% excitatory and 10-20% inhibitory), as well as additional hippocampal projecting regions in the cortex and thalamus (FIG. 1I-L). Conversely, using the Dlx5/6 promoter, a localized transgene expression principally in hippocampal interneurons was observed (FIG. 1M-P). Based on the expression patterns in excitatory and inhibitory neurons, biodistribution, and the likely need for moderate levels of Nav1.1, pan-neuronal expression mediated by the NSE promoter was chosen to drive SCN1A expression using CAV-2 vectors.

**[0122]** FIG. 1 shows promoter-driven variations in the expression patterns and biodistribution of CAV-2 vectors containing a fluorescent reporter in excitatory and inhibitory neurons following bilateral vector injection into the hippocampus of adolescent mice of 5-6 weeks of age. FIGS. 1A-D show CAG promoter-driven variations. FIG. 1E-H show hSyn promoter-driven variations. FIG. 1I-L shows NSE promoter-driven variations. FIG. 1M-P show Dlx5/6 promoter-driven variations. FIG. 1.1 shows enhancer/promoter driven variations as follows: 1<sup>st</sup> column shows E6 enhancer from SCN1A; 2<sup>nd</sup> column shows E2 enhancer from SCN1A; 3<sup>rd</sup> column shows Dlx5/6; 4<sup>th</sup> column shows NSE; and 5<sup>th</sup> column shows CAG.

#### CAV-SCN1A-Mediated Nav1.1 Activity

**[0123]** In addition to its size, the native SCN1A ORF is prone to rearrangement when subcloned into a plasmid and propagated in *E. coli*. However, codon modification can enhance its stability and, therefore, facilitate the creation of vectors. To further increase the stability of the ORF, short (10-15 bp) repeat sequences were eliminated from an engineered SCN1A. The majority of the short repeats were in the sequences coding for the transmembrane sections of Nav1.1.

**[0124]** Detection of exogenous Nav1.1 immunoreactivity can be problematic in a brain with endogenous levels. Therefore, to follow CAV-SCN1A-mediated Nav1.1 expression, a C-terminal hemagglutinin (HA) tag was also added. CAV-SCN1A was generated and purified as previously described. To determine if functional Nav1.1 channels were generated, CAV-SCN1A was incubated with DK cells. Robust voltage-gated sodium currents with the biophysical properties that are characteristic of Nav1.1 were recorded (FIGS. 2A, B). Of note, the HA tag did not have a notable effect on the biophysical properties of the channel (FIG. 2C, D). When injected into the hippocampus of adolescent mice, HA-immunoreactivity was readily detected along the dendrites and soma of excitatory neurons in the hippocampus as well as the dendrites, soma, and axon initial segment of inhibitory neurons.

#### Functional Expression of the SCN1A Transgene

**[0125]** FIG. 2 illustrates the functional expression of the SCN1A transgene. With respect to FIGS. 2A-B, the voltage current relationship (A) and the biophysical properties (B) of sodium currents following expression of CAV-SCN1A in DK cells is shown. The half voltage of activation was  $-30.4 \pm 0.74$  mV; the half voltage of inactivation was  $-65.73 \pm 0.94$  mV. FIG. 2C-D show the voltage current relationship and the biophysical properties of sodium currents in DK cells following expression of CAV-HA-SCN1A in DK cells. The half voltage of activation was  $-30.6 \pm 1.2$  mV and half voltage of inactivation  $-67.8 \pm 1.8$  mV. Inset in FIGS. 2A and C: a representative sodium current traces, calibrators: 500 pA, 2 ms. The empty symbols depict the current recorded from DK cells infected with the control CAV-GFP control vector (n=10), closed symbols depict CAV-SCN1A (n=9) or CAV-HA-SCN1A (n=7), as indicated.

**[0126]** As seen in FIG. 2E-U, CAV-HA-SCN1A.  $1 \times 10^9$  physical particles were injected bilaterally into the hippocampus of adult mice. In FIG. 2E-N, background staining is cresyl violet. HA expression is shown by immunohistology DAB staining (dark brown). Approximately 1,000 HA-immunoreactive cells/mouse, with neuronal morphology could be readily identified. FIG. 2E and H show HA immunoreactivity in the hippocampus. Scale bar 500  $\mu$ m. FIG. 2F and I show magnification of the black box in FIG. 2E and H, and additional examples FIG. 2K and M. Scale bar 50  $\mu$ m. FIG. 2G, J, L, and N show magnification of the red box. Scale bar 20  $\mu$ m. FIGS. O-U show immunofluorescence in a mouse injected with CAV-HA-SCN1A. FIG. 2O shows HA immunoreactivity (IR). FIG. 2P shows GABA IR. FIG. 2Q shows DAPI IR and merge (FIG. 2R-U). Scale bars 20  $\mu$ m.

#### CAV-SCN1A Injections Revert Epileptic Phenotypes in Adolescent DS Mice

**[0127]** There are multiple mouse models of DS that faithfully reproduce the hallmarks of DS pathology. These “DS mice” display age-dependent progression of the severity of the epilepsy with spontaneous seizures that begin around postnatal day (P) 18, and premature death that peaks during the 4th week of life. DS mice that survive this severe stage enter a chronic stage, in which the frequency of spontaneous convulsive seizures and mortality is reduced. Of note, genetic background dramatically affects the severity of the epileptic phenotype in DS mice.

**[0128]** Here, one of the most demanding models of DS was used, harboring a missense mutation (SCN1A<sup>A1783V/WT</sup>) on the C57BL/6J background. In this model, all of the mice experience spontaneous seizures, with an overall mortality rate of over 50%. This mutation was shown to cause LoF of Nav1.1, recapitulating the characteristic neuronal alterations of DS. However, unlike other models with SCN1A truncation mutations, the A1783V missense mutation does not affect the overall SCN1A mRNA or total Nav1.1 levels.

**[0129]** Due to the retrograde transport of CAV-2 vectors, it was postulated that bilateral injections into the hippocampi would be sufficient to improve the epilepsy in adolescent SCN1A<sup>A1783V/WT</sup> mice. To that end, bilateral injections of CAV-SCN1A or CAV-GFP were performed in healthy (WT) and SCN1A<sup>A1783V/WT</sup> adolescent mice (5-weeks old). As noted above, after P30, during the chronic stage of the disease, such as in those of 5-week-old adolescent mice, the

prevalence of sudden unexpected death in epilepsy (SUDEP) is low (Fadila et al., 2020; Ogiwara et al., 2013; Ricobaraza et al., 2019; Yu et al., 2006). Inasmuch, within this cohort of mock CAV-GFP injected and treated mice, only one mock-treated SCN1A<sup>A1783V/WT</sup> mouse died.

**[0130]** As shown in FIG. 3, no death occurred in WT mice injected with either CAV-GFP or CAV-SCN1A or DS mice injected with CAV-SCN1A. Premature death in DS mice mostly occurs at the 4th week of life. As shown in FIG. 3, the ability of CAV-SCN1A to ameliorate the epileptic phenotypes in a subset of mice that survived to the fifth week of life was tested. Only one DS mouse died prematurely (treated with CAV-GFP). WT: CAV-GFP n=11; WT: CAV-SCN1A n=12; DS: CAV-GFP n=9; DS: CAV-SCN1A n=12.

**[0131]** With minimal potential to effect survival, electrocorticography was used to characterize the impact of CAV-SCN1A on aberrant neuronal activity. Two weeks post-injection, depth electrodes were implanted in the hippocampus and intracranial electrodes were implanted in the somatosensory cortex for electrocorticography (ECOG) recordings. Initially, these recordings showed that CAV-SCN1A injections in WT mice did not induce aberrant neuronal activity (FIG. 4 A, C). Moreover, bilateral hippocampi CAV-SCN1A injections in SCN1A<sup>A1783V/WT</sup> mice reduced, but did not completely eliminate, the occurrence of epileptic spike (FIGS. 4A-D). Another hallmark of DS is the sensitivity to thermally-induced seizure. Effective anti-seizure medications, which are used to treat patients with DS, can elevate the threshold for thermally-induced seizures in DS mice. Strikingly, ~40% of the CAV-SCN1A-treated DS cohort showed complete protection from seizures up to 40.5° C. (FIG. 4E). Moreover, CAV-SCN1A injections in DS mice that exhibited seizures also demonstrated reduced susceptibility and elevated temperature threshold (FIG. 4E).

**[0132]** The present disclosure demonstrates the efficacy of CAV-SCN1A treatment to improve the clinical condition an outcome of epileptic phenotypes in SCN1A<sup>A1783V/WT</sup> mice during the chronic stage of DS.

CAV-SCN1A does not Alter the Behavior of WT Mice

**[0133]** Next, the Y maze spontaneous alternation test, which assesses working memory based on the natural curiosity of mice and their tendency to explore novel environments, and the open field test, which monitors activity in a novel environment, were used to examine the effect of CAV-SCN1A injections in adolescent WT and DS mice. Significant differences between the groups were not detected (FIG. 4F). However, if the alteration level was random, it was found that WT mice injected with either CAV-GFP or CAV-SCN1A exhibited alteration above chance level. Conversely, SCN1A<sup>A1783V/WT</sup> mice injected with CAV-GFP demonstrated random exploration of the maze (FIG. 4F), consistent with deficit in their working memory. Notably, DS mice injected with CAV-SCN1A exhibited exploration that was not random, and at the edge of the statistical significance (FIG. 4F), suggestive of some improvement of their cognitive abilities. In the open field test, CAV-SCN1A had no adverse effect on the performance of WT mice (FIG. 4F).

**[0134]** The present disclosure demonstrates the lack of adverse effect of CAV-SCN1A in WT mice, suggesting that overexpression of Nav1.1 is well tolerated and possesses strong therapeutic potential on both epileptic and nonepileptic DS phenotypes when administered during the chronic phase.

Hippocampal Injection of CAV-SCN1A at the Chronic Stage of DS Improves the Symptoms of Epilepsy and Cognitive Abilities.

**[0135]** FIG. 4 also illustrates that hippocampal injection of CAV-SCN1A at the chronic stage of DS improves the symptoms of epilepsy and cognitive abilities. As shown in FIG. 4, CAV-GFP or CAV-SCN1A were injected in 5-week-old WT and DS mice. FIGS. 4A-B show data from two weeks after the treatments, when depth electrodes were implanted into the hippocampus at the site of injection. Example traces are shown in FIG. 4A and quantification of the spike frequencies is shown in FIG. 4B. Epileptic activity was not detected in WT mice injected with either CAV-GFP or CAV-SCN1A (n=3 for each); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=5). FIG. 4 C-D show example traces of cortical ECoG recordings (C) and quantification of the spike frequencies (D). WT: CAV-SCN1A (n=2); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=5). FIG. 4E shows percent mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP, n=13; DS: CAV-SCN1A, n=10. See FIG. 5 for separate analysis of males and females. FIG. 4F-Left: shows spontaneous alternation in the Y maze. The dotted line signifies chance level, expected from random alternation. The markings above the bars indicate statistical analysis using one-sample t test relative to 50%. WT: CAV-GFP (n=9); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=10). FIG. 4F-Right: shows the distance moved in the open field. Statistical analysis utilized one-way ANOVA. WT: CAV-GFP (n=14); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=13); DS: CAV-SCN1A (n=13). See FIG. 6, for separated analysis for males and females. \* p<0.05; \*\* p<0.01; \*\*\* p<0.001.

**[0136]** FIGS. 5A-B illustrate the percent of male (A) and female (B) DS mice remaining free of thermally-induced seizures following hippocampal injections of CAV-GFP or CAV-SCN1A at 5 weeks of age. The dotted lines represent median seizure temperature. DS: CAV-GFP, Male n=8, Female n=2; DS: CAV-SCN1A, Male n=8, Female n=6. FIG. 5 C-D illustrate the survival curve of male (C) and female (D) DS mice injected with either CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, Male n=25, Female n=27; DS: CAV-SCN1A, Male n=25, Female n=20. FIG. 5 E-F illustrate the percent male (E) and female (F) DS mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP, Male n=6, Female n=14; DS: CAV-SCN1A, Male n=17, Female n=15.

**[0137]** FIG. 6A depicts the percent spontaneous alternation in the Y maze, of males and females, following gene therapy in adolescent mice. The test was performed 5-10 days post injection (median age P42, range P39-P43). The dotted line signifies chance level, expected from random alternation. The markings above the bars indicate statistical analysis using one-sample t test relative to 50%. WT: CAV-GFP, male n=3; female n=6; WT: CAV-SCN1A, male n=6, female n=7; DS: CAV-GFP, male n=6, female n=5; DS: CAV-SCN1A, male n=8; female n=2. In FIG. 6B, the open field test was performed 9-17 days post injection (median age P50, range P45-P53). Statistical analysis utilized one-way ANOVA followed by Tukey. WT: CAV-GFP, male n=3=9, female n=5; WT: CAV-SCN1A, male n=7, female n=6; DS: CAV-GFP, male n=6, female n=7; DS: CAV-SCN1A, male n=9, female n=4. FIG. 6C shows percent

spontaneous alternation of males and females in the Y maze following gene therapy in juvenile mice (P21). This test was performed 8-14 days post injection (median age P36, range P29-P39). The dotted line signifies chance level expected from random alternation. The markings above the bars indicate statistical analysis using one-sample t test relative to 50%. WT: CAV-GFP, male n=9; female n=10; WT: CAV-SCN1A, male n=4, female n=8; DS: CAV-GFP, male n=4, female n=9; DS: CAV-SCN1A, male n=2, female n=8. FIG. 6D shows the distance moved in an open field following gene therapy in juvenile mice. This test was performed 9-17 days post injection (median age P37, range P30-P41). Statistical analysis utilized one-way ANOVA followed by Tukey. WT: CAV-GFP, male n=8; female n=9; WT: CAV-SCN1A, male n=5, female n=7; DS: CAV-GFP, male n=3, female n=8; DS: CAV-SCN1A, male n=9, female n=4.

#### Hippocampal Injection of CAV-SCN1A at the Severe Stage of DS Ameliorates the Epileptic Phenotypes

**[0138]** As noted above, the severity of the epileptic phenotypes subsides after the 4<sup>th</sup> week of life in SCN1A<sup>-f1783V/WT</sup> mice. Thus, it was determined whether exogenous Nav1.1 activity following CAV-SCN1A injections could prevent recurrent spontaneous seizures during the severe stage of the disease, such as in juvenile DS mice younger than 5-weeks old. To that end, bilateral hippocampal injections were performed at the onset of symptoms at P21-P24. Initially, CAV-SCN1A injections reduced the occurrence of premature death by ~40% compared to mice injected with CAV-GFP (FIG. 7A). Continuous video recordings of a subset of mice, over 24-36 h post-injection, demonstrated that all of the DS mice experienced spontaneous convulsive seizures 12 h post-injection (FIG. 7B, and FIG. 8). However, by 36 h post-injection, DS mice injected with CAV-SCN1A demonstrated a significant ( $p<0.5$ ) reduction in the number of convulsive seizures, while seizures persisted in those treated with CAV-GFP (FIG. 7B, 36 h and FIG. 8).

**[0139]** Two weeks post-injection, hippocampal and neo-cortical electrodes were implanted to measure aberrant neuronal activity. It was found that CAV-SCN1A treatment reduced the number of epileptic spikes observed in both regions (FIG. 7 D-G). Treatment with CAV-SCN1A injection in DS mice also reduced the susceptibility to thermally-induced seizures, completely prevented thermally-induced seizures in ~30% of the treated mice (FIG. 7C), and increased the seizure threshold temperature in mice that retained sensitivity to thermally-induced seizures (FIG. 7C). Together, CAV-mediated expression of Nav1.1, at the severe stage of the DS, improved survival, reduced spontaneous seizures and epileptic spikes occurrence, and increased the temperature threshold of thermally-induced seizures (FIG. 7).

**[0140]** FIG. 7A shows the survival curve of WT and DS littermates injected with either CAV-GFP or CAV-SCN1A at P21-P24. WT: CAV-GFP (n=13); WT: CAV-SCN1A (n=17); DS: CAV-GFP (n=42); DS: CAV-SCN1A (n=48). For separated analysis of males and females, see FIG. 5. FIG. 7B shows the video monitoring of convulsive seizures 12 and 36 h post-injection. DS: CAV-GFP (n=5); DS: CAV-SCN1A (n=4). See FIG. 8 for additional data on individual mice. FIG. 7C shows mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP (n=20); DS: CAV-SCN1A (n=33). See FIG. 6 for separated analysis of males and females. FIG. 7

D-G show data from depth electrodes (D, E) or cortical electrodes (F, G) two weeks after treatment. Example traces (FIG. 7 D, F) and quantification of the spike frequencies are also depicted (FIG. 7 E, G). DS: CAV-GFP (n=5 for E, n=16 for G); DS: CAV-SCN1A (n=5 for E, n=19 for G). No epileptic activity was detected in WT mice injected with either CAV-GFP or CAV-SCN1A (n=2 each for depth electrodes and n=9, n=10 respectively, for cortical electrodes. \*  $p<0.05$ ; \*\*  $p<0.01$ ; \*\*\*  $p<0.001$ ).

**[0141]** FIG. 8 shows a subset of mice which were recorded on video for 14-36 h post-injection.

**[0142]** FIG. 8A depicts the number of seizures per mouse. The average number of seizures at and 36 h are depicted in FIG. 4B. FIG. 8B shows the change in the frequency of spontaneous seizures over 36 h (Chi-square test  $p=0.013$ ).

#### CAV-SCN1A Injections Rectify Background ECoG Activity and Partially Corrects Working Memory Deficits in DS Mice

**[0143]** Spectral analysis of the ECoG signals 2 weeks post-injection was performed to further explore the impact of exogenous Nav1.1 activity in WT mice, as well as the potential therapeutic effect of this treatment on background, non-epileptic brain oscillations. In WT mice, injection of CAV-GFP or CAV-SCN1A did not alter the spectral ECoG profile, and this power was also similar to that of untreated mice (FIGS. 9A-F; data for untreated mice are replotted from (Fadila et al., 2020)). The present disclosure demonstrates that CAV-2 vectors and exogenous Nav1.1 activity in excitatory and inhibitory neurons do not notably impact global brain oscillations. Mice with DS exhibit an overall lower power of background ECoG activity compared to WT mice (Fadila et al., 2020). Here too, the power of ECoG signals of DS mice injected with CAV-GFP, was lower compared to that of WT mice ( $p<0.002$ ), and similar to that of untreated DS mice (FIG. 9C, data for untreated mice are replotted from (Fadila et al., 2020)). Conversely, the power of DS mice treated with CAV-SCN1A was higher, mainly in the delta and theta frequency bands (FIG. 9 B-E). Thus, exogenous Nav1.1 activity generated by CAV-SCN1A injections also rectified the background ECoG activity in DS mice.

**[0144]** Whether exogenous Nav1.1 activity impacted the expression of other sodium channels was also tested, as it was thought there might be a physiological balance between the levels of sodium channels. It was found that CAV-SCN1A injections did not alter the mRNA level of any other voltage gated sodium channels subtypes, in either control or DS mice (FIG. 10).

**[0145]** Next, the effects of CAV-SCN1A on cognitive abilities were examined. It was found that CAV-SCN1A injections had no adverse effect on the performance of WT mice, with a tendency for improved performance of DS mice in the Y maze (FIG. 9F), as well as a trend for reduced hyperactivity in the open field (FIG. 11G). Together, in addition to the impact on epilepsy, CAV-SCN1A treatment positively affected non-epileptic DS features.

**[0146]** FIGS. 9A-B illustrate examples of background ECoG traces and power density profile of WT (A) and DS (B) mice. FIG. 9 C-E illustrate total power (C, 0.5-100 Hz), the power in the delta (D, 0.5-3.9 Hz) and theta bands (E, 4-8 Hz). Data for untreated mice are replotted from (Fadila et al., 2020). Statistical analysis in panels C-E utilized one way ANOVA (for WT or DS mice separately). WT: CAV-GFP (n=9); WT: CAV-SCN1A (n=10); DS: CAV-GFP (n=16);

DS: CAV-SCN1A (n=19). FIG. 9F illustrates spontaneous alternation in the Y maze. The dotted line signifies chance level, expected from random alternation. The markings above the bars indicate statistical analysis using one-sample t test relative to 50%. WT: CAV-GFP (n=19); WT: CAV-SCN1A (n=12); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=10). FIG. 9G illustrates the distance moved in the open field. Statistical analysis utilized one-way ANOVA: WT: CAV GFP (n=18); WT: CAV2-SCN1A (n=12); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=13). See FIG. 8, for separated analysis for males and females. \* p<0.05; \*\* p<0.01; \*\*\* p<0.001.

[0147] FIG. 10 illustrates the relative expression of voltage gated sodium channels. Hippocampi were isolated one month post treatment. For all samples, the expression was first normalized to the expression levels of 2 endogenous controls (Gusb and Tfrc) to calculate  $\Delta Ct$ , followed by normalization to expression in WT mice treated with CAV2-GFP (to calculate  $\Delta\Delta Ct$ ). WT: CAV-GFP n=13; WT: CAV-SCN1A n=8; DS: CAV-GFP n=9; DS: CAV-SCN1A n=9.

[0148] Total RNA was isolated using Purelink RNA mini kit according to the manufacturer's instructions (Thermo Fisher Scientific, Life Technologies, Carlsbad, CA, USA). cDNA was synthesized from 500 ng RNA using Maxima H Minus cDNA synthesis kit (Thermo Fisher Scientific, Life Technologies, Carlsbad, CA, USA). For quantitative real-time PCR (qPCR) reactions were performed in triplicates in a final volume of 10  $\mu$ l with 5 ng of RNA as template using TaqMan gene expression assay (Applied Biosystems, Thermo Fisher Scientific, Life Technologies, Carlsbad, CA, USA) on StepOnePlus® real-time PCR system (Applied Biosystems, Thermo Fisher Scientific, Life Technologies, Carlsbad, CA, USA). The following assays were used: Scn1a (Mm00450580\_m1), Scn2a (Mm01270359\_m1), Scn3a (Mm00658167\_m1), Scn8a (Mm00488110\_m1), Scn1b (Mm00441210\_m1), Scn2b (Mm01179204\_g1), Scn3b (Mm00463369\_m1) as well as Gusb (Mm00446953\_m1) and Tfrc (Mm00441941\_m1), as endogenous controls. Efficiency of 100%, dynamic range, and lack of genomic DNA amplification were verified for all the assays. The relative expression was calculated with  $2^{-\Delta Ct}$  method using the geometric mean of endogenous controls, and relative to the expression of WT mice injected with GFP.

#### Thalamic Delivery of CAV-SCN1A Revert Epileptic Phenotypes in Juvenile DS Mice

[0149] In addition to hippocampal dysfunction, thalamic dysfunction was shown to contribute to network hypersynchrony and DS epilepsy.

[0150] Therefore, it was tested whether thalamic injections of CAV-SCN1A also impact DS epilepsy in juvenile mice. Due to the relatively high afference to the thalamus, robust local and widespread transgene expression in WT and DS mice was found (FIG. 11). Again, CAV-SCN1A reduced the occurrence of premature mortality (FIG. 11A) and reduced the susceptibility to thermally-induced seizures (FIG. 11B). Furthermore, cortical ECoG recordings demonstrated that exogenous Nav1.1 activity reduced the frequency of epileptic spikes (FIG. 11 C, D) and corrected the power of background activity (FIG. 11E). The present disclosure demonstrates improvement of epileptic phenotypes and global brain oscillations following CAV SCN1A injection into the thalamus or the hippocampus of DS mice.

[0151] FIG. 11A illustrates the survival curve of WT and DS littermates injected with either CAV-GFP or CAV-SCN1A. WT: CAV-GFP (n=24); WT: CAV-SCN1A (n=31); DS: CAV-GFP (n=8=44); DS: CAV-SCN1A (n=25). FIG. 11B illustrates the percentage of mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP (n=28); DS: CAV-SCN1A (n=20). See FIG. 12 for separated analysis of males and females. FIG. 11 C-D illustrate data from two weeks after the treatments when cortical electrodes were implanted. Example traces (FIG. 11C) and quantification of the spike frequencies are depicted (FIG. 11D). FIG. 11E illustrates the total ECoG power (0.5-100 Hz) WT: CAV-GFP (n=11); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=14); DS: CAV-SCN1A (n=10).

[0152] FIGS. 12A-B show percent survival curve of male (A) and female (B) DS mice injected with either CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, male n=16, female n=28; DS: CAV-SCN1A, male n=15, female n=10. FIG. 12 C-D shows percent male (C) and female (D) DS mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP, male n=7, female n=14; DS: CAV-SCN1A, male n=11, female n=9.

[0153] Next, it was determined whether CAV-SCN1A injections into the thalamus and hippocampus could further enhance the therapeutic effect of exogenous Nav1.1 activity. Indeed, following these dual deposits along the needle track, DS mice treated with CAV-SCN1A demonstrated over 80% changes of survival (FIG. 13A) as well as notable protection from thermally-induced seizures, with only two mice that had thermal seizures out of 11 mice that were tested (FIG. 13B). Moreover, similar to the effect following hippocampal or thalamic administration, CAV-SCN1A reduced the number of epileptic spikes and increased the power of background ECoG.

#### Combined Thalamic and Hippocampal Injection of CAV-SCN1A in Juvenile Mice Protects from Thermally-Induced Seizures

[0154] Together, treatment of juvenile DS mice with CAV-SCN1A injections into hippocampus or the thalamus dramatically ameliorates their epileptic phenotypes. However, combined delivery provided greater protection from SUDEP and thermally-induced seizures.

[0155] FIG. 13 demonstrates that the combined thalamic and hippocampal injection of CAV-SCN1A into juvenile mice protects from thermally-induced seizures. FIG. 13A shows the survival of DS mice injected with either CAV-GFP or CAV-SCN1A. DS: CAV-GFP (n=28); DS: CAV-SCN1A (n=19). FIG. 13B shows the percentage of Mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP (n=5); DS: CAV-SCN1A (n=11). See FIG. 14 for separated analysis of males and females. FIG. 13 C-D illustrate data from two weeks after the treatments when cortical electrodes were implanted. Example traces (FIG. 13C) and quantification of the spike frequencies are depicted (FIG. 13D). FIG. 13E illustrates total ECoG power (0.5-100 Hz) WT: CAV-GFP (n=5); WT: CAV-SCN1A (n=4); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=10).

[0156] FIGS. 14A-B show the survival curve of male (A) and female (B) DS mice injected with either CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, male n=15, female n=14; DS: CAV-SCN1A, male n=9, female n=10. FIG. 14

C-D show the percent of male (C) and female (D) DS mice remaining free of thermally-induced seizures. The dotted lines represent median seizure temperature. DS: CAV-GFP, male n=4, female n=1; DS: CAV-SCN1A, male n=5, female n=6.

**[0157]** FIG. 15A illustrates that there were no statistical differences in the survival of DS mice following CAV-SCN1A injections into the hippocampus, the thalamus, or dual injections into both locations. The solid lines are the same data presented in FIGS. 7A, 11A, 13A, respectively, and the shaded areas depicts 95% confidence intervals. FIG. 15B illustrates that the injection of CAV-SCN1A into both the thalamus and hippocampus provides greater protection from thermally-induced seizures. The solid lines are the same data presented in FIGS. 7C, 11B, 13B, respectively, and the shaded areas depicts 95% confidence intervals.

Hippocampal Injection of CAV-NSE-SCN1A in Alzheimer's Mouse Models Reverts Mouse Behavior and Histopathological Markers to Near Wildtype Levels

**[0158]** FIG. 16A illustrates a design of a study in which two CAV-2 vectors, harbouring an mCitrine cassette or a codon-modified SCN1A ORF with fused HA tag, are bilaterally injected in the hippocampus of Alzheimer's mouse models (5XFAD and J20). 5XFAD mice carry a human amyloid precursor protein (APP) transgene and presenilin 1 transgenes, and develop plaques beginning at 2 months. J20 mice express the human APP695/751/770 containing the Swedish double mutations (K670N/M671L) at the  $\beta$ -secretase cleavage site and the V717F mutation at the  $\gamma$ -secretase cleavage site. The transgene is driven by a PDGF $\beta$  promoter. J20 mice develop plaque deposition and cognitive deficit at ~6 months. ITR: inverted terminal repeat.  $\psi$ : packaging signal. NSE (promoter): neuron-specific enolase. pA: polyadenylation signal.

**[0159]** In FIG. 16B, the vectors (~1 microlitre containing  $10^9$  vector particles) are injected into the hippocampus using stereotactic apparatus. Exogenous Nav1.1 is detected using immunohistology against the HA tag. Second and third columns are a higher magnification of, respectively, black & white frames of the first column.

**[0160]** FIG. 16C demonstrates the physiological effect of CAV-2 mediated exogenous Nav1.1 on working memory in the Y-maze test in 4 and 5-months-old J20 and 5XFAD mice. The Y Maze is a behavioural test measuring the willingness of rodents to explore new environments. Testing is in a Y-shaped maze with three arms at a 120° angle from each other. A mouse is allowed to freely explore the arms. Over the course of multiple entries, the mouse should show a tendency to enter a less recently visited arm. The Y Maze allows one to quantify cognitive deficits and evaluate novel entities for their effects on cognition. Many parts of the brain, in particular the hippocampus, are involved in this task.

**[0161]** FIG. 16D-E depict and demonstrate amyloid loads (white frames) as identified by Thioflavin S analyses, and quantification in the hippocampus and cortex of 9-month-old J20 mice injected with the two vectors.

## Discussion

**[0162]** DS is an intractable childhood epileptic encephalopathy, with a high mortality rate compared with other developmental epilepsies. SUDEP is the leading cause of

death, with most occurrences before the age of 10. Importantly, pharmacological seizure control in DS is notoriously difficult, despite polytherapy and recent advancements in therapeutic options. Therefore, there is an urgent need for novel treatments. In addition to the life-threatening epileptic phenotypes, individuals with DS suffer from non-epileptic comorbidities, including developmental delays, cognitive impairment, and hyperactivity. While these behavioral deficits greatly impact the quality of life of patients and families, the therapeutic toolbox for addressing these burdening issues is limited.

**[0163]** According to the present disclosure, CAV-mediated expression of Nav1.1, via a codon-modified SCN1A ORF significantly improved comorbidities in juvenile and adolescent DS mice, ameliorated the epileptic phenotypes, corrected background ECoG activity, and improved cognitive functions. Notably, the present disclosure relates to the only treatment method that is effective during the severe and chronic stages of DS.

**[0164]** C57BL/6J-Scn1a<sup>41783V/WT</sup> mice display severe epileptic phenotypes compared to other DS mouse models (Han et al., 2020; Niibori et al., 2020), which may render this model particularly resistant to treatment. Specifically, similarly to patients with DS, all the mice experience spontaneous seizures (FIG. 10) and thermally-induced seizures within the range of clinical febrile seizures. Furthermore, while the mortality of these mice is higher compared to the risk reported in patients (FIGS. 7, 11, 13), it should be noted that the mice do not receive any anti-seizure medications or emergency care with prolonged seizures. Thus, the present disclosure relates to a treatment method for severe epileptic phenotypes which faithfully represent the clinical severity of DS in humans and which treatment can be combinable with traditional anti-seizure medications to potentially achieve even greater therapeutic results. Moreover, in contrast to other models that harbor SCN1A truncation mutations, effective gene therapy treatment in this model should overcome the persistent membrane expression of the malfunctioning mutant SCN1A allele. The present disclosure demonstrates the therapeutic impact of CAV-SCN1A despite the challenges of this DS model and highlights the clinical potential of this treatment method and vector.

**[0165]** Notably, in contrast to previous efforts to provide gene-specific treatments for DS, which merely tested therapeutic effect when administered during the asymptomatic, pre-epileptic stage, or during the chronic phase, CAV-SCN1A has a demonstrated effect at multiple disease stages (FIGS. 4-13). At the severe stage of the disease, CAV-SCN1A improved survival, reduced the occurrence of spontaneous seizures, reduced the frequency of epileptic spikes and protected against thermally-induced seizures (FIGS. 7, 11, 13). At the chronic stage of the disease, as the frequency of spontaneous seizures and occurrence of SUDEP is low, amelioration of the epilepsy was demonstrated as reduced frequency of epileptic spikes and reduced sensitivity to thermally-induced seizures (FIG. 4). Moreover, as this treatment relies on vector-mediated SCN1A ORF delivery, rather than transcriptional activation of the one functional Nav1.1 copy, it should be suitable for patients with both truncation and missense mutations in SCN1A.

**[0166]** Complete cure of DS epilepsy is extremely challenging. Antisense oligonucleotide treatment to enhance SCN1A transcription, administered at P2, well within the asymptomatic period, prevented premature mortality but

spontaneous seizures were still observed. Moreover, when said treatment was given at P14, still in the midst of the pre-epileptic stage, full protection from death was also not achieved. Similarly, epileptic spikes and spontaneous seizures were still detected following neonate dCas9-based SCN1A activation, and premature death (despite improved survival) was still evident following viral mediated overexpression of voltage-gated sodium channels beta subunits. Likewise, abnormal epileptic activity still persisted when the treatments were administered during the chronic stage of the disease (FIG. 4).

**[0167]** Notably, CAV-SCN1A injections in the hippocampus or the thalamus, had similar effect on epilepsy (FIGS. 7, 11), implicating these areas in DS pathophysiology. Combined delivery into these two regions had similar protection from premature mortality (FIG. 15A), but greater protection from thermally-induced seizures (FIG. 15B). This is possibly due to larger biodistribution of the exogenous functional Nav1.1. Interestingly, distinct circuit-specific neuronal dysfunctions were described for each of these regions. Disinhibition was indicated as the culprit in the hippocampus. Conversely, complex neuronal changes were reported in the thalamus, with reduced activity of inhibitory and excitatory neurons, as well as hyperexcitability of inhibitory thalamic reticular nucleus neurons that led to augmented cortico-thalamic oscillations and seizures. Thus, despite the seemingly opposing local neuronal dysfunction, an unexpected and superior therapeutic effect of CAV-SCN1A was observed, which further highlights the efficacy and potential of this treatment.

**[0168]** One significant challenge for CNS-targeted gene delivery is the need to transduce enough neurons within a critical brain region, to trigger a global change in network function. The present disclosure further demonstrates the pivotal role of Nav1.1 expression within the injected sites and the widespread therapeutic effect of transfection with CAV vectors, and their retrograde expression capabilities, leading to widespread CNS gene expression. Despite only two injection sites, with CAV's unique properties, therapeutic effect is seen even with only a relatively small number of neurons transduced.

**[0169]** In one aspect, the present disclosure demonstrates the positive global effect triggered by restoring Nav1.1 expression within a tightly connected neuronal network that hubs at an injection site but includes multiple projecting neurons, mostly excitatory, from various additional brain regions (FIGS. 1, 2). This corrected Nav1.1 expressing neuronal ensemble can now prevent the generalization of epileptic activity, with additional corrective contribution to neuronal networks that are not directly transduced, accounting for the ability of this treatment to revert the epilepsy, correct background neuronal activity, and positively influence cognitive abilities. Furthermore, it can also account for the wide time-window for therapeutic intervention, and the ability to revert the symptoms even in adolescent mice. In some aspects, the present disclosure further illustrates that disruption of the activity of single neurons within a connected hub can disrupt epileptic network dynamics, indicating that transducing all the neurons may not be needed for effective therapy.

**[0170]** According to certain embodiments, the present disclosure relates to CAV-mediated SCN1A delivery as a therapeutic approach for children and adolescent individuals with DS-associated SCN1A missense and truncation muta-

tions. The disclosure relates to a vector for the reversion of DS or conditions thereof. In certain embodiments, the vector comprises a first nucleic acid sequence encoding parts of a CAV-2 genome and a second nucleic acid sequence encoding a functional Nav1.1 sodium channel.

**[0171]** In certain embodiments, the viral vector can also comprise a first regulatory sequence encoding a transcriptional control region. The transcriptional control region can optionally include a promoter and/or enhancer region for transcriptional control. In certain embodiments, the promoter region comprises a promoter sequence encoding at least one promoter selected from the group consisting of CAG, hSyn, NSE, and Dlx5/6. In certain embodiments, the second nucleic acid sequence is operably linked to the first regulatory sequence for expression of the functional Nav1.1 sodium channel in mammalian cells. In certain embodiments, the first regulatory sequence is controllable to drive positive expression of the Nav1.1 sodium channel. The present disclosure relates to a viral vector that is configured for transcriptional regulation and which can drive positive regulation and/or negative regulation of expression of exogenous functional Nav1.1 sodium channel.

**[0172]** According to certain embodiments, the second nucleic acid sequence is an engineered SCN1A ORF created by eliminating at least one short repeat sequence from native SCN1A. In some embodiments, the second nucleic acid sequence is created by eliminating at least one short repeat sequence encoding a transmembrane section of the functional Nav1.1 sodium channel. This disclosure relates to an engineered CAV-2 SCN1A vector wherein regions of the vector have been engineered, such as through deletion of short repeat sequences, to prevent SCN1A rearrangement when subcloned into a plasmid and propagated.

**[0173]** The disclosure also relates to a method of promoting reversion of DS diseases or conditions thereof, comprising administering to a mammal a therapeutically effective amount of the CAV-2 SCN1A viral vector. The method results in a vector-induced change in the balance of neural network activity. The mammal preferably includes humans as well as other species suitable for treatment and/or scientific research such as mice, rats, pigs, monkeys, or other suitable mammals. In certain embodiments, the viral vector is administered into a central nervous system of the mammal. It is also envisioned that the viral vector can be administered into at least one brain region. In some embodiments, the at least one brain region can be selected from the group consisting of hippocampus and thalamus. However, the disclosure is not intended to be limited, and it is envisioned that the vector can be effectively administered to other regions of the brain or CNS as well to promote positive clinical outcomes. It is a feature of the disclosure that the viral vector can be administered prior to development of a chronic form of DS disease or conditions thereof, thereby preventing premature death and promoting reversion of DS and symptoms thereof.

**[0174]** The present disclosure relates to a CAV-2 SCN1A vector which can be administered to children or adolescent humans with a DS-associated missense or truncation mutation in a SCN1A gene. In certain embodiments, after administration of the viral vector, the mammals are monitored for seizure reduction, and if desired clinical results are not obtained, a second therapeutically effective amount of the vector can be administered. Desirable clinical results are seen, for example, by way of corrected expression of Nav1.



1, DS reversion, seizure reduction, as well as improvements in the non-epileptic phenotypes of DS including cognitive deficit and hyperactivity. In one aspect of this disclosure, the method can include the co-administration of a therapeutically effective amount of anti-seizure medication.

**[0175]** The disclosure also relates to a composition for corrected expression of Nav1.1 and conditions thereof, such as, by way of example and so as not to limit the scope, DS, epilepsy, or Alzheimer's. In certain embodiments, the composition includes a viral vector for the treatment of pathological conditions of SCN1A mutation and Nav1.1 sodium channel miscoding, the viral vector comprising a first nucleic acid sequence encoding a CAV-2 vector and a second nucleic acid sequence encoding a functional Nav1.1 sodium channel. In certain embodiments, the viral vector optionally includes a first regulatory sequence, the second nucleic acid sequence operably linked to the first regulatory sequence for controlled expression of the Nav1.1 sodium channel in mammalian cells. In certain embodiments, the first regulatory sequence optionally includes a promoter region comprising a promoter sequence encoding one of the aforementioned promoters, such as NSE. It is envisioned that other promoters and/or enhancers may be used, for example, promoters and/or enhancers which are suitable for preferential expression of SCN1A within neurons.

**[0176]** In certain embodiments, the disclosure relates to a vector for the compensation of loss of function of endogenous Nav1.1 and treatment of pathological conditions associated with SCN1A mutation and Nav1.1 sodium channel miscoding. In some embodiments, the vector comprises a first nucleic acid sequence encoding at least one portion of a CAV-2 genome; a second nucleic acid sequence encoding a functional Nav1.1 sodium channel; a first regulatory sequence encoding a transcriptional control region, the transcriptional control region comprising a promoter or enhancer or elongation factor sequence encoding at least one promoter/enhancer/elongation factor selected from the group consisting of E2, E6, EF1, CAG, hSyn, Dlx5/6, and NSE, and preferentially, NSE; wherein the second nucleic acid sequence is operably linked to the first regulatory sequence for controlled transcriptional expression of an SCN1A open reading frame (ORF) in mammalian cells.

**[0177]** In certain embodiments, the vector can be designed such that the second nucleic acid sequence is an engineered SCN1A ORF; and wherein the engineered SCN1A ORF is created by eliminating at least one short repeat sequence from a codon-modified SCN1A ORF. In some embodiments, the second nucleic acid sequence is a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% homology with nucleic acid sequences selected from group consisting of Sequence ID Number 12 and Sequence ID Number 14. In other embodiments, the second nucleic acid sequence is a sequence encoding for a protein having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% homology with amino acid sequences selected from group consisting of Sequence ID Number 15 and Sequence ID Number 16.

**[0178]** In other embodiments, the vector can be designed such that the second nucleic acid sequence is created by eliminating at least one short repeat sequence in an ORF encoding a transmembrane section of the functional Nav1.1 sodium channel.

**[0179]** In more embodiments, the vector is therapeutically active in children or adolescent individuals with misexpres-

sion of the gene encoding Nav1.1, such as in the case of Dravet Syndrome-associated SCN1A missense or truncation mutations, as well as in other pathological conditions such as epilepsy or Alzheimer's.

**[0180]** In certain embodiments, the vector can be optimized for preferential expression of SCN1A ORF in neurons and/or configured for transcriptional regulation. In certain embodiments the SCN1A ORF encodes amino acid SEQ ID NOS 15 and 16, which encode WT and Synthetic Nav1.1 proteins, respectively, lacking the short amino acid sequence VIIDKPATDDN. These amino acid sequences are typically expressed in the brain, whereas, for example, SEQ ID NOS 12 and 14 encode genetic sequences for the expression of somatic Nav1.1.

**[0181]** The disclosure further relates to a method of compensating for the loss of function of Nav1.1 and treatment of pathological conditions associated with SCN1A mutation and Nav1.1 sodium channel miscoding, including administering a therapeutically effective amount of a vector to a mammal. In some embodiments, the vector can be administered into a central nervous system of the mammal, or into at least one brain region. In certain embodiments, the vector can be administered into at least one brain region selected from the group consisting of hippocampus and thalamus. In other embodiments, the vector can be administered prior to development of a chronic form of Dravet Syndrome disease or comorbidities thereof. In certain embodiments, the vector can be administered to treat a chronic form of Dravet Syndrome disease or comorbidities thereof.

**[0182]** In certain embodiments, after administration of the vector, the method further includes inducing expression of the functional Nav1.1 sodium channel. In other embodiments, the vector can be administered to children, adolescent, adult, or elderly mammals with a missense or truncation mutation in an SCN1A gene. In certain embodiments, after administration of the vector, the method further includes monitoring the mammal for desired clinical results, such as amelioration or improvement in pathological conditions—such as DS, epilepsy, Alzheimer's and other Nav1.1 associated pathological disorders—and if the desired clinical results are not obtained, administering a second therapeutically effective amount of the vector until therapeutic results are obtained.

**[0183]** In some embodiments, the vector is deposited at the injection site, and the vector can be delivered to the injection site and multiple sites that contain projecting neurons from various brain regions. In some embodiments, the treatment method further includes administering a therapeutically effective amount of anti-seizure, epilepsy, or Alzheimer medication.

**[0184]** In some embodiments, the therapeutically effective amount of the vector can be administered for the treatment of a pathological condition selected from the group consisting of Dravet Syndrome, Epilepsy, and Alzheimer's. Additionally, this method could be beneficial in cases where modifying the brain neuronal network reduces disease symptoms (e.g., Autism Spectrum Disorder (ASD)).

**[0185]** The disclosure further relates to a composition the compensation of loss of function of Nav1.1 and the treatment of SCN1A mutation and Nav1.1 sodium channel miscoding, the composition including a viral vector, the vector comprising a first nucleic acid sequence encoding at least one portion of a CAV-2 genome and a second nucleic acid sequence encoding a functional Nav1.1 sodium chan-

nel; wherein the vector optionally includes a first regulatory sequence, the second nucleic acid sequence operably linked to the first regulatory sequence for controlled transcriptional expression of an SCN1A ORF in mammalian cells; and wherein the first regulatory sequence includes a transcriptional control region comprising a promoter/enhancer/elongation factor sequence encoding at least one promoter/enhancer/elongation factor selected from the group consisting of E2, E6, EF1, CAG, hSyn, Dlx5/6, and NSE, and preferably, NSE.

## Methods

### Vectors Generation

**[0186]** All CAV-2 vectors used in this work were generated using a seamless ligation cloning extract (SLICE) strategy (Zhang et al., 2012). The following promoters were obtained from Addgene: the NSE promoter (plasmid #50958 James Bamberg, (Mi et al., 2013)); the CAG promoter (plasmid #51274, Pawel Pelczar, (Hermann et al., 2014)); hSyn promoter (plasmid #22909, Edward Callaway, (Nathanson et al., 2009)); the Dlx5/6 enhancer (plasmid #83900, Gordon Fishell, (Dimidschstein et al., 2016)) Citrine, SCN1A cDNA (Mora-Jimenez et al., 2021) and the bovine growth hormone polyA sequence. Fragments were subcloned into the E1 region of E1/E3-deleted pCAV-2. Then, vectors were expanded and purified as previously described (Ibanes and Kremer, 2013; Kremer et al., 2000).

### Animals

**[0187]** All animal experiments were approved by the institutional care and use committee of Tel Aviv University and CNRS. WT and DS mice harboring the global *Scn1a*A1783V mutation were generated by crossing conditional *Scn1a*A1783V males (The Jackson Laboratory; stock #0216133) with CMV-Cre females (stock #006054). Mice were housed in a standard animal facility at the Glöschle Eye institute at a constant temperature of 22° C., on a 12-hour light/dark cycle, with ad libitum access to food and water.

### IH

**[0188]** It is worthwhile repeating that CAV-2-mediated gene transfer is linked to CAR expression pattern on neurons (Soudais et al., 2000; Zussy et al., 2016). As the levels of CAR changes during development and in inflammatory diseases like Alzheimer's, it was possible that CAV-2 vector efficacy differs in adolescent and juvenile healthy or DS mice. Therefore CAV-GFP was injected into juvenile healthy and DS mice and transgene expression was examined. In DS mice, similar robust transgene expression at the site of injection and in afferent regions (hippocampus, neocortex, striatum, internal capsule, and thalamus) was found.

### Viral Injections

**[0189]** WT and DS mice at the age of P21-P24, or P35-P36 were randomly assigned to treatment with CAV-2-NSE-GFP (CAV-GFP) or CAV-2-NSE-SCN1A (CAV-2-SCN1A). The mice were anesthetized using ketamine/xylazine (191/4.25 mg/kg), Carprofen (5 mg/kg) was used for analgesia. The mice were placed in a stereotaxic device (Ultra Precise Stereotaxic Instruments, Stoelting, Wood Dale, IL, USA). A midline incision was made above the skull and holes were

made using a 25 G needle in the place of injection. For hippocampal injections we used the following coordinates: anterior/posterior (AP): -1.8; medial/lateral (ML):  $\pm 1.7$ ; dorsal/ventral (DV): -3 for P21-24 and AP: -1.7; ML:  $\pm 1.8$ ; DV: -3 for P35-36. For thalamic injections at P21-P24 we use the following coordinates: AP: -1.4; ML:  $\pm 2.2$  DV: -3.5. 1  $\mu$ l containing  $1 \times 10^9$  vp was injected on each side, using a 1  $\mu$ l beveled needle Hamilton syringe (1  $\mu$ l syringe, 7000 series, beveled tip; For dual thalamic-hippocampal injections the injection needle was lowered to: ML:  $\pm 1.8$ ; PL:  $\pm 1.8$ ; DV: -3.5, injected with 0.5  $\mu$ l, following a few min, the injection needle was raised to DV: 3, and injected with 0.5  $\mu$ l. The AP coordinates were slightly modified for P21 mice in which the distance between bregma and lambda was less than 3 mm, and reduced to AP: -1.7.

**[0190]** The DV coordination was measured from the tip of the beveled injection needle) at a rate of 100 nL/min (Quintessential Stereotaxic Injector, Stoelting, Wood Dale, IL, USA). After injection, the syringe was kept in place for at least 5 minutes to prevent backflow before it was slowly retracted. The skin was then closed with sutures and the mice were isolated for a period of 7 days according to TAU BSL-2 safety instructions.

### ECoG and Depth Electrode and Recordings

**[0191]** One week following viral injection, cortical or depth electrodes were implanted as previously described (Fadila et al., 2020). Briefly, a midline incision was made above the skull, and fine silver wire electrodes (130 mm diameter bare; 180 mm diameter coated) were implanted. We used the previously formed injection holes for ECoG or depth electrodes for hippocampal depth recordings, the wire electrodes were lowered using the same stereotactic coordinates used for injection. A reference electrode was placed on the cerebellum; and a ground electrode was placed subsequently behind the neck. The electrodes were connected to milmax-connector, secured with dental cement, the skin was closed with sutures. The mice were given at least two days to recover before recording.

**[0192]** Video-depth/EcoG recordings lasted 2-4 hours, during the light period, were obtained from freely moving mice, connected to a T8 Headstage (Triangle BioSystems, Durham, NC, USA), using a PowerLab 8/35 acquisition hardware and the LabChart 8 software (ADInstruments, Sydney, Australia). The electrical signals were recorded and digitized at a sampling rate of 1 KHz with a notch filter at 50 Hz. The analysis was performed using LabChart 8 (ADInstruments, Sydney, Australia). The ECoG signal was processed offline with a 0.5-100 Hz bandpass filter. Power spectral density was calculated using fast Fourier transform, with Hann (cosine-bell) data window set to 50% overlap. For each mouse, five to eight 30 s long segments of the wakefulness, immobile and epileptic-free, but following a movement as determined by the video recording, were averaged.

### Thermally-Induced Seizures

**[0193]** Thermal induction was done as described before (Almog et al., 2021) one-month post-injection. Briefly, the mice were given 10 minutes to habituate to the thermal probe and the recording chamber. The baseline body tem-

perature was measured, followed by an increase of 0.5° C. every 2 minutes until 40.5° C. or until a seizure was generated.

Behavioral Experiments

[0194] Behavioral experiments were performed as described before (Fadila et al., 2020). Spontaneous alternation in the Y maze was performed 5-14 days post-injection and the open field test was performed 9-17 days. Briefly, for the Y-Maze spontaneous alternation test the mice were placed in a symmetrical Y-maze comprised of three opaque white Plexiglas arms (each 35 cm L×7.6 cm W×20 cm H) and allowed free exploration for 10 min. For the Open-field test, mice were placed in the center of a square (50×50 cm) Plexiglas apparatus and their activity over was recorded for 10 min. Live tracking was achieved via a monochrome camera (Basler acA1300-60 gm, Basler AG, Ahren, Germany) connected with Etho Vision XT 13 software (Noldus Technology, Wageningen, Netherlands).

SEQUENCE LISTING

Sequence ID Number	Sequence Name	Sequence Type
1	BGHpA (Bovine Growth Hormone polyAdenylation)	DNA
2	CAG Promoter	DNA
3	CAV2	DNA
4	CMV Promoter	DNA
5	E2 Enhancer	DNA
6	E6 Enhancer	DNA
7	EF1a Promoter	DNA
8	hSyn Promoter	DNA
9	mDlx Enhancer	DNA
10	NSEr Promoter	DNA
11	WT SCN1A Somatic	AA
12	WT SCN1A	DNA
13	xSCN1A from GeneScript™ Somatic	AA
14	xSCN1A from GeneScript	DNA
15	WT SCN1A Brain	AA
16	xSCN1A from GeneScript™ Brain	AA

Definitions

[0195] As used herein, the singular forms “a”, “an”, and “the” include plural references unless indicated otherwise. For example, “a” component in a composition includes one or more components.

[0196] “Polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications

such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports. The 5' and 3' terminal OH can be phosphorylated or substituted with amines or organic capping groups moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-O-methyl-2'-O-allyl, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs,  $\alpha$ -anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S (“thioate”), P(S)S (“dithioate”), “(O)NR 2 (“amidate”), P(O)R, P(O)OR', CO or CH 2 (“formacetal”), in which each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (—O—) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

[0197] “Treatment” can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of disease progression, including slowing down and complete arrest; (2) reduction in the number of disease episodes and/or symptoms; (3) reduction in comorbidity episodes and/or symptoms; (4) inhibition (i.e., reduction, slowing down or complete stopping) of disease and/or comorbidity symptom progression; (5) inhibition (i.e., reduction, slowing down or complete stopping) of comorbidity progression; (6) relief, to some extent, of one or more symptoms associated with a disorder or with comorbidities thereof; (7) increase in the length of disease-free presentation following treatment; (8) decreased mortality at a given point of time following treatment; and/or (9) lack of adverse effects following treatment. Treatment can also be assessed using any endpoint indicating side effect and/or toxicity to the patient.

[0198] “Treating” or “treatment” or “alleviation” refers to therapeutic treatment wherein the object is to slow down (lessen) if not cure the targeted pathologic condition or disorder or prevent recurrence of the condition. A subject is successfully “treated” if, after receiving a therapeutic amount of a therapeutic agent, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of the particular disease or comorbid-

ties thereof. Reduction of the signs or symptoms of a disease or comorbidities may also be felt by the patient. Treatment can achieve a complete response, defined as disappearance of all signs a pathological condition, or a partial response, wherein the symptoms or presence of a pathological condition is reduced, preferably by more than 50 percent, more preferably by 75%. A patient is also considered treated if the patient experiences stable disease. In some embodiments, treatment with a therapeutic agent is effective to result in the patients being disease-free 3 months after treatment, pref-

erably 6 months, more preferably one year, even more preferably 2 or more years post treatment. These parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician of appropriate skill in the art.

**[0199]** It is understood that aspects and embodiments of the invention described herein include “comprising”, “consisting”, and/or “consisting essentially of” aspects and embodiments.

---

#### SEQUENCE LISTING

Sequence total quantity: 16

SEQ ID NO: 1                      moltype = DNA   length = 228  
 FEATURE                              Location/Qualifiers  
 source                                  1..228  
    mol\_type = other DNA  
    organism = synthetic construct

SEQUENCE: 1

cgactgtgcc	ttctagtgtgc	cagccatctg	ttgtttgccc	ctccccctg	ccttccttga	60
ccctggaagg	tgccactccc	actgtccctt	cctaataaaa	tgaggaaatt	gcactgcatt	120
gtctgagtag	gtgtcattct	attctggggg	gtgggggtgg	gcaggacagc	aagggggagg	180
attgggaaga	caatagcagg	catgctgggg	atgcggtggg	ctctatgg		228

SEQ ID NO: 2                      moltype = DNA   length = 529  
 FEATURE                              Location/Qualifiers  
 source                                  1..529  
    mol\_type = other DNA  
    organism = synthetic construct

SEQUENCE: 2

gcgttacata	acttacggta	aatggcccg	ctggctgacc	gcccacgac	ccccgcccat	60
tgacgtcaat	aatgacgtat	gttcccatag	taacgccaat	agggacttct	cattgacgtc	120
aatgggtgga	gtatttacgg	taaactgccc	acttggcagt	acatcaagt	tatcatatgc	180
caagtacgcc	ccctattgac	gtcaatgacg	gtaaatggcc	cgcttgccat	tatgccaggt	240
acatgacctt	atgggacttt	cctacttggc	agtagaccta	cgtattagtc	atcgctatta	300
ccatggtcga	ggtagacccc	acgttctgct	tcactctccc	catctcccc	ccctccccac	360
ccccaatttt	gtatttattt	attttttaat	tattttgtgc	agcagtgggg	gcggggcgag	420
gcggagaggt	gcggcgccag	ccaatcagag	cggcgcgctc	cgaaagtttc	cttttatggc	480
gaggcgccgg	cggcgcgccc	cctataaaaa	gcgaagcgcg	cggcggcg		529

SEQ ID NO: 3                      moltype = DNA   length = 27488  
 FEATURE                              Location/Qualifiers  
 source                                  1..27488  
    mol\_type = other DNA  
    organism = synthetic construct

SEQUENCE: 3

catcatcaat	aatatacagg	acaaagaggt	gtggccttaa	tttgggtgtt	gcaagggg	60
gggtcatggg	acgggtcaggt	tcaggtcacg	ccctggtcag	ggtgttccca	cgggaatgtc	120
cagtgacgtc	aaaggcgtgg	ttttacgaca	gggcgagttc	cgcggacttt	tggccggcgc	180
cccgggtttt	tgggctgtta	ttgattttgc	ggtttagcgg	gtgggtgctt	taccactgtt	240
tgcggaagat	ttagtgtgtt	atggagctgg	ttttggtgcc	agttccctcc	cggctaattg	300
caaagtattat	gtcaatataa	cagaaacact	ctgttctctg	tttacagcac	cccacctagt	360
cgactaaaaa	acctcccaca	cctccccctg	aacctgaaac	ataaaatgaa	tgcaattgcg	420
cgattttaat	cgcgcgccgg	gtacctactt	tgtcaatgtg	tgtaattgca	gcccccgagg	480
gggttgtgca	gagaatttat	ttgtttggtg	tgtatgatgc	tacttgtgac	attatgcaac	540
tgggcgaggg	aggcaatgct	gctagtgaag	gactgtgtac	ttgcgggttc	agacacagca	600
ccccttccct	gcgggcccac	tatgttaactg	acaccaggat	tgaccgggag	ctgaactctc	660
aagacacggc	tgagttcttt	agcagtgatg	aagataatgt	ttaggtgagt	agatggggcg	720
gggttggggg	agtataaaa	gggcgcggta	cgtggctgtg	tatttacagc	catggaccct	780
caacagaagg	ggcttgtgaa	cacgtgtttt	gtgactacgc	gtattccgct	ttgggcaggga	840
gcaagacaga	atgtccaccg	gtcagattta	gaaggaaagc	ccgtgccctc	agatgtgctg	900
gaaagtggag	gcccgtctgc	agcccccgcc	atcagaacct	tgtatgagga	gcagcagctg	960
aacatgcttg	cggtgaatgt	tccttttgat	gagctgaaga	tccaggtggc	tgccatgcaa	1020
aactctgtga	ctgctattca	gcgagaagta	aatgatctaa	agcaacgaat	cgcccagatg	1080
taattgtaaaa	ataaaattta	tttctttttt	gaatgataat	accgtgtcca	gcgttgtctg	1140
tctgtaaatg	ttctatcaat	tccttccatg	gcttgggtaca	ctttagcttg	aatgttaagg	1200
tacatgggga	tgagtccttc	gtcggggctc	aagtacagcc	agtcataaca	attgtcaatg	1260
ggctcagtat	tgtatacaat	ccaatcaaa	ttagtattga	ggcgggtgta	gttaaaaaata	1320
tccttaagca	ggagggaagt	agcagtggtg	tgtcccttag	tgtagatgtt	aataaaccta	1380
ttaagtggg	aaggatgcac	cttaggactg	atgatatgca	tttttgcttg	gattttttaag	1440
ttggcaatgt	ttccccctcg	gtctcgtctg	ggattcatgt	tgtgcaagac	cactataaca	1500
gagtagcctg	tgcacttggg	aaacctgtct	agcagtttag	agggaaaggc	gtgaagaagc	1560
ttggctatgc	ccctgttgcc	ccctaagtct	tccatgcact	catccattac	aatagctagt	1620
ggccctttag	aagcggccct	tgcaaaaaa	ttggtagggt	tggttaacatc	atagttggcc	1680

-continued

tcattggtga	gtttctgcata	agacatttgc	acaaacttgg	gcatgatgct	gccactctga	1740
ggaaccacag	tgttttcggg	gectgcaagg	aagtttccct	cacatatttg	ggtttcccat	1800
gctgcaattt	cctggggagg	aatcatgtcc	acctgggggg	tgataaaaaa	gactgtttct	1860
ggggcgggga	ctataagctg	ggcagacatg	aggttcctaa	gaagctggga	cttgccacac	1920
cctgtgggac	catacactgc	agcaataaag	ggttgcttgt	agtagttaag	ggatgcacag	1980
cttccatctt	tattaaaggta	cttactgacc	ttcatgcaac	actgggttat	gctatcttga	2040
atatctagta	ggtcatttaa	agactgtctc	cccccatag	aaagcagttc	ctcaaaagag	2100
gcaaaagttt	tgaggggctt	aagtcctctc	gcataatggc	tgtttggtta	gctttgtctg	2160
agagtttgca	acctgtccca	gaggtctttt	aagtcaccca	ctgcagctcc	atccaggtag	2220
tttctgtgtt	ttttgggttt	ggatgcttgc	ggctgtatgg	aatgagacga	tgcatgtcta	2280
gagcatgcag	gtttttgttc	ttccatggcc	tcagcttcc	tgtaggggtg	gtttctgtca	2340
ctgtgaaagg	ttgcacgtgg	gectgcacgc	tggtgagggt	cctgcgcagg	ctcatcctgc	2400
tggttttgaa	gacgtccgag	cctgtctgca	tgtcagcata	gtagcaagct	tttagcacat	2460
cataaagagag	ggtaggggtg	gcataacctt	tggtccctgag	cttgcccttg	cccactgtat	2520
ggcacttagg	gcagggtggg	tccttgagag	catacaacct	ggggcgccagg	tacactgatt	2580
ctgagctgta	agcatccgat	ccacacttct	cacactgtgt	ttcacactct	actagccaag	2640
tgagctctgg	gttgctggga	tcaaaagacta	gcttgccctc	attttttttg	agtcgtttct	2700
tacctttttc	ttccatcaat	ttgtaaccct	ccatgggtgt	gaagaggctg	tcagtgtctc	2760
cgtagacaga	ttttaggacc	ctgttttcaa	gtgggtgtcc	cgcgtcgttt	tcgtagagaa	2820
actgagacca	ctctgagaca	aatgcccggtg	tcctatgctag	aacaaaggag	gcaattttgt	2880
agggatatct	gttattggct	attagggggg	tggtcttttc	taaagtgtgt	aaacaaaagt	2940
catcatcttc	agcatcaata	aacatgattg	gcttataatg	gtatgacgtc	atgctaaaat	3000
tatgcataaa	aggcgcttcg	gcgagggggg	cttttagttgg	atcttctctg	ctgcaagaag	3060
gcggtgccaa	ctggcgaaag	tcagaattga	caggtgggta	cgctacgaca	aattctggca	3120
tgatttctgc	acacaaattg	tctgtttcta	tgtatgagga	tgatttgact	acataggcac	3180
cagaagcaat	ttcttttagca	atgtttgact	ctatttgatc	tgaaaaaact	gtttttttgt	3240
tgtctagctt	ggtagcaaaa	gacccataga	gggcatttga	cagcagctta	gcaatgctgc	3300
gcaggttttg	atttttgctt	ttgtctgctt	cttctttggc	actgatgttg	agctgcacat	3360
actctctggc	gagacatttc	cactctgtaa	acacgggtgt	tctgggtatc	gggatgaggg	3420
taaccttcca	cccgcggttg	tgagggttaa	taacatctat	ggaggttgca	atctccccgc	3480
gtaggggctc	gttggtccag	caagccctgc	cccccttgcg	tgagcaaaat	gggggcagca	3540
cgtccaaaaa	ctctctctgt	gggtgggtcag	catcaatggg	gaagatgcc	ggaagaagg	3600
ccttatcaaa	gtagcttaata	gttttgatgt	ttagcatttt	ttgctcataa	gcctttatgg	3660
ccagcgcccg	ctcatagggt	tttagcggtg	aaccggcggtg	aaaagggtgt	gtaagggcac	3720
ttgcatacat	gccacatatt	tcatagacaa	acactggctc	ttgcaacact	ccaatgtaag	3780
tggttgtagca	cctgcctcct	ctgatgctaa	gccttacata	ctcacacatt	tcattggagg	3840
gcgcacatgag	gatggtactt	aggtggtgtg	tgtaggctt	ttctgcttta	tacaagattt	3900
gtttaaaaat	ggcatgggag	ttggagctga	tggttggtacg	ctggaagacg	ttaaaggagg	3960
tttcaggtaa	gtttacagag	tttttaatga	agatttggtta	ggattctata	agtttgttta	4020
ccaaactgggc	ggttactttg	acgtcgagtg	cgcagtaatt	caagggtttg	ctgaattatg	4080
tcgtaagcgc	cttttttttc	ttttatccaa	aggcttttgt	taaaaggagt	ctcctcctga	4140
tccttcacgt	actttaagtc	cggaaagcca	tcggcgctct	gttggttaaga	gccaagcatg	4200
taaaactcat	tcacagcctg	tgaggagacg	cagccttttg	aaacgggttag	gctgtatgct	4260
ttggcagcat	ttttgaggtc	tggtgtgtgt	aaagagaaag	tgctacgcac	cataaaatct	4320
atgtactggc	ttttcaagtc	agacggcagt	acttgccctc	gctcccagtg	ctcgtaactc	4380
ttggcaggca	cgtagctggg	gttaggcaga	gagtaagtaa	tatcattgaa	cagcaacctt	4440
ccagcccgcg	gcctgaagtt	gcggcacaat	tcaaacacgg	gtggtatttc	tgcccgcgtg	4500
ctaacacctc	gagctgctag	caatatctca	tcaaaccccg	tgatgtgtgt	ttccactgca	4560
tacacctcaa	taaatcttgg	gtttcctttg	agcttgaaat	tttttaactg	atctggagta	4620
agctcttcag	ggctttctag	ttccaaagta	gtggtttttt	cttgaagctg	gggatttttg	4680
caaatcacgt	gggaccagag	gctggcggtc	atatgctgct	gcaagggtgc	tctgaacttt	4740
ttgaatttaa	ctctatggc	tcctttttct	ggagtgtatg	aatagtacag	agtgtcctgc	4800
tcctttaccat	tcacaaatttc	ccagttttgc	tctgttgcaa	gagttttggc	aacattgacc	4860
aggtggtcgt	ccccagcag	ttggaaaaact	agcataaatg	gcacaagtgt	ctttccaaac	4920
ttgcggtgcc	acgtgtacgt	ttccacatca	tatacaataa	acagcctttc	tggtgtgggc	4980
ggggccccaa	tggtgggtgaa	agatatattt	tcaccacagt	ctgcgctgtg	tgccggccacg	5040
tgatgggaag	aaaagtcctg	tcctctgagg	gcgcagggtg	gagtaacttt	aaaaaaagag	5100
ccgcagaact	cacacttttg	catttgagag	atgtctttta	ttaagaagac	tttaccttgc	5160
ttactaaaaa	acttgagtgg	gaagctgagc	agcggaacct	ccgcttgaaa	ctctaccctc	5220
ctcactgttc	ctcgtctggt	gtagcaaat	agactgtagg	gtgccgcggc	ctcctctatg	5280
agggcgggca	gggtgtgggc	agtgtggggc	ctgtttaagc	atgcgggttag	gtcatagagg	5340
ttagtgttgc	aaagggttagt	aagcgcgctg	gccaaagtgg	agtgtacttt	aattttccaca	5400
caactgtccat	tatccaacac	ggcggaatag	cttagtgttg	cgcgctggag	cactacggcg	5460
ccctgtgact	tgcgcttggg	tggttttact	atggtggaag	ttgcacctgc	tcgtggtgag	5520
ctggcaaaag	cctgtgctgc	atcctgagct	gggaggctag	ggccactact	ctcctgttga	5580
ttgattggat	ttggcggttc	tgtgaaaaga	ccactgggtc	cgtgaccttg	aacctaaaag	5640
aaagtcccat	agagtcaacc	tcgtgatcat	taatggccac	ttgtctgaga	atttcgctca	5700
cgtccccgct	gttttcatga	taagcaatat	ctgcataaaa	ctgctccatt	tcctcctcct	5760
ctagctcccc	tagcccagcc	ctttctacgg	tgccagccag	gtctcccgac	acgggggcca	5820
taacctggct	aaaggcattt	tcctccattt	cattccacac	ccgactgtag	accacctgcc	5880
cctcgtggtc	ctagccctgc	atgaccactt	gagctagctc	taggtcaacc	cagcggggagc	5940
aggggtggga	cagcctaagg	ttgtggtgca	ggtagttagg	gggtggtggc	acgtgctcag	6000
ctacaaaaaa	atacatgacc	caacggcgga	tggtgagctc	attaatgttg	cccagcattt	6060
ccaggcgctg	aatgacctca	taaaagtcaa	ctgcaaaagt	aaaaaactgt	tcattgcgag	6120
cagacactgt	gagttcctct	tgacggaggc	ggatagcttc	tactatagtg	tctcggaact	6180
cttcttcaaa	ggaacggcga	ggagggggagg	caggaggagg	aggagaggcc	tctgcttcgg	6240

-continued

gctcagacag	ctctcagac	accggaggcg	gcgggggagc	cctgcgtctg	cgccctgcga	6300
ctggaagcct	gtctataaac	ctttctatca	cctctocccg	cctgcgcctc	atttccctctg	6360
taactgcacg	tccattttcc	ctgggcctaa	gctcgaaggc	tccccagag	agcgggggtgc	6420
agggcgcggg	tctgggcagg	ctcaggggcg	taattatgct	ttttgttaca	gatggctgg	6480
gtaaagactg	aattgtttga	aactgtgaca	gctccggatc	agtgaatttt	tccacaaagg	6540
catcaagcca	caacaatca	caaggtaagc	ttagcatggt	gtgcgggttg	cgggggctaa	6600
ctaaaaagtt	gaaaaaagct	gtcttaagct	tacggatggt	gggtagaata	actaggtctt	6660
tgttgcccgc	ctgctgggatg	cgcatgcggt	ctgccagtc	ccatgcttcg	ttttgacact	6720
gggacaggtt	tttgtaatgg	tcttgcaaga	gccccctctac	gggcaacctgc	ctgtcgcctg	6780
ccatgttggt	ggtgccatag	ccctaagtg	gcctaataag	ggccaaatcg	gccactacgc	6840
gctctgccag	gaccgcttgc	tgaaacctgc	ccagggtctc	tgcaaaagttt	tcaaaagtcaa	6900
tgaacctgtg	gtaagctcca	gtgttaatgg	tgtatgagca	gttgccatc	accgtccagt	6960
ttagtttttg	ctgcaagggc	aggtgtatct	ctgtgtactt	tagcctgctg	taggacctgg	7020
tgtcaaaagc	gtagtcatgt	cacgttctca	ctaggtactg	gtagcccacc	aaaagggtggg	7080
gcggggggta	ccaaaacagt	ggccagccct	cggtagcggg	ctctcgaggg	ctgaggttca	7140
taagcatgag	gcggtgggat	tgttatatgt	acttggacat	ccatgccagc	cctacagagg	7200
tgggtggaagc	tctgggtgtac	tctcgaacc	gggtaaaaat	gtttctgaga	ggcctgaaca	7260
cctcaacggt	gtatgggggtt	tgtccgggtta	ggcgggcgca	gtccagcgcg	ttctgcaaaa	7320
caaaacaagg	ctcgatggca	ctttcattcg	ctccattgca	gatgcacccg	gtactgcgac	7380
agatgaagcc	cctgcccgcc	tctgccagca	agctagaagc	agagagcgag	gggtttggccc	7440
gcttacaagg	gggtgctgct	ccagagttgc	acccccgggt	gcagatgaag	caagaggcgg	7500
cggagggtta	catcccact	agcaatgtgt	ttagggataa	tgaaggagaa	gaagcagagg	7560
gcttgcgaca	cttaaaagt	gagtcgggga	ggctgtttgc	taatgaccac	acttccaagc	7620
gggtgctggg	cgagcgagac	tttgaaaagg	acccccagaa	tggcattagc	gcggccgagg	7680
cacacctaaa	gcttcgacag	ttagtcacgg	cctatgagca	tactgtgaag	gcagaggtta	7740
attttcagac	caccttttaac	aaacaatgtgc	gtaccctcat	cgccagggaa	gaggtgtgtca	7800
ttggcctgat	gcacttgtgt	gactttgtgg	aggcctttct	agaaaaccca	gtgagcaagg	7860
ccctcactgc	ccagctcttt	cttatagtgc	aacactgcag	ggacgagggg	gtgctgcggg	7920
aaagcttgct	aaaacattgcc	gagcctgaga	gcgggtggct	gggtggacctg	ttaaacctgt	7980
tacagactat	tgtgggtcaa	gagcgaggct	tggcagttgg	tgaaaaggta	gcggctataa	8040
actactctgt	gattactctc	agtataacact	atgcaagaaa	gatattcaac	tctgtgtttg	8100
tgcccatcga	caaggaagcc	aagattaaca	cattttacat	gcgcactgtt	gttaagctgc	8160
tgggtgctag	tgatgacctt	ggcatgtacc	gcaatgagcg	gattgagagg	gcagtgtctg	8220
gtgccaggca	gcgggaatta	aatgacaggg	aacttatgca	ccgactgcgg	caagccttgg	8280
cttctaaccg	actgcccagg	ctagagggcg	aagacagtgc	taattattagg	tccaaagagg	8340
agtggggggg	cggagcgggc	ggaggcggtg	cgagcgcgcg	ctacccccac	ctgctagact	8400
atgaggaaga	ggagaaccct	gatggctccg	tctcatttca	acagcatgag	cgccggcgctc	8460
aaacccatga	aaatggcggc	catgcagagt	cagcctacag	ccgacgcacg	ttgggcccgtc	8520
tctattagtc	gcattatgtc	cctaaccggcg	ggggatcgcc	acaagttttc	atcccagcct	8580
tttgctaaaca	ggctggatgc	tatatagag	gcctgggtgc	cttcccgcga	agaccctacc	8640
catgaaaaag	gtctaactat	agtaaatgcc	ctaatagaaa	atggtgccc	tagggcgggac	8700
gagggggcg	gggtgtatga	cgcctgtgtg	caccgcgtgt	ccaagtacaa	cagcttgaat	8760
gccccaaagca	acctagagta	gttggctgga	gacgtgaggg	aggcggtagc	gcagcaggatg	8820
cgcacgcga	cgggcaacct	tgggtcccta	accgcactta	atggcctttt	ggcacgcctg	8880
cccgccaatg	tggagcgggg	ccaggagaa	tacactggct	ttgtgtcagc	ccttaagctg	8940
ctggtaagcg	aggtgcccag	tacagaggtg	taccagtctg	ggcctcacta	ctttttgcaa	9000
agcagtcgca	acggcaccca	gacagttaac	cttaccaatg	cctttgagaa	cctaaagccc	9060
ctttggggag	ttaaggcccc	cactatggaa	aggctcagca	tctcagccct	gctcaccccc	9120
aaactagac	tgtctgtttt	gctagtgtct	ccctttacag	acagtgttag	cattagcagg	9180
gactcctact	tgggttaacct	gcttaccctg	tacaggggag	ccttggggcg	caatcatttg	9240
gatgagcgt	ctcttgaaga	ggtcacagag	gtcagcaggg	ccatgggcag	tgagaacata	9300
aaacaactgc	aaagccacct	taactttttg	ctaaccaata	gacaaaaaag	aattcccaaa	9360
gactactccc	taaccccaga	ggaggagagg	atagttaggt	ttgtacagca	ggccgtgagc	9420
ttgcgcagt	tgcaggaaaa	cttgagcccc	actgaagctt	tggacgtaac	cgccggccaac	9480
atggagccca	gcttctatgc	cagcaacagg	gattttatta	ataagcttat	ggactacttt	9540
caccgcgctg	cggtctatggc	tccagactac	tttttggggg	cagtgtagaa	tccccgctgg	9600
ctccccctcg	agggcttctt	tactgggggt	tttgactttc	ctgaaaaggga	cagctacacc	9660
tgggatggac	tccatagactc	tttggagctg	acgcgcagg	atgccatgcg	gtttctgtaa	9720
gacaagtta	tggacgatga	ccagagaaca	gagtcctgca	gcctcagcag	agttaccacc	9780
ccagctagct	ctaggcgggtc	ctcggtgacc	atgccacctg	ggggcctttat	gggcctagata	9840
aataacaaca	aaaacgataa	catcctcagg	gagatagatg	gattagcaga	caagctggct	9900
cgggtgaaaa	catacaagcg	ttagtcagag	gaggtcctgt	tgtccctgcc	tgcggtagta	9960
aggcctaagc	agtacaggcc	ccgctccctc	atctccagcg	atgacagtga	tgatgggatg	10020
agcaggccag	accggtttct	caagtttgag	gggagtggaa	acccttttgc	ccacctacgc	10080
cccaagctgg	ggcgtggcct	gtaaaagtga	taaaatactc	accagagaca	tgacgttagc	10140
gtttttttat	agcaatggag	ttttcgtcgt	ctcctcccc	gtcttatgaa	acagtgatgg	10200
cacaagtgcc	ttcgatcctg	gcgcgcctgg	tacccccgcg	gtacaaaagg	gctacagaag	10260
gaagaacacg	tatccgttat	tcccagctgc	cgccctctgt	tgacactaca	aagctgtacc	10320
tcattgacaa	caagtcttca	gacattcagg	ccctcaatta	ccaaaatgac	cacagcaact	10380
ttttaaccac	tgtggtgcaa	aatgctaatt	acacgcccac	ggagggctagc	accagctcca	10440
tccagctgga	cgagcggctg	cgtctgggtg	gggaatttta	gtccatttta	cacatgaaca	10500
tgccataatgt	gacagagtac	atgttttagca	ggcataacct	cccgccacag	10560	
cagacaacct	tggcaagggtg	ctcacctatg	agtgttacac	cctaaccatt	cccgagggtta	10620
actattctga	ggttatgctt	tggacctgc	tgaacaacgc	gggtgggtggg	aactatctgg	10680
ccacggggcg	ccagcataat	gttagggagg	aggacatggg	cctcaagttt	gacaccagaa	10740
actttcacct	gggctttgat	cccagaccca	agctggtcat	gcggggcttc	tacactaacg	10800

-continued

aggccttcca	ccctgacata	gtgctaagtc	caggetgtgc	ggtggacttt	accacagca	10860
ggctcaacaa	cttttttaggc	attagaaaaa	ggctaccata	ccaggaggga	tttgtgatta	10920
cctgggaggga	cctgcagggt	ggcaacattc	cagccctgtt	agacctggaa	aattacaacc	10980
cagacattcc	cggcgccgat	atcacaccac	tgatgtatga	ctccaaggga	aggccttacc	11040
atgttggtga	ggatoccagc	gcggggcagta	ccttcacctg	gtaccgcagc	tggtttgtgg	11100
cctataacta	cggtcctgcc	gatggcatca	agagcaaaac	tgtactggtg	gcccctgaca	11160
ttacttgccg	agtggagcaa	atttactgga	gcctgccaga	tatggcgggt	gacccagtaa	11220
cttttacctc	tagccacaat	cccagcagct	acccagtggt	gggcacggag	ctgctaccat	11280
tactgccaa	aagcttttac	aatggatctt	cagtgtacag	ccagctgttg	caagaaagca	11340
ccagtcacaa	tcaagtgttt	aaccgctttc	cggagaatgc	aattctttaa	aggcccccctg	11400
ctcccaccat	tatcagcatc	agcgagaacg	tgcccgcctt	cagtaaccat	ggcacctgcc	11460
cctaaaaaac	aacattcccg	gggtgcagcg	ggtgaccatt	acggatgcaa	gaagaagagt	11520
gtgtccctac	gtgtacaaaa	gcttgggggt	cgttgtgcct	cgctgtgtgt	ccagtaaaac	11580
cttctatga	caaaacttttt	ctttttatta	gcaaagccat	ggccatctta	atatcaccga	11640
ctaacaacac	cggctggggc	ctaggcactc	acaagctctt	tggaggagcc	aaacaaaaat	11700
cagatcagca	tcccgtttat	gtccaagctc	actaccgggc	ctcgtggggc	agcaaaaggc	11760
gcgcgcgcgc	tcaaggccga	gcccgcgggg	cccccttga	ccctaaaact	gaagcagaaa	11820
tgggtgccac	catcgacgag	gtggcgcgca	acgggtcccc	ggcgcgcgcg	ttggtgctgg	11880
aggctgccc	gagagtgggg	gcttacaacc	tcogtcgagc	gcgcaagcta	accctgccc	11940
ggcgtgccat	gatggccatg	cgcgcgcgtc	agatggtaaa	gcaggctaa	aaaagggaagc	12000
gcagggttcg	ctttagacaa	taaagtctgt	cctcacatac	acacataccc	gagtgtatgg	12060
ctattttttt	cttgaagcct	catcgccatg	gcagcaatca	gtcgcgccat	caagcaggaa	12120
ctgctggaag	acctcaaaac	tgaatatctat	ctgccaccac	agtcacacaa	acggagaaact	12180
aaagttaaaa	cagaggaaaa	agttgatgtg	aaaaccctag	tcaatgccaa	gagcagaaaag	12240
cgcagggtcg	ccaaggatga	gctggaagag	gatgtagagt	ttgttaggcg	ctttgctccc	12300
cggcgtccct	accagtggcg	gggtcgcgcg	gtgcgcgctc	tgcctaggcc	cgggggtgcc	12360
gtggtgttta	ctcccgcgca	gaggtcgggc	accgcctcaa	aaaggtctta	tgacgaagtg	12420
tacgcagatg	aggatgtact	ggaccaggcg	ggaaacatga	ttaatgagtt	tgcttatggc	12480
aagcgagtca	gggtgctttac	ccacaaaaac	cccactccct	cacacagtc	catcaccccc	12540
caggagcccg	tggcgcgctc	tggcgaggca	cacctgctac	ccacagtcca	agtgtcggtc	12600
ccgcgaggct	ctaggcggga	aaccatgttg	cccgtaacca	agtcggagg	gggagacgtg	12660
aaagtggaaa	acaagggtct	tgagcaaatc	accccggggc	tgggggtgca	gactgtagac	12720
atcaaaagtc	ccgtgaagcg	caaaggcgat	gcagaggatg	aaataataaa	gagggttaag	12780
atggagcttg	aaccatatga	ccacactatg	aaaatggagt	actctgagga	gccccagggt	12840
gaggcttttg	acacagggat	agagcccagc	tctttttttg	agggtgcgctc	tcaagcgcgt	12900
cccactcgct	tggctaggaa	gcgcgcgacc	gcagctgcca	gcgcccccg	tgtagaggtg	12960
atggaggttc	agcaaaagca	ccctgccacc	ccagctaccg	ctgcgcgcag	aaccgcgacc	13020
gcgctggggc	cgcgtttggc	tcgtcgccct	tcaagatggg	ggcccgcgca	tgccatcttt	13080
ccagattaca	aataccaccc	cagcatcacg	gctaggaaaa	tgagggggcc	caagcctaca	13140
ggcaagatca	gcccgtgggg	gcttgccaac	agcatcctgc	ctgaggtgcg	gctgcacccc	13200
agcatgggtg	ctgcgggtgac	cagagctgcc	cctcgcagag	tcacaaaaac	ccggagacgc	13260
cggcgtgcc	gaacccgcga	ggcttttttg	ctgcgcgcgc	gcaccaaagc	gggcgcgctg	13320
ctttcccaga	acgtgcgctg	ccacccttcc	atctccttgc	tccgcgcgagc	ctaactctga	13380
tgttttgctt	tgcgcaagga	tggccggcag	gaatgtcacc	cttcgtctga	gagtcaccag	13440
gcgcacaaaa	attacaggcg	caggtcgctg	gcgcgggacg	gcgccacgcg	gcatacgctg	13500
cgggcgcagt	agaggaggct	ttttgccagc	cctcatccct	ttgatagctg	ccgccattgg	13560
ggcagtagca	ggaatagctt	cggtagcgct	ccaagctgcc	cggcactagc	tttttacaga	13620
ttgactcact	cccatttttc	ttgtgccaga	agaagacaaa	atggatgctg	tcaatttttc	13680
catcttgcca	ccacgctacg	gggcccaccc	tatgatgagt	ggttggctcg	gcactggcac	13740
cagcggcagt	aacggcgggg	cccttaactg	ggggggcatt	tggagcggca	tcaaaaaact	13800
tggcagtaat	gtaaaaagct	ggggcagcaa	ggcttggaa	agccaaaacg	gcaagctgct	13860
caggcaaaa	cttaagtaca	ccaaagttag	agaaaaagctg	gtggagggca	tttccaccgg	13920
ggtgcacggg	gcacttgata	tcgccaaaca	ggagttagca	aagcaaaatg	agcggcggtt	13980
ggagcgtcag	cagcccctag	agccggaggt	ggaggtagag	gagggaagtag	tggacataaa	14040
acccgaagcg	caggcccccg	tgggtgtaca	aatacccaaa	aagcgccccc	gcgacgaaga	14100
cttgctcata	actcgggacg	agcctccctc	ctatgaagag	tccatcaaaa	ccatggcacc	14160
cctgatgccc	atgacccgac	cgcacccttc	catggccaaa	cctgtttttg	tagaccgtcc	14220
caccaccttg	gagctaaagg	cctctgacca	gccgcacgac	tactcccccc	cggcgccccc	14280
cgcgctcagg	gtcacagtgc	cctctaacat	tcccgtggct	actcctgcca	gaagcagagg	14340
ctggcaagga	actctggcca	acattgtagg	agtggtgcta	agtaacgtga	agcgcgctag	14400
atgcttctaa	ctgtgattaa	atatactcaa	gtgacttgaa	gtttgcggac	cctgtctttt	14460
tttgaccgcg	ccagctgaga	agatggcaac	cccgtcgatg	ctgccacaat	ggtctttacat	14520
gcacattgct	ggccaggacg	ccgcgcaata	cttgtctccc	gcccctggct	agtttgccca	14580
agcaaccagt	tcttacttta	agttggacaa	caagttcaga	aacccccactg	tggcccccac	14640
ccacgatgtg	accactgaga	ggtcgcagcg	cttgacagctg	cgttttgtgc	cagtcagca	14700
agaggatggc	cagtacactt	acaaaaccgc	cttccagctt	gcggtgggag	acaacagggt	14760
gctggacatg	gccagtactt	acttcgatat	caggggtacc	ctagacagag	gccccctcct	14820
caagccttac	agcggcacgc	cctacaatgc	cctgcgcccc	aaggccgggg	ctaacaactg	14880
tctttttaat	ggacagggtg	ccaatattaa	cactttagcc	caggtgccct	ctgcagggtg	14940
cataactgtg	aatggccaag	ctgctgtcac	aaacaatacc	taccagcagc	agccccagct	15000
gggcacctga	agctgggtcg	atggcagcct	agcagagctg	gggagtgctg	ctggccgtgc	15060
ccttaaggct	tcaaccccgc	gcatgccttg	ctatggttcc	tatgctcccc	ccaccaacga	15120
aaatggagggt	caagcaactg	gtccagtgga	atccagattt	tataagggtga	ccaccaacaa	15180
taacaatgaa	gcagatgcc	tgtctatacac	tgaagatgta	aacctgcagg	ccccagacac	15240
ccactgggtg	caccaagtg	cagagggtca	ggttacagg	gtgcaagggc	tgggcccagca	15300
ggctgcgccc	aacaggccga	actacatagg	cttcagggac	aacttcagat	gcctcatgta	15360

-continued

ctacaatagt	aatggaaacc	taggggtgct	ggcgggtcag	tcatctcage	tcaatgccgt	15420
ggtggacttg	caagacagaa	acacagagct	ctcttaccag	ctgctgctgg	atgccctcac	15480
agacagggtcc	cgctactttt	ccatgtggaa	ccaggctgta	gatagctatg	accaggatgt	15540
taggattatt	gacaaccatg	gcgtggaaga	tgatatgccc	aactattgct	acccactgag	15600
cggcatgggg	cccctaacca	acatgaccac	catgaagggt	aacaaccaaa	acttttcaggc	15660
agaaaatacc	aatgtggggc	ccattcaaaa	gattgggttt	ggaaatgttg	aggccatgga	15720
aatcaacctc	aattgccaac	ctctcaaaa	cttcctttac	tccaatgtgg	ccttatactt	15780
gcctgatgcc	tttaaatata	cacctgaaaa	cattgtggcc	cctgccaatg	tgaataccta	15840
tgcttacatg	aatgttagat	tacccgccgc	caaccttata	gatacctttg	taaatattgg	15900
cgccagatgg	taccagatg	taattggacac	tgtaatcct	ttcaaccacc	acagaaatgc	15960
aggactccgc	taccgttcac	aactgcttgg	caatggccgc	tattgctcgt	tccatattca	16020
ggtccctcaa	aaattttttg	caatcaaaaa	tctcctccta	ctgcctggaa	cgtacacgta	16080
cgagtgggtc	ttcagaaaag	atgtaaacat	gatccttcaa	agcagcttgg	gcaatgacct	16140
ccgagtggat	ggggccacca	tcaacattca	gagcatcaac	ctatatgcaa	gctttttccc	16200
aatggccacac	aactgctcct	ccactctgga	agccatgctg	cgcaacgatg	taaatgacca	16260
gtcctttgca	gactacgtgt	ctcttgccaa	catgctttat	cccatccctg	ccaacactac	16320
taacctggca	atctccattc	ccgccagaaa	ctgggcggga	tttagagggt	ggagctttac	16380
cagaattaa	caacgagaaa	ctcctgccct	gggctcgcc	tatgatccct	acttcaacta	16440
ttcgggcagt	attccatata	tgatgcaaac	ttttacctc	agccacacct	ttagaagagt	16500
ttccatcatg	tttgactctt	ccgtgtcttg	gcctggcaat	gacaggctgc	ttaccccaaa	16560
tgagtttgag	attaaaaggt	atgtagacgg	tgaagggtac	aatgtggccc	agtcacaacat	16620
gacaaaagac	tggttcctgg	ttcaaatgct	agccactac	aacatcggt	accaaggcta	16680
ccacctggca	gaaagctaca	aggacagaa	gtactccttc	ctaagaaact	ttgagcccat	16740
gtgcagacag	ttggtggaag	tgcccaacta	tgtgcctac	cagccgggta	ccgtggggca	16800
ccagcataac	aattctgggt	attctagcgc	cctttcgcc	tttaaccgcg	gtgaggggca	16860
cccataccga	gaaacttgcc	cttaccact	cattggagcc	aatgcagtac	ccactgtcac	16920
ccagaaaaag	ttcctctcgc	acaggtccct	gtggcgcatc	ccattctcct	ccaactttat	16980
gtctatggga	accctcaact	acctggggca	aaactgctg	tactctaact	ccgccacgc	17040
ccttgacatg	acttttgagg	ttgatgccat	gaatgagccc	actctgttgt	acgttttgtt	17100
tgaagtgttc	gacgtggcac	gcgtccatca	gcccaccggg	gggtgtgatt	aggtagtgtt	17160
cctcagaact	cccttctcgc	ccggcaacgc	caccacctaa	gctaataatg	cggaaggagg	17220
gtcctcagaa	gaagagctgc	gagccatagt	acataactta	ggcgtgtctc	catttttctt	17280
gggcaccttt	gacaagaggt	ttccgggttt	catctcttca	caaagaatgg	cctgcgccat	17340
agtaaacacc	gcagccgaga	aacggggggc	gtgcaactgc	tggccatggc	ctggaacccc	17400
cgctcaaaaa	cgcttttcat	ggttgacccc	tttggtttt	cagacagtaa	gctcaagcaa	17460
gtgtacagct	ttgagtatg	gggcctactc	aggcgacagc	ccatagcctc	cagcccggtt	17520
agggtgtgtc	ctttggccaa	aagcaatgaa	accattcagg	gtcccaatag	cgccgctctg	17580
ggactgtttt	gtttgatgtt	tttgcatgcc	tttgcaact	ggcctgacga	cccccttgac	17640
cacaatccca	ccatgggacc	cctcaagagc	gtgcctaact	acaaactcaa	tgatcccaca	17700
gtgcagtatg	tgcctctggg	aaatcaagaa	aagctgtata	agtttttgga	aaaacactct	17760
gcttacttct	gcgcccacgc	cgctgcaatt	aaagccagga	ctgcttttaa	taaaattgaa	17820
caataaacgc	tttattcgaa	aaatataaat	ggtttacagt	gtgattatta	aaaaaggaca	17880
aggctcatgt	catgctggcc	ctggggcaaa	atggatattt	ggtacctgtg	ttcatcggac	17940
cagtgggaact	ctgggaattt	aattgggggc	ctctcgccca	ctgtggacgt	ccatatattgc	18000
tagacaattt	ggcacatgta	caccagggtc	acgctggaaa	tcttaaaatc	acaatttttt	18060
tggggggcgg	ccttgctgtg	gcggtacact	ggattgcaac	attgaaacac	tagcatggcg	18120
gggttattaa	gggtggctag	catttttttg	tcatccactt	cactcttgct	aatgtgacta	18180
gcgcttgcaa	gagagaatgg	ggtaactctg	caagtttgcc	tgcccagcaa	aggaagggtt	18240
ctgttccaat	tgactcaca	cttgagtggc	attagcaagt	gactctcagc	atttggcata	18300
gaggggtagc	aagccttaag	aaaagccatg	atctgctgaa	aggccataat	agctttgggt	18360
ccatcggtat	aaaacatacc	gcaagaggcc	ccgctaaaat	tgcccccgct	catattaaca	18420
ttcatgtctc	agcagaaaagc	atcctcattc	ttaaactgta	ctacattcct	tccccaccgg	18480
ttagaaacaa	ttttgggttt	ttctgggttt	tccttaaggg	cccgtctggc	attttcactg	18540
ttaacatcca	tttctactag	ctgctctttt	tggatcatgg	gcgaccctgt	cagacacata	18600
aggctgtctc	ggcatccatg	ttgccacacc	acacacccgc	tgggggtaac	cccaggggca	18660
agctctgctg	ctttgatcac	aaaaatcaagc	agcaggcgcc	ctgcccacgtg	caaaaaaggt	18720
ttctgggttg	taaagggtga	agtaacgtgc	gttttagagg	tggttaatga	agcctggact	18780
gcttttttaa	agcactccag	cgtgccctcg	ctcggaagca	aggttagctt	gctgtggtct	18840
acctggtagc	cggtgagaac	cctaagggca	agctccatgg	cagactgcca	cttggtctca	18900
ctagctttaa	aaaacttaga	ggccactagc	cccagggggc	cggtgggctt	gctccaaacg	18960
gacttttgct	tgggtgggat	aaataccaca	tttccctcct	tgtcagtgct	caccgttttg	19020
ccacaaaaag	tctgcactac	aatgctcccg	ggatccccc	gcgccttgag	ggtggcgggtg	19080
gcttgacggg	ctatttcgac	catggcttgg	tggcccttg	gctcctcaac	ggctttccgc	19140
tggcgcttct	tggggggcgc	cgtaggcggt	gccacaggaa	cctcttcac	gctggagctt	19200
tcagagattg	caacaaacct	cttgtggctc	atctttttcc	tagatgtcag	aagagcccg	19260
cagtgggact	accgtggaga	caaaggagga	cattcacaca	cctccaaact	cccctgtcct	19320
cgagacaatc	tctctaagcc	ccgaacccga	ggctgaggcc	tgccccaaata	cagacaaata	19380
cctaagcacc	aatttgcttt	gcaaacacct	gcaacgtcaa	agcgcaattg	ttctggacag	19440
tatcaaagat	catctacaag	tgcccaccag	tgtatcagag	ctaagctgcg	cctacgaacg	19500
aagcttatct	tccccaaaca	ccccaccaag	gcaacaaaag	aatggaacgt	gtgaagcaaa	19560
tcctaaacct	aaacttttacc	ctactttttt	ggtgcctgaa	actttggcaa	cttatcacat	19620
cttttttgtt	aatcaaaaga	taccagtatc	ttgcagagct	aacagagcta	aagcagacag	19680
agctcttgct	ttgcaagagg	gagattgctt	acctgactat	gaaacaatgg	acacagctcag	19740
ccgggtgttt	gaggggttag	gcgggtgaggt	ggttgccgat	cacgcgctgc	aaaataatga	19800
ctctgtatta	gtggagctta	aggaagacaa	ccccggttg	gctgtggtca	aaagaacct	19860
cagcgtctcc	cactttgctt	accccgccgt	gcacctgccc	ccaaagggtca	taaccactgt	19920



-continued

catggacaac	ctgctagcta	aaagggccgc	ccccagcgcc	gacgtctcag	agctagatcc	19980
cgaggggggc	caagaggtgg	tgtctgacac	cgagctaagt	aagtggttaa	acacctctga	20040
ccccaggcc	ttagaaaagc	agcgcaagac	agtaaatggga	agcgtgctgg	ttactgtagt	20100
gcttgagtgc	atgcaaaagg	ttttcacctc	agaagaaatg	gtgaaaaaaa	ttggggaggc	20160
cctccactac	accttttaggc	acggctacgt	atctctggct	tgcaagattt	ctaagttaga	20220
gctgaccaac	gtggtcacc	atatgggcat	cctgcatgaa	aaccgcctgg	gtcaaacac	20280
cctgcatcac	acagtgcagg	gcgaggcccg	tcgagactac	attagggact	ccatcttcct	20340
catccttato	catgocctggc	aaaccgcgat	gggcatctgg	cagcagtgcc	tcgaagaggga	20400
aaaccttaaa	gaactagcca	aactgctgca	aaggattaaa	aagccattgt	acactgaaac	20460
ctcccagcgc	ctcatgggca	agcgctggc	aaacgtagtc	ttcccaccca	aactgctaga	20520
aaacctccac	aagggccttc	ctgatattgt	tagccaaagc	atgatgcaaa	actttagggtc	20580
tttcattttg	gagaggctcg	gcacccctgc	ctccatgacc	tgccgcctgc	ccacagattt	20640
tgtaccaatt	cactttaaag	agtgcctccc	cactatgtgg	ccctacacct	acttgcctca	20700
attagcaaac	ttcttttagt	atcacaatga	cctttgctat	gatgtgggga	gcgagggcct	20760
gctagagcac	tactgcgcgt	gcacccctctg	cacccccacc	cgttgctcag	ccaccaaccc	20820
cgccatgctt	aatgaaactc	agctaataag	tacctttgat	attcgggggtc	ccggcggaga	20880
aaacggagca	gagtcttctc	ctggccttaa	gctcacccgt	ggaatgtgga	cttcgcgtgt	20940
tctgcgaaaa	tttgaaagct	ctgattatca	cgccccaaaa	attcagtttt	atgaaaaacca	21000
atcaaaagcc	ccctcagtg	agccactcc	ctgcgtcatc	accctaaagta	gcattttggc	21060
ccaatgtcat	gacattaaaa	aagcaaggga	ggagtctctg	ctcaaaagcg	ggcaggggtca	21120
gtatctagac	cctcagactg	gggagccgct	caacgctgcg	gatccttcg	tagaaaagcag	21180
ccatgagttc	caaggagatg	gaagcacacag	aaaccctaag	cgtggaagac	atttcgggca	21240
gcgaggagga	cctagaaaagc	ctcccagagt	ccatgccgga	gcagagcgag	atgtcagagg	21300
aacgagctcc	tagatgggac	caaaaagaga	agcctctggg	taagcagccc	cgcaactacc	21360
actcctggag	agcgcataag	tttaagattc	ttagctgcct	gggcgcctagt	gggaacaatg	21420
tagcctttac	cagaagatag	atgctctttc	gcgaggaggt	taacctccc	aacaacatca	21480
tcaactacta	taactctcgc	taccgcagca	aaacagaagc	tcaagcgcag	accgacccca	21540
ctaaagggcc	caaagccagc	cgccggtgag	gacaaccacc	agacaaggca	gctgcgcaac	21600
cgcatttttc	caaacactga	gcacatcttc	caacaaagca	gaggctcccc	cacggcatta	21660
aaaataaaaa	acagatccct	caagatccctc	ctaagaagct	gtctctacca	caagtgcagag	21720
gagcagctgc	tgccgcacgc	aaacgacgcc	gaagctttgc	tcaacaaata	ctgtcaaggga	21780
ctcgagtccg	gcacagactg	agcaatgtct	aaagaaatac	caacccctta	tatgtggagc	21840
taccaaccgc	aaacgggaca	cgccgcggcg	gcctcccagg	actactccac	ccaaatgaat	21900
tggttttagt	ctgggccaac	aatgattagt	caagtttatg	gcattagaga	cttgccgaac	21960
aaagttttga	taaccocagg	agaaataacc	aaaactccca	gaacaataat	ggatcccgca	22020
atttggccag	ctgccaatgct	tgttcaggaa	gcgcgccacc	ccaaacagg	cactctgccc	22080
agaaccacac	ccctagaaca	ggctatgacc	aactctgggg	cgagctagc	gggagagaca	22140
cagctgtgcc	cctcccaaat	aggtataaaa	agcccagtg	tggtggcac	gggcattcag	22200
cttagcgaa	acatccccag	cgccctcctg	atcaggcccg	acggcatatt	ccagctagga	22260
gggggggtct	gctcgtcctt	cgcccacacg	caagcattcc	tcacctgca	acaggcatcc	22320
tcgacgcgcg	gcgcaggagg	cgtgggcacc	taccagtttg	tgccggaatt	tgtgcccagag	22380
gtataacctta	accttttttc	aggaccaccg	gacaccttcc	ctgatcagtt	catctcctaac	22440
tacgacattg	taaccaactc	tgtcagatgg	tatgactgag	gagagcatgg	accaggttta	22500
aacgcgatcg	cctcgaggcg	cgccggcccg	cctcagcctt	ctaattgggac	taaacacaaa	22560
aatcaggccc	atgtagattg	tcaataaaac	ttacctaat	tttgctaaga	cgtctgggtc	22620
ctgcgtttct	atgtccacca	aagtcctccc	ttcccagctt	tggtacttcc	acttgtgcgc	22680
gcgagccagc	ttgcggatgt	gcttgaaaga	taattgtggt	ttccccaa	gcttcccgtt	22740
caccagcacc	agggccatga	agcgagacag	aagagctcta	cctgcgaatt	atgacctgt	22800
atatccatag	gcgcggcccg	ggtcttccac	acaacccctt	ttttttaata	acaagcaagg	22860
ttctactgag	tcacccccag	gaacctggc	tgtcaatggt	ttccctccac	taaccttttc	22920
tacgttaggt	gccattaaac	ttccacagc	tcgggagctc	acctcgaacg	agggcaagtt	22980
acaagccagc	ttagggcccg	gcctcatcac	aaataccgag	ggccaaatca	ctgttgaaaa	23040
tgtcaacaag	gttttgtctt	ttacctccc	attacataaa	aatgaaaaa	ctgtatccct	23100
agcgctagga	gatgggttag	aagatgaaaa	tggcaccctt	aaagtgaact	ttccctactcc	23160
ccctccccc	ctacaattct	ccctccctc	cacaaaaaca	ggtggtagctg	tttccctggc	23220
cctgcaagac	ttcatgcaag	tgacaaatgg	aaaactgggc	gttaagccta	ccacctacgc	23280
acctcccttg	aaaaaaactg	accagcaagt	tagcctccaa	gtaggctcgg	gtctcacctg	23340
gattaaacgaa	cagttgcaag	ctgtccagcc	tcggcgaacc	acctacaacg	agcctctttc	23400
caaaactgac	aattctgttt	ctctgcaagt	agggtccggc	cttgccgtgc	agagcggagc	23460
tttggtggca	acctctcccc	cgccctctac	ctttacatca	cccttagaaa	aaaatgaaaa	23520
cacagtgtcg	ctacaagttag	gcgcgggctt	gtctgtacaa	aacaacgccc	tagtagccac	23580
acctccccca	cccttaacct	ttgcctatcc	cttagtaaaa	aatgacaacc	atgtagctct	23640
aagtgttgga	agtgggttaa	gaatatctgg	aggcagcctc	acggtggcca	ctggacctgg	23700
cctttcccat	caaaatggaa	caataggggc	tgtagtaggt	gcaggcctca	agtttgaaaa	23760
caatgccatt	cttgcaaaac	taggcaacgg	tctaaccatt	agagatggcg	ctattgaaag	23820
aaaccaaccc	ccagctgccc	ccataactct	gtggactggg	cctggcccta	gcattaatgg	23880
ctttattatg	gacactccag	taattaggtg	ctttatatgc	ctaaccagag	acagcaactt	23940
agtcacagta	aatgctagct	ttgtgggaga	gggggggtat	cgaatagtca	gccctaccca	24000
gtcacaaatt	agcctaatta	tggagtttga	tcagtttggga	cagcttatgt	ccacaggaaa	24060
cattaaactcc	accactactt	ggggagaaaa	gccctggggg	aataaacatg	tacagccacg	24120
cccaagccac	acctggaaac	tgtgcattg	taacagagaa	gtttactcca	ctccgcgcgc	24180
cacctctccc	cgctgtggac	tagacagcat	tgcagtcgac	gggtgccccca	gcagaagtat	24240
cgactgcatg	ctaattatta	acaaacccaa	aggcggttgc	acttacaccc	ttacctttag	24300
gttttttaaac	tttaacagac	taagcggagg	tacctgtttt	aaaactgatg	ttttaacctt	24360
tacctatgta	ggcgaaaaac	aataaaaacca	agtttaaaag	agtttaaaag	ctttattttt	24420
catcacgcgc	agcggtaagg	ctgcgcctt	caggaaaaag	tactctgtaa	acagttcttt	24480

-continued

```

cacaacagca caaaacatag gtattagtta acagttcatt tgggctataa taatatacat 24540
tttcttgggt ggcaaaagcaa gggtcggtaa tctcaacaaa accatcaact ggaatgcaag 24600
aatagtcagg cacggtgggt tcaatctaaa aatgaagaaa cgcggttgagg ttactaagc 24660
acaggttttg aatctgtcgg cagcgtccat gcacatagc ttgtctcaaa gcagattgtc 24720
ttctttcttc tgctttggaa gtggtttggt gaagcactac aggtgtcttt tcaacctctt 24780
tcagcaccgg ctctattaca gatctcacc acacagcaca gtttttaaga gaacaatagt 24840
tttgaaggct acaagattta cacttaagca ccagccagta attataagtg cttttaagaa 24900
ctaccocctag ctacgggtta atgcacottt taatggcctc catgcaggct ttatggacag 24960
ttctaaaaaa agacagctta aataaatgt agtgagtgtt tctaaatata atactcccca 25020
catagttaat ttcacaggc ctgctagaat ttacaaactc tcggtaccac atatactttt 25080
tattcatagc cccaccctta ataaagtctt caatcacttt ctgaaccaca tgcttgctag 25140
ccatgcattg taaagacaag ctgttagagc agtgacagtg tactcgccac gtttgagcct 25200
ctgcccaggca gcagtgttca gttactatca actcaatacc cgcattgcat gtaaaccccc 25260
caaaagagcag tttttcagc ctgtgtagca catcatccca caaaatagga atttcatagc 25320
ataaagcaaa gcaattacaa tctttaggaa ctctcaccac agcagtcacg tgacatgttg 25380
tctcagcagt gcagttgctt taccctctac aattatgaac aaaaactaaa cacttctaac 25440
aaagatacag tgacaattct ccttctctca aaagcattgt ttacattagg gtgattatta 25500
acaacgctcag aaatttcttt aattaaagt cctttaaaat gtgcaagagc atcatcatac 25560
tcaaaaccaa gctgagagta aaagaccacc ttaaagtaa tcccaggctt gtttttatca 25620
acagccttaa acatgctttc acaaaatata gaagcagtaa catcatcaat ggtgtcgaag 25680
agaaactcca taggagactc cagcattgat ccaagctctc taacaaaaat ttctcaaaa 25740
tgaataatgc cctttacaca aacgcggggc agacgatggg gggccatcgc gtaaacctga 25800
aacacatttt acagtaaaac aagctagctc cgcagtggta aagtcagtc caggggtgag 25860
gccccaaatc ttaaaaaagc tatctaagta gttggtctac ccctcagtta aaaagttttg 25920
cagctgggtg gtgcatacca catagtgcga gcttatagct acaaagacct ccacccctc 25980
cttagcagac agctcttgca cacacgcagt aactatccac cgcttaagaa aagctttaag 26040
cccagcgcac ataacagctc caatgttttt atccaaggag agcaaaattt cagcaagcgc 26100
aggctcaaca gtaatagtga agcagaggca tttcagacga ggctcactag ctgcagtcgc 26160
catttatagc gtctgcgaat aaaaaacaat catcagcagc tgaaaaagtg cactttgacc 26220
tcattaagcc actgcatatg caagtctctc tctatgccgc agcccgagac ctcaatccag 26280
ccccgaatgt acactttaat aaagagattca acctcttctt ttacgcaaat acacatgctg 26340
tttgactagc tatacacaat agaagtcaca atgagggggc cgctgtggct ggaaagcctg 26400
cgcacagccc gaagggtaaa aatggactgt aacagcattg aaaccccgcg acacagggtca 26460
gtctcgcggt ctgtatctct tattatagcg accaaatggt ccttcagagt gatgttgac 26520
tcatagaagt aggcagctcc ggcagccatt ctgcaaaata acaaaacacc actaagcata 26580
gcaccatcac caagcatgaa aacaggtaaa aacaaaagca acacttactt attcagcagt 26640
cacaagaatg ttgggtctcc aagtcacaga caagcctaag gcaaggtggg cacagtcctc 26700
cggaataagt tgacaaaaag acgcgcgcaa agcttctcga agagaaaagg cggtagcctg 26760
gatattctga acggacccaa aaccttcagt gtcacttcca ataaacagat aaaactctaa 26820
atagtcccca cttaaaaccg aaacagccgc ggcaaaagta ggacacggac gcacttctg 26880
agccctaata aggctaataa ccacacggcg cagttcagaa ggcaaaaagg ctgtaagctc 26940
tagctgagca cacacactct ccactagact cttgtgaagc ctacagacaa aacatgctcc 27000
catagacact cctaaagctc ccttggtact cacggacggc tggctgtcag aggagagcta 27060
tgaggatgaa atgccaaagc cagcgtttat atagtcctca aagtagggcg tgtggaaaac 27120
gaaaaggaa ataacggggc gtttgaggaa gtggtgcca gtacagtcac aaaatgtggg 27180
cgctgtgtaa atgttaagtg cagtttccct ttggcgggtg gccgggaaag ttcacaaaaa 27240
gtacagcacg tccttgctac cgtgtcaacc acaaaaccac aaataggcac aacgccccaa 27300
aaccggggcg gccgggcaaa agtcgcggga actgcgcctg tcgtaaaacc acgcctttga 27360
cgtcactgga cattcccggt ggaacaccct gaccagggcg tgacctgaac ctgaccgtcc 27420
catgaccccg ccccttgcaa cgcccaaat taagccacac ctctttgttc tgtatattat 27480
tgatgatg 27488

```

```

SEQ ID NO: 4      moltype = DNA length = 617
FEATURE          Location/Qualifiers
source           1..617
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 4
acattgatta ttgactagtt attaatagta atcaattacg gggtcattag ttcatagccc 60
atatatggag ttccgcgtta cataacttac ggtaaaatggc ccgcctgggt gaccgcccac 120
cgacccccgc ccattgacgt caataatgac gtatgttccc atagtaacgc caataggggac 180
tttccattga cgtcaatggg tggagtattt acggtaaact gccacttggc cagtacatca 240
agtgtatcat atgccaaagta cgcacctat tgacgtcaat gacggtaaat ggccgcctg 300
gcattatgcc cagtacatga cttatggga ctttcctact tggcagtaga tctacgtatt 360
agtcacgcct attaccatgg tgatgcgggt ttggcagtag atcaatgggc gtggatagcg 420
gtttgactca cggggatttc caagtctcca cccattgac gtcaatggga gtttgttttg 480
gcacaaaat caacgggact ttccaaaatg tcgtaaacac tccgccccat tgacgcaaat 540
ggcggttagg gggtaggtcta tataagcaga gctctctggc taactagaga 600
acccactgct tactggc 617

```

```

SEQ ID NO: 5      moltype = DNA length = 903
FEATURE          Location/Qualifiers
source           1..903
                 mol_type = other DNA
                 organism = synthetic construct

```

SEQUENCE: 5

-continued

```

aatctaacaat ggctgctata gcttactgac tagaagttaa gtgcacactt cctaaaagaa 60
ggcttttgaca caagccactt cagttccctc ctcaattttct tgtccccatt cctctctctg 120
tagaattctg agatttcaat tcagttttat acagaaacca cattactgta agccctacaa 180
agttatggca atatagctat atggagtcac gtaatgtagg ttattttttt cccaatgggtg 240
ctgggtgaagg tggcaattat gtgactatac ttagcagact gaggaatttc tgctagagtc 300
agcattttgtc tcttcattgc tatgaacag taatggaaaa ataaacaaaa acaaaaggca 360
aacactatgc ataattccct cagatcatat taacatgtga tgttgagta aattgttata 420
acccattttt ggaaataactt accttaatta actatgattt ccttaaaata atgcagtatt 480
tacaatctat atgaaagcac tatatgggac acatgggatg atggaacagt gcaccaaga 540
gacaccaaga acatttctgt ctgtggcagt cttttctcta tacagaggca tttagtctca 600
attgctcaga gttattttaa acttccctga gcccgggctg ggcataaaag tcagggcaga 660
gccatctatt gcttacattt gcttctagcc tgcaagtcga ggagcgcagc cttccagaag 720
cagagcgcg cgcttaagc tgcagaagtt ggtcgtgagg cactgggcac gtaagtatca 780
aggttacaag acagggttaa ggagaccaat agaaactggg cttgtcgaga cagagaagac 840
tcttgcgttt ctgataggca cctattggtc ttactgacat ccactttgcc tttctctcca 900
cag

```

```

SEQ ID NO: 6          moltype = DNA length = 891
FEATURE              Location/Qualifiers
source                1..891
                     mol_type = other DNA
                     organism = synthetic construct

```

```

SEQUENCE: 6
ttgtcacttt gttactctac agtgttcgct ggagttcgat acttcattac tctatagtgg 60
gggtgaagaag ttcaccttct tattttcatt tcttccctc aatgatttct tcagagctag 120
ctcttaccag ctagaatttc ttcaaacgac actcgtgcct tcttccacac aggttgaact 180
attttgtctc aatgccctaa agtactgggt ttcaatcttc caggcacttc caatgatctg 240
aaatctgacc tcttaggttc agctggctct gagattatgg tattctagtc ctcaaaccaa 300
cctgttggct cgctgggttt gtaccaaaca cactgactta catagctcaa aataccactg 360
gccttttaaa aatggcatat cacattccag gggaggatca aaactgctgg ctgggtgatat 420
ttgtcaagtc tctcaaaagt gcactttcca ggattttcaa ttcactgaat tcttagacag 480
acatgtttat gtgaaagaat tctttatata tttttctcc tctttgagt ggcaaatgaa 540
aatcttgacc tctgggttcc ttattttatt tgactctctg tagtatttaa atcttaaaat 600
tttctaaac ttcctgcagc ccgggctggg cataaaagtc agggcagagc catctattgc 660
ttacatttgc ttttagcctg caagtcgagg agcgcagcct tccagaagca gagcgcggcg 720
ccttaagctg cagaagttgg tctgtaggca ctgggcacgt aagtatcaag gttacaagac 780
aggtttaagg acaccaatag aaactgggct tgtcgagaca gagaagactc ttgcgtttct 840
gataggcacc tattggctct actgacatcc actttgcctt tctctccaca g 891

```

```

SEQ ID NO: 7          moltype = DNA length = 1179
FEATURE              Location/Qualifiers
source                1..1179
                     mol_type = other DNA
                     organism = synthetic construct

```

```

SEQUENCE: 7
ggctccggtg ccctgcagtg ggcagagcgc acatcgccca cagtcgccga gaagtggggg 60
ggaggggtcg gcaattgaac cgggtgcctag agaaggtggc gccgggtaaa ctgggaaagt 120
gatgtcgtgt actggctccg cctttttccc gaggggtggg gagaaccgta tataagtgca 180
gtagtccgcc tgaacgtttc ttttcgcaac ggggtttgcc ccagaacaca ggtaagtgcc 240
gtgtgtggtt cccgcggggc tggcctcttt acgggttatg gcccttgcgt gccttgaatt 300
acttccacct ggctgcagta cgtgattctt gatcccgagc ttccgggttg aagtgggtgg 360
gagagttcga ggccttgccg ttaaggagcc ccttcgcctc gtgcttgagt tgaggcctgg 420
cctggggcgt ggggcccgcg cgtgcgaatc tgggtggcac ttccgcctg tctcgtctgt 480
tccgataagt cctagccat ttaaaatttt tgatgacctg ctgcgacgct tttttctggy 540
caagatagtc ttgtaaatgc gggccaaagt ctgcacactg gtatttcggt ttttggggcc 600
ggcggcgggc acggggcccg tgcgtcccag cgcacatgtt cggcgaggcg gggcctgcga 660
gcgcggccac cgagaatcgg acgggggtag tctcaagctg gccggcctgc tctgggtgct 720
ggcctcgcgc cgcctgtgat cgcgccgcc tgggcggcaa ggcctggccc gtcggcacca 780
gttgctgtag cggaaagatg gccgcttccc ggccttgcgt cagggaagctc aaaatggagg 840
acgcggcgct cgggagagcg ggcgggtgag taccaccac aaaggaaaaa ggcctttccg 900
tcctcagccg tgccttcatg tgactccacg gagtaccggg cgcctccag gcacctgat 960
tagttctcga gcttttgag tacgtcgtct ttaggttggg gggaggggtt ttatgcgatg 1020
gagtttcccc acctgagtg ggtggagact gaagttaggc cagcttgcca cttgatgtaa 1080
ttctccttgg aatttgcct ttttgagttt ggaacttggg tcattctcaa gcctcagaca 1140
gtggttcaaa gttttttct tccatttcag gtgtcgtga 1179

```

```

SEQ ID NO: 8          moltype = DNA length = 448
FEATURE              Location/Qualifiers
source                1..448
                     mol_type = other DNA
                     organism = synthetic construct

```

```

SEQUENCE: 8
agtgaagtg ggttttagga ccaggatgag gcgggggtgg ggtgcctacc tgacgaccga 60
ccccgacca ctggacaagc acccaacccc cattccccaa attgcgcac cctatcaga 120
gagggggagg ggaacagga tgcggcaggg cgcgtgcgca ctgccagctt cagcacccgc 180
gacagtgcct tgcccccgc ctggcggcgc gcgccaccgc cgcctcagca ctgaaggcgc 240

```

-continued

```

getgacgtca ctcgcccgtc ccccgcaaac tccccctccc ggccaccttg gtcgcgtccg 300
cgccgcccgc ggcccagccg gaccgcacca cgcgaggcgc gagatagggg ggcacgggcg 360
cgaccatctg cgtcgccgcg ccggcgactc agcgcctgcct cagtctgcgg tgggcagcgg 420
aggagtctgt tctgtcctga gagcgcag                                     448

```

```

SEQ ID NO: 9      moltype = DNA length = 823
FEATURE          Location/Qualifiers
source           1..823
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 9
tatacactca cagtgggttg gcatatat ttgtgaaatt ttaaggaaa aattagtgtt 60
ggtttcgata attggtagct tttctcttaa cataatttga ataattcagc aaagccctac 120
taccagctgt actctctcag cctcttccat tctttccagc attataattt tggtaattt 180
tcaattttag gtccctacgtc tctgcaattt gtgtatgaat aacagaataa tttccctctt 240
ttgtttcgcc tttcctgttc ctgaatctaa ataaagatgg ctttttagta ttaaaagtgg 300
aagaaaaatta caggttaatta tctttgacgg taaaaacgct gtaatcagcg ggctacatga 360
aaaattactc taattatggc tgcatttaag agaattggaaa aaaaccttct tgtggataaa 420
aaccttaaat tgcctccaat gctcgttcca aattggatgg cactgcagct ggaggctttg 480
ttcagaattg atcctgggga gctacgaacc caaagtttca cagttaggaag cttgatatcg 540
aattcctgca gcccgggctg ggcataaaag tcagggcaga gccatctatt gcttacattt 600
gcttctagcc tgcaggtcga ggagcgcagc cttccagaag cagagcgcgg cgcttaagc 660
tgcagaagtt ggctggtgag cactgggcag gtaagtatca aggttacaag acaggtttaa 720
ggagaccaat agaaactggg cttgtcgaga cagagaagac tcttgcgttt ctgataggca 780
cctattggtc ttactgacat ccactttgcc tttctctcca cag                                     823

```

```

SEQ ID NO: 10     moltype = DNA length = 1194
FEATURE          Location/Qualifiers
source           1..1194
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 10
ttaaggggac agtaaaagtg atggcaggaa ggcagcccc ggaggtcaaa ggctggggac 60
gocggaggag agggccagagt cagaggctgc gggatatctc gatatgaagg aaagatgaga 120
gaggtcagag aagaggtaag aaaagacaca agagaccaga gaaggggaaa gaattagaga 180
gggaggcaga ggaccgctgt ctctacagac atagctggtg gagactggga ggaagggatg 240
aacctgagc gcatgaaggg aaggaggtgg ctggtggtat atggaggatg tagctgggac 300
agggaaaaga tctctgcaaa aaaatctgaa gctaaaaata acaggacacg ggggtggagag 360
gcgaaggag ggagatttga ggcagagaga ctgagaggcc tggggatgtg ggcattccgg 420
tagggcacac agttcactgt tcttctcttt ttccaggagg ccaaagatgc tgacctaaag 480
aactcataat accccagtg ggcaccgcgc attcatagcc ctgtttacaag aagtgggaga 540
tgttcctttt tgtcccagac tggaaatcca ttacatcccg aggtcagggt tctgtgggtg 600
tcactctgt gtggtctgtt ctgtgggcct acctaaagtc ctaagcacag ctctcaagca 660
gatccgaggg gactaaagtg ctagtggggg ttgtctggag agaagagccg aggaggtggg 720
ctgtgatgga tcagttcagc tttcaataaa aaaggcgttt ttatattctg tctcagattc 780
gtgaacccct gttgtgggct tctccatctg tctgggttag tacctgccac tatactgaa 840
taaggggacg cgtctctccc tcgagttggc tggacaaggt tatgagcatc cgtgtactta 900
tgggttgccc agcttggttc tggatcgccc gggcccttcc cccaccggtt cggttcccc 960
ccaccaccgc gctcgtctcg tgcgtctccg cctgcagctc ttgactcatc ggggcccccg 1020
ggtcacatgc gctcgtctcg cctctatagg gccgccccct gccacccccc cggccgcgct 1080
gggagccgca gccgcccga ctcctgctct cctctgcgcg ccgccgtcac caccgccacc 1140
gccaccggct gagtctgcag tcctccgaaa cgggccctct agactcgagc ggcc 1194

```

```

SEQ ID NO: 11     moltype = AA length = 2009
FEATURE          Location/Qualifiers
source           1..2009
                 mol_type = protein
                 organism = Homo sapiens

```

```

SEQUENCE: 11
MEQTVLVPFG PDSFNFFTRE SLAAIERRIA EEKAKNPKPD KKDDDENGPK PNSDLEAGKN 60
LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVLNKGKATF RFSATSALYI LTPFNPLRKI 120
AIKILVHSLF SMLIMCTILT NCVFMTMSNP PDWTKNVEYT FTGIYTFESL IKIARGFCL 180
EDFTFLRDPW NWLDFTVITF AYVTEFVDLG NVSALRTFRV LRALKTISVI PGLKTIIVGAL 240
IQSVKLLSDV MILTVFCLSV FALIGLQLFM GNLNRKCIQW PPTNASLEEH SIEKNITVNY 300
NGTLINETVF EFDWKSQYID SRYHYFLEGF LDALLCGNSS DAGQCPEGYM CVKAGRNPNY 360
GYTSFDTFW AFLSLFLRMT QDFWENLYQL TLRAAGKTYM IFFVLVIFLG SFYLINLILA 420
VVAMAYEEQN QATLEEAEQK EAEFQQMIEQ LKKQEEAAQ AATATASEHS REPSAAGRLS 480
DSSSEASKLS SKSAKERRNR RKKRKQKEQS GGEEKDEDEF QKSESEDSIR RKGFRRFSIEG 540
NRLTYEKRY SPSHQSLLSIR GSLFSPPRNS RTSLSFSRGR AKDVGSENDF ADDEHSTFED 600
NESRRDSL FV PRRHGERRNS NLSQTSRSSF MLAVFPANGK MHSTVDCNGV VSLVGGPSVP 660
TSPVGQLLPE VIIDKPATDD NGTTTETEMR KRRSSSFHVS MDFLEDPSQR QRAMSIASIL 720
TNTVEELEES RQKCPPCWYK FSNIFLIWDC SPYWLKVKHV VNLVMDPFV DLAITICIVL 780
NTLFLMAMEH PMTDHFNVL TVGNLVFTGI FTAEMFLKII AMDPYYYFQE GWNIFDGFIV 840
TSLSLVELGLA NVEGLSVLRS FRLLRVFKLA KSWPTLNMLI KIIGNSVGL GNLTLVLAI 900
VFIFAVVGMQ LFGKSYKDCV CKIASDCQLP RWHMNDFFHS FLIVFRVLCE EWETMWD CM 960
EVAGQAMCLT VFMMVMVIGN LVVLNLFLAL LLSFSFADNL AATDDDNEMN NLQIAVDRMH 1020

```

-continued

KGVAIVKRKI	YEFIQQSFR	KQKILDEIKP	LDDLNNKKDS	CMSNHTAEIG	KLDYLKDVN	1080
GTTSGIGTGS	SVEKYIIDES	DYMSFINNPS	LTVTVPIAVG	ESDFENLNTE	DFSSESDLEE	1140
SKEKLNESS	SSEGSTVDIG	APVEEQPVVE	PEETLEPEAC	FTEGCVQRFK	CCQINVEEGR	1200
GKQWNLRR	CFRIVEHWNF	ETFIVFMILL	SSGALAFEDI	YIDQRKTIKT	MLEYADKVFT	1260
YIFILEMLLK	WVAYGYQTYF	TNAWCWLDPL	IVDVSLVSLT	ANALGYSELG	AIKSLRTLRA	1320
LRPLRLSRF	BGMRVVVAL	LGAIPSIMNV	LLVCLIFWLI	FSIMGVNLFA	GKFYHCINTT	1380
TGDRFDIEDV	NNHTDCLKLI	ERNETARWKN	VKNVFDNVGF	GYLSLLQVAT	FKGWMMDIMYA	1440
AVDSRNVELQ	PKYEESLYMY	LYFVIFIIFG	SFFTLNLFIG	VIIDNFNQOK	KKFGGQDIFM	1500
TEEQKKYYNA	MKKLGSKKPQ	KPIPRPGNKF	QGMVDFDVTR	QVFDISIMIL	ICLNMVTMMV	1560
ETDDQSEYVT	TILSRINLVF	IVLFTGECVL	KLISLRHYFF	TIGWNIQDFV	VVILSIVGMF	1620
LAELIEKYFV	SPTLFRVIRL	ARIGRILRLI	KGAKGIRTLL	FALMMSLPAL	FNIGLLFLV	1680
MFIYAIFGMS	NFAYVKREVG	IDDMFNFTF	GNSMICLFQI	TTSAGWDGLL	APILNSKPPD	1740
CDPNKVNPGS	SVKGDGCGNS	VGIFFFVSYI	IISFLVVVNM	YIAVILENFS	VATEESAEP	1800
SEDDFEMFYE	VWEKFDPDAT	QFMEFEKLSQ	FAAALEPPLN	LPQPNKLQLI	AMDLPVMSGD	1860
RIHCLDILFA	FTKRVLGEGS	EMDALRIQME	ERFMASNPSP	VSYQPIITTL	KRKQEEVSAV	1920
IIQRAYRRHL	LKRTVKQASF	TYNKNKIKGG	ANLLIKEDMI	IDRINENSIT	EKTDLTMSTA	1980
ACPPSYDRVT	KPIVEKEHQE	GKDEKAKGK				2009

SEQ ID NO: 12                   moltype = DNA   length = 6030  
 FEATURE                       Location/Qualifiers  
 source                         1..6030  
                               mol\_type = genomic DNA  
                               organism = Homo sapiens

SEQUENCE: 12

atggagcaaaa	cagtgcctgt	accaccagga	cctgacagct	tcaacttctt	caccagagaa	60
tctcttcgcg	ctattgaaag	acgcattgca	gaagaaaagg	caaagaatcc	caaaccagac	120
aaaaaagatg	acgacgaaaa	tgccccaaag	ccaaatagtg	acttggaagc	tggaagaagc	180
cttccatttta	tttatggaga	cattcctcca	gagatggtgt	cagagccctc	ggaggacctg	240
gacccttact	atatcaataa	gaaaaacttt	atagtattga	ataaagggaa	ggccatcttc	300
cgggttcagtg	ccacctctgc	cctgtacatt	ttaactccct	tcaactctct	taggaaaaata	360
gctatttaaga	ttttggtaca	tctcattatt	agcatgctaa	ttatgtgcac	tattttgaca	420
aactgtgtgt	ttatgacaat	gagtaaccct	cctgattgga	caaagaatgt	agaatacacc	480
ttcacaggaa	tataactttt	tgaatcactt	ataaaaaatta	ttgcaagggg	attctgttta	540
gaagatttta	ctttccttcg	ggatccatgg	aactggctcg	atttcaactgt	cattacattt	600
gcgtacgtca	cagagtttgt	ggacctgggc	aatgtctcgg	cattgagaac	attcagagtt	660
ctccgagcat	tgaagacgat	ttcagtcatt	ccaggccctga	aaaccattgt	gggagccctg	720
atccagtcctg	tgaagaagct	ctcagatgta	atgatcctga	ctgtgttctg	tctgagcgta	780
tttgccttaa	ttgggctgca	gctgttcctg	ggcaacctga	ggaataaatg	tatacaatgg	840
cctccccacca	atgcttcctt	ggaggaacat	agtatagaaa	agaatataac	tgtgaattat	900
aatggtagac	ttataaatga	aactgtcttt	gagtttgact	ggaagtcata	tattcaagat	960
tcaagatata	attatttctt	ggagggtttt	ttagatgcac	tactatgtgg	aaatagctct	1020
gatgcaggcc	aatgtccaga	gggatatatg	tgtgtgaaaag	ctggttagaaa	tcccaattat	1080
ggctacacaa	gctttgatac	cttcagttgg	gcttttttgt	cctgtgttcg	actaatgact	1140
caggacttct	gggaaaaatc	ttatcaactg	acattacgtg	ctgctgggaa	aacgtacatg	1200
atattttttg	tattggtcat	ttcttggggc	tcatctacc	taataaattt	gatcctggct	1260
gtgggtggcca	tgccctacga	ggaacagaat	caggccacct	tggaagaagc	agaacagaaa	1320
gaggccgaat	ttcagcagat	gattgaacag	cttaaaaaagc	aacaggaggc	agctcagcag	1380
gcagcaacgg	caactgcctc	agaacattcc	agagagccca	gtgcagcagg	caggctctca	1440
gacagctcat	ctgaagcctc	taagtgtagt	tccaagagtg	ctaaggaaag	aagaaatcgg	1500
aggaagaaaa	gaaaacagaa	agagcagctc	ggtgggggaa	agaaagatga	ggatgaattc	1560
caaaaatctg	aatctgagga	cagcatcagg	aggaagaggt	ttcgtctctc	cattgaaagg	1620
aaaccgattga	catatgaaaa	gaggtactcc	tccccacacc	agtctttgtt	gagcatccgt	1680
ggctccctat	tttcaccaag	gcgaaaatagc	agaacaagcc	ttttcagctt	tagagggcga	1740
gcaaaggatg	tggtgatctga	gaacgacttc	gcagatgatg	agcacagcac	ctttgaggat	1800
aacgagagcc	gtagagattc	cttgtttgtg	ccccgacgac	acggagagag	acgcaacagc	1860
aacctgagtc	agaccagtag	gtcatcccg	atgctggcag	tgtttccagc	gaatgggaag	1920
atgcacagca	ctgtggattg	caatggtgtg	gtttccttgg	ttggtggacc	ttcagttcct	1980
acatcgctcg	ttggacagct	cttgccagag	gtgataatag	ataagccagc	tactgatgac	2040
aatggaacaa	ccactgaaac	tgaatgaga	aagagaaggt	caagtctctt	ccacgtttcc	2100
atggactttc	tagaagatcc	ttcccaagg	caacgagcaa	tgagtatagc	cagcatttcta	2160
acaaatacac	tagaagaact	tgaagaatcc	aggcagaaat	gccaccctcg	ttggtataaa	2220
ttttccaaca	tattcttaat	ctgggactgt	tctccatatt	ggttaaaagt	gaaacatgtt	2280
gtcaaccttg	ttgtgatgga	ccattttgtt	gacctggcca	tcaccatctg	tattgtctta	2340
aatactcttt	tcatggccat	ggagcactat	ccaatgacgg	accatttcaa	taatgtgctt	2400
acagtaggaa	acttgggttt	cactgggatc	tttacagcag	aaatgtttct	gaaaattatt	2460
gcatgggatc	cttactatta	tttccaagaa	ggctggaata	tctttgacgg	ttttattgtg	2520
acgcttagcc	tggtagaact	tggaactcgc	aatgtggaag	gattatctgt	tctccgttca	2580
tttcgatctg	tcgaggtttt	caagtgtgga	aaatcttggc	caacgttaaa	tatgctaata	2640
aagatcatcg	gcaattccgt	gggggctctg	ggaaatttaa	ccctcgtctt	ggccatcatc	2700
gtcttcattt	ttgccgtggt	cggcatgcag	ctcttttgta	aaagctacaa	agattgtgtc	2760
tgcaagatcg	ccagtgatgt	tcaactccca	cgtgggcaca	tgaatgactt	cttccactcc	2820
ttcctgattg	tgttcccgct	gctgtgtggg	gagtgagtag	agaccatgtg	ggactgtatg	2880
gaggttgctg	gtcaagccat	gtgccttact	gtcttcatga	tggtcatggt	gattggaaac	2940
ctagtgtgct	tgaatctctt	cttgcccttg	cttctgagct	catttagtgc	agacaacctt	3000
gcagccactg	atgatgata	tgaatgaat	aatctccaaa	ttgctgtgga	taggatgcac	3060
aaaggagtag	cttatgtgaa	aagaaaaata	tatgaattta	ttcaacagtc	cttcattagg	3120

-continued

```

aaacaaaaga ttttagatga aattaaacca cttgatgato taaacaacaa gaaagacagt 3180
tgtatgtcca atcatacagc agaaattggg aaagatcttg actatcttaa agatgtaaat 3240
ggaactacaa gtggtatagg aactggcagc agtgttgaaa aatacattat tgatgaaagt 3300
gattacatgt catcataaaa caacccagc cttactgtga ctgtaccaat tgctgtagga 3360
gaatctgact ttgaaaattt aaacacggaa gacttttagt gtgaatcgga tctggaagaa 3420
agcaaaagaga aactgaatga aagcagtagc tcatcagaag gtagcactgt ggacatcggc 3480
gcacctgtag aagaacagcc cgtagtggaa cctgaagaaa ctctgaacc agaagcttgt 3540
ttcactgaag gctgtgtaca aagattcaag tgttgtcaaa tcaatgtgga agaaggcaga 3600
ggaaaacaat ggtggaacct gagaaggacg tgtttccgaa tagttgaaca taactggttt 3660
gagaccttca ttgttttcat gattctcctt agtagtggtg ctctggcatt tgaagatata 3720
tatattgac agcgaaagac gattaagacg atggtggaat atgctgacaa ggttttccact 3780
tacattttca ttctggaat gcttctaaaa tgggtggcat atggctatca aacatatttc 3840
accaatgcct ggtgttggct ggacttctta attgttgatg tttcattggt cagttaaaca 3900
gcaaatgcct tgggttacct agaacttggg gccatcaaat ctctcaggac actaagagct 3960
ctgagacctc taagagcctt atctcgattt gaagggatga ggggtggtgt gaatgccctt 4020
ttaggagcaa ttccatcctt catgaatgtg cttctgggtt gtcttatatt ctggctaatt 4080
ttcagcatca tgggcgtaaa ttgtttgctt ggcaaaattt accactgtat taacaccaca 4140
actggtgaca ggtttgacat cgaagacgtg aataatcata ctgattgcct aaaactaata 4200
gaaagaaatg agactgctcg atggaaaaat gtgaaagtaa actttgataa tgtaggattt 4260
gggtatctct ctttgcctca agttgccaca ttcaaaggat ggatggatat aatgtatgca 4320
gcagttgatt ccagaaatgt ggaactccag cctaagtagt aagaaagtct gtacatgtat 4380
ctttaactttg ttattttcat catcttggg ccttctctca cctgaacct gtttatggt 4440
gtcatcatag ataatttcaa ccagcagaaa aagaagtttg gaggtcaaga catctttatg 4500
acagaagaac agaagaaata ctataatgca atgaaaaaat taggatcgaa aaaaccgcaa 4560
aagcctatac ctgcaccagg aaacaaattt caaggaatgg tcttgactt cgtaaccaga 4620
caagtttttg acataagcat catgattctc atctgtctta acatgggtcac aatgatggtg 4680
gaaacagatg accagagtga atatgtgact accattttgt cagcgcataa tctggtgttc 4740
attgtgctat ttaactggaga gtgtgtactg aaactcatct ctctacgcca ttattatttt 4800
accattggat ggaatatattt tgattttgtg gttgtcattc tctccattgt aggtatgttt 4860
cttgccgagc tgatagaaaa gtatttcgtg tccctacccc tgttccgagt gatccgtctt 4920
gctaggattg gccgaatcct acgtctgac aaaggagcaa aggggattcc cagcgtgctc 4980
tttgcttga tgatgtccct tctgcgttg tttaacatcg gccctcact ctctcctagt 5040
atgttcatct acgcatcttt tgggatgtcc aactttgcct atgttaagag ggaagttggg 5100
atcgatgaca tgttcaactt tgagaccttt ggcaacagca tgatctgcct attccaaatt 5160
acaaacctctg ctggctggga tggatgtgta gcacccattc tcaacagtaa gccaccgcac 5220
tgtgacccta ataaagttaa ccttgaagc tcagttaagg gagactgtgg gaaccatct 5280
gttggaaattt tcttttttgt cagttacatc atcatatcct tctggttgtt ggtgaacatg 5340
tacatcgctg tcactcctgga gaacttcagt gttgctactg aagaaagtgc agagcctctg 5400
agtgaggatg actttgagat gttctatgag gtttgggaga agtttgatcc cgaatgcaact 5460
cagttcatgg aatttgaata attatctcag tttgcagctg cgcttgaacc gcctctcaat 5520
ctgccacaac caaacaact ccagctcatt gccatggatt tgcccatggt gagtgtgtgac 5580
cggatccact gtcttgatct cttatttgc tttacaagc ggggttctagg agagagtgga 5640
gagatggatg cttctagaa acagatggaa gagcgattca tggcttccaa tcttccaaag 5700
gtctcctatc agccaactc tactacttta aaacgaaaac aagaggaagt atctgctgtc 5760
attattcagc gtgcttcagc agccacacct ttaaagcgaa ctgtaaaaca agcttccctt 5820
acgtacaata aaaacaaact caaaggtggg gctaactctt ttataaaaga agacatgata 5880
attgacagaa taaatgaaaa ctctattaca gaaaaaactg atctgaccat gtccactgca 5940
gcttgtccac cttctatga ccgggtgaca aagccaattg tggaaaaaca tgagcaagaa 6000
ggcaaagatg aaaaagccaa agggaaataa 6030

```

```

SEQ ID NO: 13      moltype = AA length = 2009
FEATURE            Location/Qualifiers
source              1..2009
                    mol_type = protein
                    organism = synthetic construct

```

```

SEQUENCE: 13
MEQTVLVPPG PDSFNFFTRE SLAAIERRIA EEKAKNPKPD KKDDDENGPK PNSDLEAGKN 60
LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVLNKGKAIF RFSATSALYI LTPFNPLRKI 120
AIKILVHSLF SMLIMCTILT NCVFMTMSNP PDWTKNVEYT FTGIYTFESL IKI IARGFCL 180
EDFTFLRDPW NWLDFTVITF AYVTEFVDLG NVSALRTFRV LRALKTISVI PGLKTIVGAL 240
IQSVKKLSDV MILTVFCLSV FALIGLQLFM GNLRNKCIQW PPTNASLEEH SIEKNITVNY 300
NGTLINETVF EFDWKSQYID SRYHYFLEGF LDALLCGNSS DAGQCPEGYM CVKAGRNPNY 360
GYTSFDTFW AFLSLFLRMT QDFWENLYQL TLRAAGKTYM IFFVLVIFLG SFYLINLILA 420
VVMAYEEQN QATLEEBQK EAEFQQMIEQ LKKQQEAAQQ AATATASEHS REPSAAGRLS 480
DSSEASKLS SKSAKERNRN RKRKQKEQS GGEEKDEDEF QKSESEDSIR RKGFRFSIEG 540
NRLTYEKRY SPSHQLLSIR GSLFSPRRNS RTSLSFSFRGR AKDVGSSENF ADDEHSTFED 600
NESRRDSL FV PRRHGERRNS NLSQTSRSSF MLAVFPANGK MHSTVDCNGV VSLVGGSVP 660
TSPVGQLLPE VIIDKPATDD NGTTTETEMR KRRSSSFHVS MDFLEDPSQR QRAMSIASIL 720
TNTVEELEES RQKCPWCWYK FSNIFLIWDC SPYWLKVKHV VNLVMDPFV DLAITICIVL 780
NTLFMAMEHY PMTDHFNVL TVGNLVFTGI FTAEMFLKII AMPYYVFQE GWNIFDGIV 840
TSLVELGLA NVLGLSVLRS FRLRLVFKLA KSWPTLNMLI KIIGNSVGAL GNLTFLVLAII 900
VFIFAVVGMQ LFGKSYKDCV CKIASDCQLP RWHMNDFFHS FLIVFRVLCG EWIETMWD CM 960
EVAGQAMCLT VFMVMVIGN LVVLNLFLAL LLSFSFADNL AATDDNEMN NLQIAVDRMH 1020
KGVAVYKRKI YEFIQQSFIR KQKILDEIKP LDDLNNKKDS CMSNHTAEIG KLDLYLKDVN 1080
GTTSGIGTGS SVEKIIDES DYMSFINNPS LTVTVPIAVG ESDFNENLNT DFSSESDLEE 1140
SKEKLNES SSGSTVDIG APVEEQPVVE PEETLEPEAC FTEGCVQRFK CCQINVEEGR 1200

```

-continued

GKQWNLRRRT	CFRIVEHNWF	ETFIVFMILL	SSGALAFEDI	YIDQRKTIKT	MLEYADKVFT	1260
YIFILEMLLK	WVAYGYQTYF	TNAWCWLDPL	IVDVSLSLST	ANALGYSELG	AIKSLRTLRA	1320
LRPLRALSRF	EGMRVVVNAL	LGAIPSIMNV	LLVCLIFWLI	FSIMGVNLFA	GKFYHCINTT	1380
TGDRFDIEDV	NNHTDCLKLI	ERNETARWKN	VKNFNDNVGF	GYLSLLQVAT	FKGWMDIMYA	1440
AVDSRNVELQ	PKYEESLYMY	LYFVIFIIFG	SFFTLLNLFIG	VIIDNFNQOK	KKFGGQDIFM	1500
TEEQKKYYNA	MKKLGSKKPQ	KPIPRPGNKF	QGMVDFDVTR	QVFDISIMIL	ICLNMVTMMV	1560
ETDDQSEYVT	TILSRINLVF	IVLFTGECVL	KLISLRHYFF	TIGWNIQDFV	VVILSIVGMF	1620
LAELIEKYFV	SPTLFRVIRL	ARIGRILRLI	KGAKGIRTLL	FALMMSLPAL	FNIGLLFLV	1680
MFIYAIIFMS	NFAYVKREVG	IDDMFNFTF	GNSMICLFQI	TTSAGWDGLL	APILNSKPPD	1740
CDPNKVNPGS	SVKGDGNGPS	VGIFFFVSYI	IISFLVVVNM	YIAVILENFS	VATEESAEP	1800
SEDDFEMFYE	VWEKFDPDAT	QFMEFEKLSQ	FAAALEPPLN	LPQPNKLQLI	AMDLPVMVSGD	1860
RIHCLDILFA	FTKRVLGESG	EMDALRIQME	ERFMASNPSK	VSYQPITTTL	KRKQEEVSAV	1920
IIQRAYRRHL	LKRTVKQASF	TYNKNKIKGG	ANLLIKEDMI	IDRINENSIT	EKTDLTMTSTA	1980
ACPPSYDRVT	KPIVEKHEQE	GKDEKAKGK				2009

SEQ ID NO: 14                   moltype = DNA   length = 6036  
 FEATURE                   Location/Qualifiers  
 source                   1..6036  
                           mol\_type = other DNA  
                           organism = synthetic construct

SEQUENCE: 14

gccaccatgg	agcagacagt	cctgggtccca	cccgccctg	attcattcaa	ctttttcaca	60
agagagagcc	tggcagctat	cgagcgacgg	attgccgagg	agaaggccaa	gaacccaaa	120
cccgacaaga	aggacgatga	cgagaacggc	cctaagccaa	attccgacct	ggaggccggc	180
aagaatctgc	cttcatctca	cgcgacatc	ccccctgaga	tgggtgtctga	gccctgggag	240
gacctggacc	cctactatat	caacaagaag	acctttatcg	tgtgtaataa	gggcaaggcc	300
atctttagat	tctccgccac	atctgcccctg	tatatcctga	ccccattcaa	ccccctgcgg	360
aagatcgcca	tcaagatcct	ggtgcacagc	ctgttttcca	tgtgtatcat	gtgcacaa	420
ctgaccaatt	gcgtgttcat	gacaaatgagc	aacccaccgc	actggaccaa	gaatgtggag	480
tacaccttca	ccggcatcta	taccttcgag	tccctgatca	agatcatcgc	caggggcttc	540
tgcctggagg	acttcacctt	ctcgagggac	ccctgggaact	ggctggactt	caccgtgatc	600
accttcgcct	acgtgaccca	gtttgtggac	ctgggcaacg	tgagcgcctt	gaggacattc	660
agagtgtctc	gggcccgtga	gaccatctct	gtgatccctg	gcctgaagac	aatcgtgggc	720
gccctgatcc	agtcogtgaa	gaagctgtct	gatgtgatga	tcctgacagt	gttttgcctg	780
agcgtgtctc	ccctgatcgg	cctccagctg	ttcatgggca	acctgaggaa	taagtgtatc	840
cagtggtctc	caacccaacgc	cagcctggag	gagcactcca	tcgagaagaa	tatcacagt	900
aactacaatg	gcacactgat	caacgagaca	gtgttcgagt	tcgactggaa	gtcttatatc	960
caggatagcc	gctatcacta	ctttctggag	ggcttccctg	acgcactgct	gtcgggcaac	1020
agctccgatg	caggacagtg	ccctgagggc	tacatgtgcg	tgaaggccgg	cagggaaccca	1080
aattatggct	acacatcctt	tgacaccttc	tcttgggcct	ttctgagcct	gttccgcctg	1140
atgacccagg	atttctggga	gaacctgtac	cagctgacac	tgaggggcgc	cggcaagacc	1200
tatatgatct	tcttcgtgct	ggctcatctt	ctgggctcct	tctacctgat	caatctgatc	1260
ctggccgtgg	tggctatggc	ctacgaggag	cagaaccagg	ccacactgga	ggaggccggag	1320
cagaaggagg	ccgagttcca	gcagatgatc	gagcagctga	agaaacagca	agaagccgct	1380
cagcaagctg	ccaccgccac	cgcactctgag	cacagcagag	agccactcgc	cgcggcccg	1440
ctgtctgact	ctagctccga	ggccagcaag	ctgtctagca	agtcggccaa	ggagaggaga	1500
aaccggcgca	agaagcgcaa	gcagaaggag	cagagcggcg	gcgaggagaa	ggacgaggat	1560
gagtttcaga	agtcgtagag	caggagactcc	atcaggagaa	agggcttttag	gttctctatc	1620
gagggcaaca	gactgacctc	cgagaagcgg	tattctctc	cccaccagtc	cctgctgtct	1680
atcagaggca	gctgtgtctc	ccctcggcgc	aattctcgga	ccagcctgtt	ttctctcagg	1740
ggcagagcca	aggacgtggg	ctccgagaat	gattttgcgc	atgacagcca	ctctacattc	1800
gaggacaaca	tgtctaggag	agatagcctg	tttgtgcctc	ggcgccacgg	cgagaggaga	1860
aactctaacc	agtgccagac	ctcccgacgc	tccaggatgc	tggccgtgtt	cccagccaac	1920
ggcaagatgc	acagcaccgt	ggactgcaat	ggagtgggtg	ccctggctcg	aggaccttcc	1980
gtgccaaatc	ctcccgctgg	ccagctgctg	cctgaagtga	tcacgataa	gccagccacc	2040
gatgacaacg	gcaccacaac	cgagacagag	atgcccgaag	ggcgctctag	ctcctttcac	2100
gtgagcatgg	atttctggga	ggacccttcc	cagaggcaga	gggcaatgtc	tatcgccagc	2160
atcctgacaa	ataccgtgga	ggagctggag	gagagcaggc	agaagtgcgc	cccttgttgg	2220
tacaagtttt	ctaatactct	cctgatctgg	gactgctccc	cttattggct	gaaggtgaag	2280
cacgtggtga	acctgggtgg	catggacccc	tctgtggacc	tggccatcac	aatctgtatc	2340
gtgctgaata	ccctgtttat	ggctatggag	cactacccaa	tgacagacca	cttcaacaat	2400
gtgctgacgg	tgggcaacct	ggtgtttaca	ggcatcttca	ccgcccagat	gtttctgaag	2460
atcatcgcta	tggaccccta	ctattacttc	caggagggct	ggaatatctt	tgatggcttc	2520
atcgtgaccc	tgtccctggg	ggagctgggc	ctggcaaacg	tggaggccct	gagcgtgtctg	2580
agatcctttc	ggctgtgcgc	cgtgttcaag	ctggccaaag	cttggccaac	cctgaacatc	2640
ctgatcaaga	tcacgcgcaa	cagcgtgggc	gccctgggca	atctgacact	ggtgctggcc	2700
atcatcgtgt	tatatcttcg	cgtggtgggc	atgcagctgt	tcggcaagag	ctacaaggac	2760
tgcgtgtgca	agatgcacac	cgattgccag	ctgccaaagt	ggcacatgaa	cgacttcttt	2820
cacagcttcc	tgatcgtgtt	cagggtgctg	tgcggcgagt	ggatcgagac	aatgtgggat	2880
tgcattgagg	tggcaggaca	ggcaatgtgc	ctgacagtgt	tcattgatgtt	catggctcatc	2940
ggcaacctgg	tggtgttgaa	ctgtttctg	gccctgctgc	tgtctagctt	ctccgcgcac	3000
aaacctggcag	caacccgatga	cgataatgag	atgaacaacc	tccagatcgc	cgtggataga	3060
atgcacaagg	gcgtggcccta	cgtgaagcgg	aaaatctacg	agtttatcca	gcagagcttc	3120
atcagaaaag	agaagatcct	ggacgagatc	aagccactgg	acgatctgaa	caataagaag	3180
gattcctgca	tgtctaatac	caacgcggag	atcggaagg	acctggatta	cctgaaggac	3240
gtgaacggca	caacctccgg	catcggcaca	ggctcctctg	tggagaagta	catcatcgac	3300

-continued

gagctctgatt	atatgagctt	catcaacaat	ccctccctga	cagtgaacct	gectatcgcc	3360
gtgggcgaggt	ctgactttga	gaacctgaat	accgaggact	tcagctccga	gtccgatctc	3420
gaggagctcta	aggagaagct	gaacgagctct	agctcctcta	gcgagggcag	cacagtggaac	3480
atcggcgcccc	cagtggagga	gcagcctgtg	gtggagccag	aggagacact	ggagcccgag	3540
gcctgcttta	ccgagggctg	cgtgcagagg	ttcaagtgc	gtcagatcaa	tgtggaggag	3600
ggcaggggca	agcagtggtg	gaacctgagg	agaacctgtt	ttagaatcgt	ggagcacaac	3660
tggtttgaga	cattcatcgt	gtttatgata	ctgctgtcct	ctggcgccct	ggccttcgag	3720
gacatctaca	tcgaccagcg	gaagacaatc	aagaccatgc	tggagtacgc	cgacaagggtg	3780
tttacctata	tcttcactct	ggagatgctg	ctgaagtggg	tggcctatgg	ctaccagaca	3840
tactttacca	acgcctgggtg	ctggctggat	ttcctgatcg	tggacgtgag	cctgggtgtcc	3900
ctgaccggca	atggcctggg	ctattctgag	ctgggcgcca	tcaagagcct	gaggaccctg	3960
agagccctgc	ggccctcgcg	cgccctgtcc	agattcgagg	gcatgagggt	ggtggtgaat	4020
gcactgctgg	gagccatccc	cagcatcatg	aacgtgtcgc	tgggtgtgct	gatcttttgg	4080
ctgatctctt	atctgtccct	cgtgaatctg	tttgccggca	agttctacca	ctgcataaac	4140
acaaccacag	gcgacagatt	cgacatcgag	gacgtgaaca	atcacaccga	ctgtctgaag	4200
ctgatcgagc	gcaacgagac	agccaggtgg	aagaatgtga	aggtgaactt	tgataatgtg	4260
ggcttcggct	atctgtccct	gctccagggtg	gccaccttca	aggcctggat	ggacatcatg	4320
tacgcccgcg	tggatagccg	gaacgtggag	ctgcaacctc	agtatgagga	gtccctgtat	4380
atgtacctgt	attctgtgat	ctttatcatc	ttcggcagct	tctttacct	gaatctgttt	4440
atcggcgctga	tcactcgacaa	cttcaatcag	cagaagaaga	agtttgccgg	ccaggacatc	4500
ttcatgacag	aggagcagaa	gaagtattac	aacgccatga	agaagctggg	ctccaagaag	4560
ccacagaagc	ccatccctac	accaggcaat	aagtttcagg	gcatggtgtt	tgactctgtg	4620
acccggcagg	tgttcgacat	ctctatcatg	atcctgatct	gcctgaacct	ggtgacaatg	4680
atggtggaga	cagacgatca	gtctgagtac	gtgaccacaa	tcctgagccg	catcaatctg	4740
gtgtttatcg	tgtctgtcac	cgccgagtg	gtgctgaagc	tgatcagcct	gaggcactat	4800
tactttacaa	tcggctggaa	catctttgac	ttcgtgggtg	tcacctgtgc	tatcgtgggc	4860
atgttctctg	ccgagctgat	cgagaagtat	tttgtgagcc	ccaccctgtt	cagagtgtatc	4920
agactggcaa	ggatcgagc	catcctgagg	ctgatcaagg	gcgccaagg	catcagaaca	4980
ctgctgtttg	ccctgatgat	gagccctgcca	gccctgttca	acatcgccct	gctgctgttc	5040
ctgggtcatgt	tcactctacgc	catctttggc	atgtccaatt	tcgcctatgt	gaagcgggaa	5100
gtgggcatcg	acgatattgt	taacttcgag	acattcgcca	acagcatgat	ctgctgttcc	5160
cagatcacca	caagcgcccg	ctgggacggc	ctgctggcac	caatcctgaa	ctctaagcca	5220
cccgactcgc	atcccaacaa	ggtcaatcct	ggcagctccg	tgaagggcga	ttgtggcaat	5280
cctagcgtgg	gcactctctt	ttcgtgagc	tacatcatca	tctcctttct	ggtggtggtg	5340
aacatgtata	tgcccgctgat	cctggagaat	ttctccgtgg	caaccgagga	gtctgcccag	5400
ccactgagcg	aggacgat	tgagatgttc	tacgaagtgt	gggagaagtt	tgacctgat	5460
gccacacagc	tattggagtt	cgagaagctg	agccagttcg	ccgcccctct	ggagcctcca	5520
ctgaacctgc	cccagcctaa	caagctccag	ctgatcgcta	tggacctgcc	tatgggtgtct	5580
ggcgacagaa	tccactgcct	ggacatcctg	tttgccctca	ccaagcgggt	gctgggagag	5640
agcggagaga	tggatgcctg	gcgcattccag	atggaggaga	ggttcatggc	ctctaacca	5700
agcaagggtg	cctaccagcc	catcaccaca	accctgaagc	ggaagcagga	ggaggtgtcc	5760
gccgtgatca	tccagagggc	ataccggcgc	cacctgtcta	agaggacagt	gaagcaggcc	5820
tcttttacct	ataacaagaa	taagatcaag	ggcggcgcca	acctgctgat	caaggaggat	5880
atgatcatcg	acagaatcaa	cgagaatagc	atcacagaga	agaccgacct	gacaatgtcc	5940
accgcccgtc	gtcccccttc	ttatgatcgg	gtgactaaac	ctattgtgga	aaaacacgag	6000
caggagggaa	aggatgagaa	ggcaaaagga	aagtga			6036

SEQ ID NO: 15                      moltype = AA   length = 1998  
 FEATURE                              Location/Qualifiers  
 source                                1..1998  
                                       mol\_type = protein  
                                       organism = Homo sapiens

SEQUENCE: 15

MEQTVLVPPG	PDSFNFFTRE	SLAAIERRIA	EEKAKNPKPD	KKDDDENGPK	PNSDLEAGKN	60
LPFIYGDIPP	EMVSEPLEDL	DPYYINKKTF	IVLNKGKAIF	RFSATSALYI	LTPFNPLRKI	120
AIKILVHSLF	SMLIMCTILT	NCVFMTMSNP	PDWTKNVEYT	FTGIYTFESL	IKI IARGFCL	180
EDFTFLRDPW	NWLDFTVITF	AYVTEFVDLG	NVSALRTFRV	LRALKTISVI	PGLKTIVGAL	240
IQSVKKLSDV	MILTVFCLSV	FALIGLQLFM	GNLRNKCIQW	PPTNASLEEH	SIEKNITVNY	300
NGTLINETVF	EFDWKSIIQD	SRHYFLEGF	LDALLCGNSS	DAGQCPEGYM	CVKAGRNPNY	360
GYTSFDTFW	AFLSLFRLMT	QDFWENLYQL	TLRAAGKTYM	IPFVLVIFLG	SFYLINLILA	420
VVAMAYEEQN	QATLEEAQK	EAEFQQMIEQ	LKKQQEAAQQ	AATATASEHS	REPSAAGRLS	480
DSSSEASKLS	SKSAKERRNR	RKKRKQKEQS	GGEEKDEDEF	QKSESEDSIR	RKGFRFSIEG	540
NRLTYEKRY	SPHQSLLSIR	GSLSFSPRRNS	RTSLFSFRGR	AKDVGSENDF	ADDEHSTFED	600
NESRRDLSFV	PRRHGERRRS	NLSQTSRSSR	MLAVFPANGK	MHSTVDCNGV	VSLVGGPSVP	660
TSPVGQLLPE	GTTTETEMRK	RRSSSFHVM	DFLEDPSQRQ	RAMSIASILT	NTVEELESER	720
QKPPCWYKF	SNIFLIWDCS	PYWLKVKHVV	NLVVMDPFVD	LAITICIVLN	TLFMAMEHYP	780
MTDHFNNVLT	VGNLVFTGIF	TAEMFLKIIA	MDPYFFQEG	WNIFDGFIVT	LSLVELGLAN	840
VEGLSVLRSF	RLLRVFKLAK	SWPTLNMLIK	IIGNSVGLG	NLTVLVLAIV	FIFAVVMQML	900
FGKSYKDCVC	KIASDCQLPR	WHMNDFFHSP	LIVFRVLCGE	WIETMWDCE	VAGQAMCLTV	960
FMVMVIGNL	VVLNLFALLL	LSSFSADNLA	ATDDDNEMNN	LQIAVDRMHK	GVAYVKRKTY	1020
EPIQQSFIRK	QKILDEIKPL	DDLNNKKDSC	MSNHTAEIGK	DLVYKDVNG	TTSGIGTGSS	1080
VEKYIIDESD	YMSFINNPSL	TVTVPPIAVGE	SDFENLNTED	FSSSEDLEES	KEKLNESSES	1140
SEGSTVDIGA	PVEQPVPVEP	EETLEPEACF	TEGCVQRFKC	CQINVEEGRG	KQWNNLRRTC	1200
FRIVEHNWFE	TFIVFMILLS	SGALAFEDIY	IDQRKTIKTM	LEYADKVFTY	IFILEMLLKW	1260
VAYGYQTYFT	NAWCWLDFLI	VDVSLVSLTA	NALGYSELGA	IKSLRTLRLAL	RPLRLALSRFE	1320
GMRVVVNALL	GAIPSIMNVL	LVCLIFWLIF	SIMGVNLFAG	KFYHCINTTT	GDRFDIEDVN	1380



-continued

NHTDCLKLIE	RNETARWKNV	KVNFDNVGFG	YLSLLQVATF	KGWMDIMYAA	VDSRNVELQP	1440
KYEESLYMYL	YFVIFIIFGS	FFTLNLFIGV	IIDNFNQQKK	KFGGDIFMT	EEQKKYYNAM	1500
KKLGSKKPQK	PIPRPGNKQK	GMVDFVTRQ	VFDISIMILI	CLNMVTMMVE	TDDQSEYVTT	1560
ILSRINLVFI	VLFTGECVLK	LISLRHYFT	IGWNIFDFV	VILSIVGMFL	AELIEKYFVS	1620
PTLFRVIRLA	RIGRILRLIK	GAKGIRTLF	ALMMSLPALF	NIGLLLFLVM	FIYAIFGMSN	1680
FAYVKREVG	DDMFNFETFG	NSMICLFQIT	TSAGWDGLLA	PILNSKPPDC	DPNKVNPSS	1740
VKGDCGNPSV	GIFPFVSII	ISPLVVVNM	IAVILENFSV	ATEESAEP	EDDFEMFYE	1800
WEKFDPDATQ	FMEFEKLSQF	AAALEPPLNL	PQPNKLQLIA	MDLPMVSGDR	IHCLDILFAP	1860
TKRVLGESGE	MDALRIQME	RFMASNP	SYQPITTTLK	RKQEEVSAVI	IQRAYRRHLL	1920
KRTVKQASFT	YNKNIKKGA	NLLIKEDMII	DRINENSITE	KDRLTMSTAA	CPPSYDRVTK	1980
PIVEKHEQEG	KDEKAKGK					1998

SEQ ID NO: 16                      moltype = AA   length = 1998  
 FEATURE                           Location/Qualifiers  
 source                              1..1998  
                                      mol\_type = protein  
                                      organism = Homo sapiens

SEQUENCE: 16

MEQTVLVP	PDSPNFFTRE	SLAAIERRIA	EEKAKNPKPD	KKDDDENGPK	PNSDLEAGKN	60
LPFIYGDIPP	EMVSEPLEDL	DPYYINKKTF	IVLNKGKAIF	RFSATSALYI	LTPFNPLRKI	120
AIKILVHSLF	SMLIMCTILT	NCVFMTMSNP	PDWTKNVEYT	FTGIYTFESL	IKIARGFCL	180
EDFTFLRDPW	NWLDFTVITF	AYVTEFVDLG	NVSALRTFRV	LRALKTISVI	PGLKTIVGAL	240
IQSVKKLSDV	MILTVFCLSV	FALIGLQLFM	GNLRNKCIQW	PPTNASLEEH	SIEKNITVNY	300
NGTLINETVF	EFDWKSIIQD	SRHYFLEGF	LDALLCGNSS	DAGQCPEGYM	CVKAGRPNPY	360
GYTSPDTFSW	AFLSLFLRMT	QDFWENLYQL	TLRAAGKTYM	IFFVLVIFLG	SFYLINLILA	420
VVAMAYEEQN	QATLEEAQK	EAEFQQMIEQ	LKKQQEAAQ	AATATASEHS	REPSAAGRLS	480
DSSSEASKLS	SKSAKERRNR	RKKRKQKEQS	GGEEKDEDEF	QKSESEDSIR	RKGRFRSIEG	540
NRLTYEKRY	SPHQSLLSIR	GSLSFSPRRNS	RTSLFSFRGR	AKDVGSEMEF	ADDEHSTFED	600
NESRRDLSFV	PRRHGERRNS	NLSQTSRCSR	MLAVFPANGK	MHSTVDCNGV	VSLVGGPSVP	660
TSPVGQLLPE	GTTTETEMRK	RRSSSFHVS	DFLEDPSQRQ	RAMSIASILT	NTVEELEEER	720
QKCPKCYK	SNIFLIWDC	PYWLKVKHVV	NLVVMDPFVD	LAITICIVLN	TLFMAMEHYP	780
MTDHFNNVLT	VGNLVFTGIF	TAEMFLKIIA	MDPYFYFQEG	WNIFDGFIVT	LSLVELGLAN	840
VEGLSVLRSF	RLLRVFKLAK	SWPTLNMLIK	IIGNSVGALG	NLTLLVLAII	FIFAVVGMQL	900
FGKSYKDCVC	KIASDCQLPR	WHMNDFFHSF	LIVFRVLCGE	WIETMWDCE	VAGQAMCLTV	960
FMVMVIGNL	VVLNLFALL	LSSFSADNLA	ATDDDNEMMN	LQIAVDRMHK	GVAYVKRKIY	1020
EFIQQSFIRK	QKILDEIKPL	DDLNNKIDSC	MSNHTAEIGK	DLDYLDKDVNG	TTSIGITGSS	1080
VEKYIIDESD	YMSFINNPSL	TVTVPVIAVGE	SDFENLNTED	FSSSEDLSES	KEKLNESSES	1140
SEGSTVDIGA	PVEEQPVVEP	EETLEPEACF	TEGCVQRFKC	CQINVEEGRG	KQWNLRRTC	1200
PRIVEHNWFE	TFIVFMILLS	SGALAFEDIY	IDQRKTIKTM	LEYADKVFTY	IFILEMLLKW	1260
VAYGYQTYFT	NAWCWLDFLI	VDVSLVSLTA	NALGYSELGA	IKSLRTLRL	RPLRALSRFE	1320
GMRVVVNALL	GAIPSIMNVL	LVCLIFWLIF	SIMGVNLPAG	KFYHCINTTT	GDRFDIEDVN	1380
NHTDCLKLIE	RNETARWKNV	KVNFDNVGFG	YLSLLQVATF	KGWMDIMYAA	VDSRNVELQP	1440
KYEESLYMYL	YFVIFIIFGS	FFTLNLFIGV	IIDNFNQQKK	KFGGDIFMT	EEQKKYYNAM	1500
KKLGSKKPQK	PIPRPGNKQK	GMVDFVTRQ	VFDISIMILI	CLNMVTMMVE	TDDQSEYVTT	1560
ILSRINLVFI	VLFTGECVLK	LISLRHYFT	IGWNIFDFV	VILSIVGMFL	AELIEKYFVS	1620
PTLFRVIRLA	RIGRILRLIK	GAKGIRTLF	ALMMSLPALF	NIGLLLFLVM	FIYAIFGMSN	1680
FAYVKREVG	DDMFNFETFG	NSMICLFQIT	TSAGWDGLLA	PILNSKPPDC	DPNKVNPSS	1740
VKGDCGNPSV	GIFPFVSII	ISPLVVVNM	IAVILENFSV	ATEESAEP	EDDFEMFYE	1800
WEKFDPDATQ	FMEFEKLSQF	AAALEPPLNL	PQPNKLQLIA	MDLPMVSGDR	IHCLDILFAP	1860
TKRVLGESGE	MDALRIQME	RFMASNP	SYQPITTTLK	RKQEEVSAVI	IQRAYRRHLL	1920
KRTVKQASFT	YNKNIKKGA	NLLIKEDMII	DRINENSITE	KDRLTMSTAA	CPPSYDRVTK	1980
PIVEKHEQEG	KDEKAKGK					1998

1. A vector for providing exogenous Nav1.1 sodium channels, comprising:

- a first nucleic acid sequence encoding at least one portion of a CAV-2 genome;
- a second nucleic acid sequence encoding a functional Nav1.1 sodium channel;
- a first regulatory sequence encoding a transcriptional control region, the transcriptional control region comprising a promoter/enhancer/elongation factor sequence encoding at least one promoter/enhancer/elongation factor selected from the group consisting of an endogenous SCN1A promoter, an endogenous SCN1A enhancer, an endogenous SCN1A transcription factor, E2, E6, EF1, CAG, hsyn, Dlx5/6, and NSE, and preferably, NSE;

wherein the second nucleic acid sequence is operably linked to the first regulatory sequence for controlled

transcriptional ex an SCN1A open reading frame (ORF) in mammalian cells.

2. The vector of claim 1, wherein the second nucleic acid sequence is Sequence ID Number 12 or Sequence ID Number 14, or encodes for Sequence ID Number 15 or Sequence ID Number 16.

3-5. (canceled)

6. The vector of claim 1, wherein:

the second nucleic acid sequence is an engineered SCN1A ORF;

and wherein the engineered SCN1A ORF is created by eliminating at least one short repeat sequence from a codon-modified SCN1A ORF, or

the second nucleic acid sequence is created by eliminating at least one short repeat sequence in an ORF encoding a transmembrane section of the functional Nav1.1 sodium channel.

7. (canceled)

**8.** The vector of claim **1**, wherein the vector is designed for use in the treatment of pathological conditions associated with SCN1A mutation or network dysfunction.

**9.** (canceled)

**10.** The vector of claim **1**, wherein the vector is therapeutically active in individuals with SCN1A missense mutations or SCN1A truncation mutations, or with neuronal dysfunction, or with a loss of function of endogenous Nav1.1 activity, or with a pathological condition selected from the group consisting of Dravet Syndrome, epilepsy, Alzheimer's, and autism spectrum disorder.

**11.** The vector of claim **1**, wherein the vector is optimized for preferential expression of SCN1A ORF in neurons.

**12-17.** (canceled)

**18.** A method for providing exogenous Nav1.1 channels, comprising:

administering a therapeutically effective amount of the vector of claim **1** to a mammal, possibly into a central nervous system of the mammal or into at least one brain region, possibly selected from the group consisting of hippocampus and thalamus.

**19-21.** (canceled)

**22.** The method of claim **18**, wherein the vector is administered prior to development of Dravet Syndrome phenotypes or comorbidities thereof, or after development of Dravet Syndrome phenotypes or comorbidities thereof.

**23.** (canceled)

**24.** The method of claim **18**, wherein the vector is administered to treat Dravet Syndrome or comorbidities thereof, or to prevent the development of Dravet Syndrome or comorbidities thereof.

**25.** (canceled)

**26.** The method of claim **18**, wherein after administration of the vector, the method further comprises:

inducing expression of the functional Nav1.1 sodium channel.

**27.** The method of claim **18**, wherein the vector is administered to an individual with a missense mutation or a nonsense mutation in SCN1A, or to an individual with a

truncation mutation in SCN1A, or to an individual with a mutation that affects splicing of SCN1A transcripts, or to an individual with a frameshift mutation involving SCN1A, or to an individual with a mutation in a promoter/enhancer/regulatory region of SCN1A.

**28-31.** (canceled)

**32.** The method of claim **18**, wherein after administration of the vector, the method further comprises:

monitoring the mammal for desired clinical results, and if the desired clinical results are not obtained; administering a second therapeutically effective amount of the vector.

**33.** (canceled)

**34.** The method of claim **18**, further comprising:

administering a therapeutically effective amount of seizure medication, or

administering a therapeutically effective amount of Alzheimer's disease medication, or

administering a therapeutically effective amount of epilepsy medication.

**35-36.** (canceled)

**37.** The method of claim **18**, wherein:

a therapeutically effective amount of the vector is administered for the treatment of Dravet Syndrome, or

a therapeutically effective amount of the vector is administered for the treatment of epilepsy, or

a therapeutically effective amount of the vector is administered for the treatment of Alzheimer's disease, or

a therapeutically effective amount of the vector is administered for the treatment of autism spectrum disorder, or

a therapeutically effective amount of the vector is administered for the treatment of neurodevelopmental disorders.

**38-41.** (canceled)

**42.** A composition for providing exogenous Nav1.1 channels, the composition comprising:

the vector of claim **1**.

\* \* \* \* \*